



(86) Date de dépôt PCT/PCT Filing Date: 2003/12/10
 (87) Date publication PCT/PCT Publication Date: 2004/07/08
 (85) Entrée phase nationale/National Entry: 2005/06/20
 (86) N° demande PCT/PCT Application No.: IB 2003/005888
 (87) N° publication PCT/PCT Publication No.: 2004/056750
 (30) Priorité/Priority: 2002/12/23 (0230036.6) GB

(51) Cl.Int.⁷/Int.Cl.⁷ C07C 235/40, A61K 31/22, A61K 31/194,
A61K 31/4453, A61K 31/44, A61K 31/275, C07D 213/30,
C07C 233/63, C07C 255/54, C07D 295/182


(71) Demandeur/Applicant:
PFIZER INC., US

(72) Inventeurs/Inventors:
DACK, KEVIN NEIL, GB;
MAGUIRE, ROBERT JOHN, GB

(74) Agent: SIM & MCBURNEY

(54) Titre : COMPOSES GLUTARAMIDE A SUBSTITUTION CYCLOPENTILE UTILISES COMME INHIBITEURS DE
L'ENDOPEPTIDASE

(54) Title: CYCLOPENTIL-SUBSTITUTED GLUTARAMIDE COMPOUNDS AS ENDOPEPTIDASE INHIBITORS



(57) Abrégé/Abstract:

The invention relates to NEP inhibitors for treating cardiovascular disorders. Preferred NEP inhibitors are compounds of formula (I) wherein R¹ is C₁-C₆alkyl, C₁-C₆alkoxyC₃alkyl or C₁-C₆alkoxyC₁-C₆alkoxyC₃alkyl; R² is hydrogen or C₁-C₆alkyl; L is a three 5 atom linkage selected from -CH₂-X-CH₂- and -CH₂-CH₂-X- where the right hand side of the linkage is attached to R³ and where X is oxygen, sulfur or methylene; R³ is phenyl or aromatic heterocyclyl, either of which may be independently substituted by one or more groups selected from: C₁-C₆alkyl, halo, haloC₁-C₆alkyl, C₁-C₆alkoxy, haloC₁-C₆alkoxy, C₁-C₆alkylthio, haloC₁-C₆alkylthio and nitrile; and R⁴ and R⁵ are either both hydrogen, or one of R⁴ and R⁵ is hydrogen and the other is a biolabile ester-forming group that in the body of a patient is replaced by hydrogen.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau




(43) International Publication Date
8 July 2004 (08.07.2004)

PCT

(10) International Publication Number
WO 2004/056750 A1

- (51) International Patent Classification⁷: **C07C 235/40**, 233/63, 255/54, A61K 31/44, 31/194, 31/275, 31/22, 31/4453, C07D 213/30, 295/182
- (21) International Application Number: PCT/IB2003/005888
- (22) International Filing Date: 10 December 2003 (10.12.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 0230036.6 23 December 2002 (23.12.2002) GB
- (71) Applicant (for GB only): **PFIZER LIMITED** [GB/GB]; Ramsgate Road, Sandwich, Kent, CT13 9NJ (GB).
- (71) Applicant (for all designated States except GB, US): **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, NY 10017 (US).
- (72) Inventors; and
(75) Inventors/Applicants (for US only): **DACK, Kevin, Neil** [GB/GB]; Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent, CT13 9NJ (GB). **MAGUIRE, Robert, John** [GB/GB]; Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).
- (74) Agents: **WOOD, David, J.** et al.; Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ (GB).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— with international search report
- (48) Date of publication of this corrected version: 16 June 2005
- (15) Information about Correction: see PCT Gazette No. 24/2005 of 16 June 2005, Section II
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CYCLOPENTIL-SUBSTITUTED GLUTARAMIDE COMPOUNDS AS ENDOPEPTIDASE INHIBITORS



(I)

(57) Abstract: The invention relates to NEP inhibitors for treating cardiovascular disorders. Preferred NEP inhibitors are compounds of formula (I) wherein R¹ is C₁-C₆alkyl, C₁-C₆alkoxyC₃alkyl or C₁-C₆alkoxyC₁-C₆alkoxyC₃alkyl; R² is hydrogen or C₁-C₆alkyl; L is a three 5 atom linkage selected from -CH₂-X-CH₂- and -CH₂-CH₂-X- where the right hand side of the linkage is attached to R³ and where X is oxygen, sulfur or methylene; R³ is phenyl or aromatic heterocyclyl, either of which may be independently substituted by one or more groups selected from:

C₁-C₆alkyl, halo, haloC₁-C₆alkyl, C₁-C₆alkoxy, haloC₁-C₆alkoxy, C₁-C₆alkylthio, haloC₁-C₆alkylthio and nitrile; and R⁴ and R⁵ are either both hydrogen, or one of R⁴ and R⁵ is hydrogen and the other is a biolabile ester-forming group that in the body of a patient is replaced by hydrogen.



WO 2004/056750 A1


CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE COMPOUNDS AS ENDOPEPTIDASE INHIBITORS

The invention relates to a series of cyclopentyl substituted glutaramide derivatives and compositions and uses thereof. The derivatives are potent and selective inhibitors of neutral endopeptidase (NEP) and may be used to treat a number of diseases and conditions particularly cardiovascular disorders, especially hypertension.

WO91/08195 discloses a series of 3-styryl β -alanine substituted glutaramide derivatives which have inhibitory activity against NEP.

10

According to a first aspect, the invention provides a compound of formula (I), a pharmaceutically acceptable salt or solvate thereof



wherein

- 15 R^1 is C_1 - C_6 alkyl, C_1 - C_6 alkoxy C_1 - C_3 alkyl or C_1 - C_6 alkoxy C_1 - C_6 alkoxy C_1 - C_3 alkyl;
 R^2 is hydrogen or C_1 - C_6 alkyl;
 L is a three atom linkage selected from $-CH_2-X-CH_2-$ and $-CH_2-CH_2-X-$ where the right hand side of the linkage is attached to R^3 and where X is oxygen, sulfur or methylene;
- 20 R^3 is phenyl or aromatic heterocyclyl, either of which may be independently substituted by one or more groups selected from: C_1 - C_6 alkyl, halo, halo C_1 - C_6 alkyl, C_1 - C_6 alkoxy, halo C_1 - C_6 alkoxy, C_1 - C_6 alkylthio, halo C_1 - C_6 alkylthio and nitrile; and
 R^4 and R^5 are either both hydrogen, or one of R^4 and R^5 is hydrogen and the other is a biolabile ester-forming group that in the body of a patient is replaced by
- 25 hydrogen.

Unless otherwise indicated, any alkyl group may be straight or branched and is of 1 to 6 carbon atoms, preferably 1 to 4.

- 30 Unless otherwise indicated, any carbocyclyl group contains 3 to 8 ring-atoms, and may be saturated, unsaturated or aromatic. Preferred saturated carbocyclyl groups are cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. Preferred unsaturated carbocyclyl

groups contain up to 3 double bonds. A preferred aromatic carbocyclyl group is phenyl. The term carbocyclic should be similarly construed. In addition, the term carbocyclyl includes any fused combination of carbocyclyl groups, for example naphthyl, phenanthryl, indanyl and indenyl.

5

Unless otherwise indicated, any heterocyclyl group contains 5 to 7 ring-atoms up to 4 of which may be hetero-atoms such as nitrogen, oxygen and sulfur, and may be saturated, unsaturated or aromatic. Examples of heterocyclyl groups are furyl, thienyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, dioxolanyl, oxazolyl, thiazolyl, imidazolyl, imidazoliny, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyranyl, pyridyl, piperidinyl, dioxanyl, morpholino, dithianyl, thiomorpholino, pyridazinyl, pyrimidinyl, pyrazinyl, piperazinyl, sulfolanyl, tetrazolyl, triazinyl, azepinyl, oxazepinyl, thiazepinyl, diazepinyl and thiazolinyl. In addition, the term heterocyclyl includes fused heterocyclyl groups, for example benzimidazolyl, benzoxazolyl, imidazopyridinyl, benzoxazinyl, benzothiazinyl, oxazolopyridinyl, benzofuranyl, quinolinyl, quinazolinyl, quinoxalinyl, dihydroquinazolinyl, benzothiazolyl, phthalimido, benzofuranyl, benzodiazepinyl, indolyl and isoindolyl. The term heterocyclic should be similarly construed.

20 Halo means fluoro, chloro, bromo or iodo.

Unless otherwise indicate, any haloalkyl, haloalkoxy or haloalkylthio group contains one or more halo atoms which halo atoms may be the same or different.

25 Preferably R^1 is C_1 - C_6 alkyl or C_1 - C_6 alkoxy C_1 - C_3 alkyl. More preferably R^1 is propyl or methoxyethyl.

Preferably R^2 is hydrogen.

30 Preferably L is a three atom linkage selected from $-CH_2-O-CH_2-$, $-CH_2-CH_2-O-$ and $CH_2-CH_2-CH_2-$, where the right hand side of the linkage is attached to R^3 . More preferably L is $-CH_2-CH_2-O-$ or $CH_2-CH_2-CH_2-$.

35 Preferably R^3 is phenyl which may be independently substituted by one or more groups selected from: C_1 - C_6 alkyl, halo, halo C_1 - C_6 alkyl, C_1 - C_6 alkoxy, halo C_1 - C_6 alkoxy, C_1 - C_6 alkylthio, halo C_1 - C_6 alkylthio and nitrile. More preferably R^3 is phenyl which may be

independently substituted by one or more groups selected from: C₁-C₆ alkyl, halo, haloC₁-C₆alkyl, C₁-C₆alkoxy and halo C₁-C₆alkoxy. More preferably still R³ is 4-fluorophenyl, 4-chlorophenyl, 4-methoxyphenyl or 4-methylphenyl.

5 The term biolabile ester-forming group is well understood in the art as meaning a group which provides an ester that can be readily cleaved in the body to liberate the corresponding diacid of formula (I) wherein R⁴ and R⁵ are both hydrogen. A number of such ester groups are well known, for example in the penicillin area or in the case of the ACE inhibitor hypertensives such as enalapril and quinapril. Compounds of formula (I)
 10 containing such biolabile ester-forming groups are particularly advantageous in providing compounds suitable for oral administration. The suitability of any particular ester-forming group can be assessed by conventional animal or *in vitro* enzyme hydrolysis studies. For optimum effect, the ester should only be hydrolysed after absorption. Accordingly the ester should be resistant to hydrolysis before absorption by digestive enzymes but
 15 should be readily hydrolysed by, for example, liver or plasma enzymes. In this way the active diacid is released into the blood stream following oral absorption.

Preferred biolabile ester-forming groups are C₁-C₆alkyl, carbocyclyl or heterocyclyl each of which may be substituted.

20


More preferred biolabile ester-forming groups are: i) C₁-C₆alkyl optionally substituted by hydroxy, oxo, halo, haloC₁-C₆alkyl, C₁-C₆alkoxy, haloC₁-C₆alkoxy, C₁-C₆alkylthio, haloC₁-C₆alkylthio, nitrile, carbocyclyl, heterocyclyl, carbocycliloxy, heterocycliloxy, C₁-C₇alkylcarbonyloxy, carbocyclylcarbonyloxy, heterocyclylcarbonyloxy,
 25 alkylcarbonylamino, and alkylaminocarbonyl, wherein any carbocyclyl or heterocyclyl group is optionally substituted by C₁-C₆alkyl, halo, haloC₁-C₆alkyl, C₁-C₆alkoxy, haloC₁-C₆alkoxy, C₁-C₆alkylthio, haloC₁-C₆alkylthio or nitrile; or ii) carbocyclyl or heterocyclyl optionally substituted by C₁-C₆alkyl, halo, haloC₁-C₆alkyl, C₁-C₆alkoxy, haloC₁-C₆alkoxy, C₁-C₆alkylthio, haloC₁-C₆alkylthio or nitrile. In the definitions of i) and ii) any carbocyclic
 30 group is preferably phenyl and any heterocyclic group is aromatic.

Still more preferred biolabile ester-forming groups are selected from the list: ethyl, propyl, butyl, isobutyl, cyclopentyl, benzyl, 1-(2,2-diethylbutyryloxy)ethyl, 2-ethylpropionyloxymethyl, 1-(2-ethylpropionyloxy)ethyl, 1-(2,4-dimethylbenzoyloxy)ethyl,
 35 1-benzoyloxy)benzyl, 1-(benzoyloxy)ethyl, 2-methyl-1-propionyloxypropyl, 2,4,6-trimethylbenzoyloxymethyl, 1-(2,4,6-trimethylbenzyloxy)ethyl, pivaloyloxymethyl,

phenethyl, phenpropyl, 2,2,2-trifluoroethyl, 1-naphthyl, 2-naphthyl, 2,4-dimethylphenyl, 4-t-butylphenyl, 5-(4-methyl-1,3-dioxalynyl-2-onyl)methyl, N,N-diethylaminocarbonylmethyl and 5-indanyl.

5 Preferably R^4 and R^5 are both hydrogen.

A preferred compound is of formula (Ia) wherein R^1 , R^2 , R^3 , R^4 , R^5 and L are as defined in the first aspect.



10

A preferred compound of formula (Ia) is where

R^1 is C_1 - C_6 alkyl or C_1 - C_6 alkoxy C_1 - C_3 alkyl;

R^2 is hydrogen;

L is a three atom linkage selected from: $-CH_2-O-CH_2-$, $-CH_2-CH_2-O-$ and $CH_2-CH_2-CH_2-$,

15

where the right hand side of the linkage is attached to R^3 ;

R^3 is phenyl which may be independently substituted by one or more groups selected from: C_1 - C_6 alkyl, halo, halo C_1 - C_6 alkyl, C_1 - C_6 alkoxy, halo C_1 - C_6 alkoxy, C_1 - C_6 alkylthio, halo C_1 - C_6 alkylthio and nitrile; and

R^4 and R^5 are either both hydrogen, or one of R^4 and R^5 is hydrogen and the other is a biolabile ester-forming group that in the body of a patient is replaced by hydrogen.

20

A more preferred compound of formula (Ia) is where

R^1 is C_1 - C_6 alkyl or C_1 - C_6 alkoxy C_1 - C_3 alkyl;

25

R^2 is hydrogen;

L is $-CH_2-CH_2-O-$ or $CH_2-CH_2-CH_2-$ where the right hand side of the linkage is attached to R^3 ;

R^3 is phenyl which may be independently substituted by one or more groups selected from: C_1 - C_6 alkyl, halo, halo C_1 - C_6 alkyl, C_1 - C_6 alkoxy and halo C_1 - C_6 alkoxy; and

30

R^4 and R^5 are either both hydrogen, or one of R^4 and R^5 is hydrogen and the other is a biolabile ester-forming group that in the body of a patient is replaced by hydrogen.

A still more preferred compound of formula (Ia) is where

R¹ is C₁-C₆alkyl or C₁-C₆alkoxyC₁-C₃alkyl;

R² is hydrogen;

5 L is -CH₂-CH₂-O- or CH₂-CH₂-CH₂- where the right hand side of the linkage is attached to R³;

R³ is phenyl which may be independently substituted by one or more groups selected from: C₁-C₆alkyl, halo, haloC₁-C₆alkyl, C₁-C₆alkoxy and haloC₁-C₆alkoxy; and

R⁴ and R⁵ are both hydrogen.

10

A still more preferred compound of formula (Ia) is where

R¹ is propyl or methoxyethyl;

R² is hydrogen;

15 L is -CH₂-CH₂-O- or CH₂-CH₂-CH₂-, where the right hand side of the linkage is attached to R³;

R³ is 4-fluorophenyl, 4-chlorophenyl, 4-methoxyphenyl or 4-methylphenyl; and

R⁴ and R⁵ are either both hydrogen, or one of R⁴ and R⁵ is hydrogen and the other is a biolabile ester-forming group that in the body of a patient is replaced by hydrogen.

20

A still more preferred compound of formula (Ia) is where

R¹ is propyl or methoxyethyl;

R² is hydrogen;

25 L is -CH₂-CH₂-O- or CH₂-CH₂-CH₂-, where the right hand side of the linkage is attached to R³;

R³ is 4-fluorophenyl, 4-chlorophenyl, 4-methoxyphenyl or 4-methylphenyl; and

30 R⁴ and R⁵ are either both hydrogen, or one of R⁴ and R⁵ is hydrogen and the other is a biolabile ester-forming group that in the body of a patient is replaced by hydrogen, selected from: i) C₁-C₆alkyl optionally substituted by hydroxy, oxo, halo, haloC₁-C₆alkyl, C₁-C₆alkoxy, haloC₁-C₆alkoxy, C₁-C₆alkylthio, haloC₁-C₆alkylthio, nitrile, carbocyclyl, heterocyclyl, carbocycloxy, heterocycloxy, alkylcarbonyloxy, carbocyclylcarbonyloxy, heterocyclylcarbonyloxy, alkylcarbonylamino, and alkylaminocarbonyl, wherein any carbocyclyl or heterocyclyl group is optionally substituted by C₁-C₆alkyl, halo, haloC₁-C₆alkyl, C₁-C₆alkoxy, haloC₁-C₆alkoxy, C₁-C₆alkylthio, haloC₁-C₆alkylthio or nitrile; or ii)

35

carbocyclyl or heterocyclyl optionally substituted by C₁-C₆alkyl, halo, haloC₁-C₆alkyl, C₁-C₆alkoxy, haloC₁-C₆alkoxy, C₁-C₆alkylthio, haloC₁-C₆alkylthio or nitrile.

A most preferred compound of formula (Ia) is where

- 5 R¹ is propyl or methoxyethyl;
 R² is hydrogen;
 L is -CH₂-CH₂-O- or CH₂-CH₂-CH₂-, where the right hand side of the linkage is attached to R³;
 R³ is 4-fluorophenyl, 4-chlorophenyl, 4-methoxyphenyl or 4-methylphenyl; and
 10 R⁴ and R⁵ are both hydrogen.

A particularly preferred compound of formula (I) is selected from:

- (2*S*)-2-[(1-[[[(1*R*)-2-carboxy-1-[(4-chlorobenzyl)oxy]methyl]ethyl]-amino]carbonyl]cyclopentyl)methyl]-4-methoxybutanoic acid (Example 16);
 15 (3*S*)-3-[(1-[(2*R*)-2-carboxypentyl]cyclopentyl)carbonyl]amino]-5-(4-chlorophenoxy)pentanoic acid (Example 41);
 Ethyl (3*S*)-3-[(1-[(2*S*)-2-Carboxy-4-methoxybutyl]cyclopentyl)carbonyl]amino]-5-(4-chlorophenoxy)pentanoate (Example 47);
 (3*S*)-3-[(1-[(2*S*)-2-carboxy-4-methoxybutyl]cyclopentyl)carbonyl]amino]-5-(4-
 20 chlorophenoxy)pentanoic acid (Example 48);
 (2*S*)-2-[(1-[[[(1*S*)-3-butoxy-1-[2-(4-chlorophenoxy)ethyl]-3-oxopropyl]amino]carbonyl]cyclopentyl)methyl]-4-methoxybutanoic acid (Example 49);
 (3*S*)-3-[(1-[(2*S*)-2-carboxy-4-methoxybutyl]cyclopentyl)carbonyl]amino]-6-(4-
 25 chlorophenyl)hexanoic acid (Example 53);
 Ethyl (3*S*)-3-[(1-[(2*S*)-2-carboxy-4-methoxybutyl]cyclopentyl)carbonyl]amino]-6-(4-chlorophenyl)hexanoate (Example 52); and
 (3*S*)-3-[(1-[(2*S*)-2-carboxy-4-methoxybutyl]cyclopentyl)carbonyl]amino]-6-(4-methoxyphenyl)hexanoic acid (Example 54).

30

For the avoidance of doubt, unless otherwise indicated, the term substituted means substituted by one or more defined groups. In the case where groups may be selected from a number of alternative groups, the selected groups may be the same or different.

35

For the avoidance of doubt, the term independently means that where more than one substituent is selected from a number of possible substituents, those substituents may be the same or different.

5 The pharmaceutically or veterinarily acceptable salts of the compounds of the invention which contain a basic centre are, for example, non-toxic acid addition salts formed with inorganic acids such as hydrochloric, hydrobromic, hydroiodic, sulfuric and phosphoric acid, with carboxylic acids or with organo-sulfonic acids. Examples include the HCl, HBr, HI, sulfate or bisulfate, nitrate, phosphate or hydrogen phosphate, acetate, benzoate,
10 succinate, saccharate, fumarate, maleate, lactate, citrate, tartrate, gluconate, camsylate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate salts. Compounds of the invention can also provide pharmaceutically or veterinarily acceptable metal salts, in particular non-toxic alkali and alkaline earth metal salts, with bases. Examples include the sodium, potassium, aluminium, calcium, magnesium, zinc
15 and diethanolamine salts. For reviews on suitable pharmaceutical salts see Berge *et al*, J. Pharm, Sci., 66, 1-19, 1977; P L Gould, International Journal of Pharmaceutics, 33 (1986), 201-217; and Bighley *et al*, Encyclopedia of Pharmaceutical Technology, Marcel Dekker Inc, New York 1996, Volume 13, page 453-497.

20 The pharmaceutically acceptable solvates of the compounds of the invention include the hydrates thereof.

Also included within the scope of the invention and various salts of the invention are polymorphs thereof.

25

Hereinafter, compounds their pharmaceutically acceptable salts, their solvates or polymorphs, defined in any aspect of the invention (except intermediate compounds in chemical processes) are referred to as "compounds of the invention".

30 The compounds of the invention may possess one or more chiral centres and so exist in a number of stereoisomeric forms. All stereoisomers and mixtures thereof are included in the scope of the present invention. Racemic compounds may either be separated using preparative HPLC and a column with a chiral stationary phase or resolved to yield individual enantiomers utilising methods known to those skilled in the art. In addition,
35 chiral intermediate compounds may be resolved and used to prepare chiral compounds of the invention.

The compounds of the invention may exist in one or more tautomeric forms. All tautomers and mixtures thereof are included in the scope of the present invention. For example, a claim to 2-hydroxypyridinyl would also cover its tautomeric form, α -pyridonyl.

5

The invention also includes all suitable isotopic variations of a compound of the invention. An isotopic variation of a compound of the invention is defined as one in which at least one atom is replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulphur, fluorine and chlorine such as ^2H , ^3H , ^{13}C , ^{14}C , ^{15}N , ^{17}O , ^{18}O , ^{31}P , ^{32}P , ^{35}S , ^{18}F and ^{36}Cl , respectively. Certain isotopic variations of the invention, for example, those in which a radioactive isotope such as ^3H or ^{14}C is incorporated, are useful in drug and/or substrate tissue distribution studies. Tritiated, i.e., ^3H , and carbon-14, i.e., ^{14}C , isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with isotopes such as deuterium, i.e., ^2H , may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased *in vivo* half-life or reduced dosage requirements and hence may be preferred in some circumstances. Isotopic variations of the compounds of the invention can generally be prepared by conventional procedures such as by the illustrative methods or by the preparations described in the Examples and Preparations hereafter using appropriate isotopic variations of suitable reagents.

The compounds of the invention, by inhibiting NEP (particularly EC.3.4.24.11), can potentiate the biological effects of bioactive peptides and thus there is rationale for the compounds of the invention to treat or prevent number of diseases and conditions.

Shepperson *et al* have demonstrated that the NEP inhibitor candoxatrilat lowers systolic blood pressure in hypertensive rats [see Clin.Sci (Lond), Vol 80(3):265-9]. Kosoglou *et al* have demonstrated that the NEP inhibitor SCH34826 significantly lowered supine blood pressure in a clinical study of 24 black patients with essential hypertension [Circulation, Supplement III, Vol 82, No. 4, page 554, 2201]. Stergiou *et al* have demonstrated that when added to the ACE inhibitor lisinopril, candoxatril (the oral prodrug of candoxatrilat) led to a marked reduction in both supine and erect blood pressure in a clinical study involving 37 hypertensive patients [J. Hypertens, Vol 12, No 11, page 1310-1311]. Accordingly, the compounds of the invention should treat or prevent cardiovascular

diseases and conditions, particularly hypertension, pulmonary hypertension, peripheral vascular disease, heart failure, angina, renal insufficiency, acute renal failure, cyclical oedema, Menière's disease, hyperaldosteronism (primary and secondary) and hypercalciuria. The term hypertension includes all diseases characterised by

5 supranormal blood pressure, such as essential hypertension, pulmonary hypertension, secondary hypertension, isolated systolic hypertension, hypertension associated with diabetes, hypertension associated with atherosclerosis, and renovascular hypertension, and further extends to conditions for which elevated blood pressure is a known risk factor. Accordingly, the term "treatment of hypertension" includes the treatment or

10 prevention of complications arising from hypertension, and other associated co-morbidities, including congestive heart failure, angina, stroke, glaucoma, impaired renal function, including renal failure, obesity, and metabolic diseases (including Metabolic Syndrome). Metabolic diseases include in particular diabetes and impaired glucose tolerance, including complications thereof, such as diabetic retinopathy and diabetic

15 neuropathy.

The compounds of the invention should be particularly efficacious in treating or preventing hypertension.

20 Wayman *et al* [WO 02/079143] have demonstrated that NEP inhibitors increase vaginal and clitoral blood flow in a rabbit model of female sexual arousal disorder (FSAD). Accordingly the compounds of the invention should treat or prevent female sexual dysfunction, particularly FSAD.

25 Wayman *et al* (WO 02/03995) have demonstrated that NEP inhibitors potentiate nerve-stimulated erections in anaesthetised dog model of penile erections. Accordingly the compounds of the invention should treat or prevent male erectile dysfunction (MED).

As a result of their ability to inhibit NEP, the compounds of the invention should treat or

30 prevent menstrual disorders, pre-term labour, pre-eclampsia, endometriosis, and reproductive disorders (especially male and female infertility, polycystic ovarian syndrome, implantation failure).

In addition, the compounds of the invention should: treat or prevent asthma,

35 inflammation, leukemia, pain, epilepsy, affective disorders, dementia and geriatric confusion, septic shock, obesity and gastrointestinal disorders (especially diarrhoea and

irritable bowel syndrome); promote wound healing (especially diabetic and venous ulcers and pressure sores); modulate gastric acid secretion; and treat hyperreninaemia, cystic fibrosis, restenosis, diabetic complications and atherosclerosis.

- 5 As used herein, the terms "treat", "treating" and "treatment" include palliative, curative and prophylactic treatment.

Compounds of the invention may be prepared, in known manner in a variety of ways. In the following reaction schemes and hereafter, unless otherwise stated, R¹ to R⁵, L and X
10 are as defined in the first aspect. These processes form further aspects of the invention.


Throughout the specification, general formulae are designated by Roman numerals I, II, III, IV etc. Subsets of these general formulae are defined as Ia, Ib, Ic etc, IVa, IVb, IVc etc.

15

Compounds of formula (Ib), i.e. compounds of general formula (I) where R⁴ and R⁵ are hydrogen and L is -CH₂OCH₂-, may be prepared according to reaction scheme 1, by deprotecting a compound of general formula (II) where P¹ is a suitable carboxyl
20 protecting group, such as C₁-C₄ alkyl or benzyl, preferably ethyl or t-butyl.

20

Scheme 1




- 25 Deprotection can be performed using standard methodology, as described in "Protecting Groups in Organic Synthesis" by T.W. Greene and P. Wutz". When P¹ is t-butyl, then the preferred conditions are 9-40% trifluoroacetic acid in dichloromethane (by volume) at room temperature for 1 to 72 hours. When P¹ is allyl, preferred conditions are pyrrolidine (4 equiv), tetrakis(triphenylphosphine) palladium (0) (catalytic) in tetrahydrofuran at room
30 temperature for 2-3 hours. When P¹ is ethyl, preferred conditions are 1N sodium

hydroxide in dioxan, methanol or tetrahydrofuran at a temperature between room temperature and reflux for 2-18 hours.

Compounds of formula (II) may be prepared by reacting compounds of formula (III) with R^3CH_2Y (where Y is a halogen atom, preferably bromine or iodine).

Scheme 2




Preferred conditions comprise reacting (III) with R^3CH_2Y in the presence of a suitable alkali metal base (for example sodium hydride, potassium carbonate or caesium carbonate) in a suitable solvent (for example tetrahydrofuran or N,N-dimethylformamide), optionally in the presence of a catalyst (for example imidazole or 4-dimethylaminopyridine). Particularly preferred conditions are sodium hydride (6-10 equiv), imidazole (0.2 equiv) and R^3CH_2Y (1.1 equiv) in tetrahydrofuran at between -15°C and room temperature for 2-3 hrs.

Compounds of formula (III) may be prepared from compounds of formula (IV) according to reaction scheme 3.

20

Scheme 3




Preferred reaction conditions comprise reacting compounds of formula (IV) under acid conditions (for example hydrochloric acid) or basic conditions (for example sodium hydroxide or caesium hydroxide) in the presence of a catalyst in a suitable solvent (for

25

example methanol or dioxan) at a temperature of between room temperature and the reflux temperature of the reaction mixture. Preferred conditions are 1N sodium hydroxide:methanol (25:75, by volume) at room temperature for 18 hours.

- 5 Compounds of formula (IV) may be prepared by reacting compounds of formula (V) with compounds of formula (VI) according to reaction scheme 4.

Scheme 4



10

Typical reaction conditions comprise generating the acid chloride of compounds of formula (V) followed by addition of compounds of formula (VI), optionally in the presence of an excess of tertiary amine (such as triethylamine, Hünig's base or N-methylmorpholine) in a suitable solvent (such as dichloromethane or tetrahydrofuran) at

15 room temperature for between 1 to 24 hours.

Alternative reaction conditions comprise reacting compounds of formula (V), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (WSCDI) /1,3-dicyclohexylcarbodiimide (DCC), 1-hydroxybenzotriazole hydrate (HOBT) /HOAT and

20 compounds of formula (VI), with an excess of a tertiary amine (such as N-methylmorpholine, triethylamine or Hünig's base) in a suitable solvent (for example tetrahydrofuran, dichloromethane or ethyl acetate) at room temperature for between 4 to 48 hours.

25 Further reaction conditions comprise reacting a compound of formula (V), PYBOP[®]/PyBrOP[®]/Mukaiyama's reagent and an excess of compound of formula (VI), with an excess of tertiary amine (N-methylmorpholine, triethylamine or Hünig's base) in a suitable solvent (such as tetrahydrofuran, dichloromethane or ethyl acetate) at room temperature for 4 to 24 hours.

30


Preferred reaction conditions comprise reacting compounds of formula (VI) (1 equiv), a compound of formula (V) (1-1.1 equiv), WSCDI (1-1.1 eq), 1-hydroxybenzotriazole

hydrate (HOBT) (1-1.1 eq) and N-methylmorpholine (2 equiv) in dichloromethane at room temperature for about 18 hours.

Compounds of formula (V) may be prepared by published methods, or by simple
 5 modifications of these methods. See for example: A.S. Cook *et al.*, European Patent Application EP 1 258 474 A2 (Pfizer Ltd. *et al.*); S. Challenger *et al.*, International Patent Application WO02/79143 (Pfizer Ltd. *et al.*); C.G. Barber *et al.*, International Patent Application WO02/02513 (Pfizer Ltd. *et al.*); C.J. Cobley *et al.*, Tetrahedron Letts. 42(42), 7481-7483 (2001); S. Challenger, European Patent Application 0 644 176 A1
 10 (Pfizer Ltd.).

Compounds of formula (Ic), i.e. compounds of general formula (I) where R⁵ is hydrogen, R⁴ is nor hydrogen and L is -CH₂OCH₂-, may be prepared from compounds of formula (II) according to reaction scheme 5.

15

Scheme 5

Compounds of formula (VII) may be prepared by reacting a compound of formula (II) (where P^1 is a protecting group removable under acidic conditions, such as t-butyl) with P^2Y^1 (where P^2 is an acid stable protecting group, such as benzyl or allyl, and Y^1 is a leaving group, typically halogen, preferably bromine or iodine), with an excess of an alkali metal base (for example potassium carbonate or caesium carbonate), or a tertiary amine base (for example triethylamine) in a suitable solvent (for example N,N-dimethylformamide or acetonitrile) at room temperature. Preferred reaction conditions comprise reacting a compound of formula (II) with P^2Y^1 (2.3 equiv) and potassium carbonate (1-3 equiv) in N,N-dimethylformamide for 18 to 72 hours.

10


Compounds of formula (VIII) may be prepared from compounds of formula (VII). When P^1 is t-butyl, then the preferred conditions are 9-40% trifluoroacetic acid in dichloromethane (by volume) at room temperature for 1 to 72 hours.

15 Compounds of formula (IX) may be prepared from compounds of formula (VIII) using analogous methods described for the preparation of compounds of formula (VII) replacing P^2Y^1 with R^4Y^1 .

20 Compounds of formula (Ic) may be prepared from compounds of formula (IX). When P^2 is benzyl, preferred conditions comprise hydrogenation. When P^2 is allyl preferred conditions comprise pyrrolidine, tetrakis(triphenylphosphine) palladium (0) (catalytic) in tetrahydrofuran at room temperature for 2-3 hours.

25 Compounds of formula (Id), i.e. compounds of general formula (I) where R^4 is hydrogen, R^5 is not hydrogen and L is $-CH_2OCH_2-$, may be prepared according to reaction scheme 6, where P^1 is a suitable carboxyl protecting group, preferably t-butyl.

15


Scheme 6

Compounds of formula (X) where P^1 is a suitable carbonyl protecting group preferably t-butyl, may be prepared from compounds of formula (II) in analogous fashion to the preparation of compounds of formula (IX) (see scheme 5).

Compounds of formula (Id) may be prepared from compounds of formula (X) in analogous fashion to scheme 1. For example when P^1 is t-butyl preferred reaction conditions comprise trifluoroacetic acid or hydrochloric acid.


Alternatively compounds of formula VII may be prepared according to reaction scheme 7.

16

Scheme 7

- Compounds of formula (XII) may be prepared by treating a compound of formula (XI) with R³CH₂Hal in analogous fashion the methods described for Scheme 2 where P⁴ is a suitable nitrogen protecting group, such as tert-butyloxycarbonyl (Boc) or benzyloxycarbonyl (CBz), preferably Boc. The amine protecting group P⁴ in compounds of formula (XII) may then be selectively removed using standard methodology, as described in "Protecting Groups in Organic Synthesis" by T.W. Greene and P. Wutz". Preferred conditions, when P⁴ is Boc are hydrochloric acid in ethyl acetate, ethanol or dichloromethane or, trifluoroacetic acid in dichloromethane at room temperature for between 15 minutes and 3 hours. Preferred conditions when P⁴ is CBz are hydrobromic acid in acetic acid at room temperature for about 5 hrs. Compounds of formula (VII) may then be obtained by reaction compounds of formula (XIII) with compounds of formula (V) in analogous fashion to the methods described for Scheme 4.

Compounds of formula (Id), i.e. compounds of general formula (I) where R⁴ and R⁵ are hydrogen and L is -CH₂CH₂O-, may be prepared according to reaction scheme 8.

Scheme 8


- 5 Compounds of formula (XV) may be prepared by reacting a compound of formula (V) with a compound of formula (XIV) using analogous conditions to those described for Scheme 4, where P^1 and P^2 are suitable carboxyl protecting groups, typically C_1 - C_4 alkyl or benzyl, preferably ethyl or t-butyl, and P^3 is a suitable hydroxyl-protecting group, typically silyl. Compounds of formula (XVI) may be prepared by removal of the alcohol protecting group using standard methodology, as described in "Protecting Groups in Organic Synthesis" by T.W. Greene and P. Wutz".
- 10 When P^3 is a silyl group, such as t-butyl dimethylsilyl, preferred conditions are acetic acid:tetrahydrofuran:water (50:25:25) at room temperature for 2 hours. Compounds of formula (XVII) may be prepared by

reacting (XVI) with R^3OH using Mitsunobu conditions described in Synthesis 1 (1981) or Org. React. 42; 335 (1992). Preferred reaction conditions comprise diisopropylazodicarboxylate (DIAD) (1.3 equiv), triphenylphosphine (1.3 equiv), R^3OH (1.3 equiv) in tetrahydrofuran for 18 hours at room temperature. Compounds of formula 5 (Id) may be prepared in two steps from (XVII) by deprotection methodology described previously in Scheme 1.

Compounds of formula (Id) where X is S, may be prepared by reaction of (XVI) with R^3SH , under the Mitsunobu conditions described for the preparation of (XVII), followed by removal of the carboxyl protecting groups, as described in step for scheme 1.

Compounds of formula (XIV) may be prepared according to reaction scheme 9 by reacting compounds of formula (XIX) where P^2 is a suitable carboxyl protecting group, typically C_1 - C_4 alkyl or benzyl, preferably ethyl or t-butyl, and P^3 is a suitable hydroxyl protecting group, typically silyl, with a suitable chiral amine according to the methods described by Davies et. al. (Tet. Asymm. 1991; 2; 183).

Scheme 9




Preferred conditions comprise n-butyl lithium (1.5 equiv) and the chiral auxiliary NH(benzyl)(α -methylbenzyl) (1.6 equiv) in tetrahydrofuran at $-78^\circ C$ for about 3 hours. The N-benzyl protecting groups may be removed by reacting (XX) in the presence of a

suitable palladium catalyst (such as palladium on charcoal or palladium hydroxide) in a suitable solvent (such as acetic acid or ethanol). Preferred conditions are 10% palladium on charcoal in acetic acid at room temperature for up to 72 hours.


- 5 Compounds of formula (Ie), i.e. compounds of general formula (I) where R^4 is hydrogen, R^5 is not hydrogen and L is $-\text{CH}_2\text{CH}_2\text{O}-$ may be prepared from compounds of formula (XVII) according to reaction scheme 10, wherein P^1 is a suitable carboxyl protecting group, typically C_1 - C_4 alkyl or benzyl, preferably, t-butyl.

10 Scheme 10



- Compounds of formula (XXI) may be prepared by removal of the protecting group P^2 from compounds of formula (XVII) using analogous methods to those described for Scheme 5 and 6. Compounds of formula (XXII) may be prepared in turn by reaction of compounds of formula (XXI) with R^5Hal using analogous methods described for the preparation of compounds of formula (VII). Compounds of formula (Ie) may be prepared from compounds of formula (XXII) by deprotection methods as described for Scheme 6.


- Compounds of formula (If), i.e. compounds of general formula (I) wherein L is $-\text{CH}_2\text{CH}_2\text{CH}_2-$, and R^4 and R^5 are both hydrogen may be prepared according to reaction scheme 11 where P^1 and P^2 are suitable carboxyl protecting groups, typically C_1 - C_4 alkyl or benzyl, preferably t-butyl. P^4 is a suitable amino protecting group, preferably benzyloxycarbonyl.

Scheme 11

Compounds of formula (XXIV) may be prepared from compounds of formula (XXIII) under the conditions described by Evans et. al (J.Org.Chem. 1999; 64; 6411) or Talley
 5 (EP 0561758). Compounds of formula (XXIII) may be prepared in analogous fashion to the methods described by Beeley et. al. in WO 9504033. Preferred conditions for the preparation of compounds of formula (XXIV) are diphenylphosphoryl azide (1 equiv), triethylamine (1.2 equiv) in toluene at reflux for 2 to 3.5 hours, followed by addition of benzyl alcohol (3 equiv) at a temperature between room temperature and reflux for
 10 about 18 hours. Compounds of formula (XXV) may be obtained from compounds of formula (XXIV) by removal of protecting group P⁴ using methods analogous to those described for the preparation of compounds of formula (XIII) (see scheme 7).
 Compounds of formula (XXVI) may be prepared by coupling compounds of formula (XXV) with the compounds of formula (V) using analogous methods to those described for Scheme 4. Removal of the protecting groups from compounds of formula (XXVI)
 15 using analogous methods to those described for Scheme 1 gave compounds of formula (If).

Compounds of formula (I_g), i.e. compounds of general formula (I) where L is -CH₂CH₂CH₂-, R⁴ is hydrogen and R⁵ is not hydrogen may be prepared according to reaction scheme 12 where P¹ and P² are suitable carboxyl protecting groups, typically C₁-C₄ alkyl or benzyl, preferably t-butyl, and P⁴ is a suitable amino protecting group, preferably CBz.

Scheme 12



10 Compounds of formula (XXVII) may be prepared by deprotecting compounds of formula (XXIV). When P² is t-butyl and P⁴ is benzyloxycarbonyl, preferred conditions are hydrobromic acid in acetic acid at room temperature for about 5 hours. Compounds of formula (XXVIII) may be obtained by reacting compounds of formula (XXVII) with R⁵OH under acid catalysis. Compounds of formula (XXIX) may be prepared by coupling the

15 compounds of formula (XXVIII) with compounds of formula (V) using methods analogous to those described for Scheme 4. Removal of the protecting groups from compounds of

formula (XXIX) using methods analogous to those described for Scheme 6 gave compounds of formula (I_g).

It will be appreciated by those skilled in the art, that certain compounds of formula (I) where R⁴ or R⁵ are not hydrogen may be converted to compounds of formula (I) where R⁴ or R⁵ are hydrogen, using standard ester hydrolysis conditions analogous to those described for Scheme 1.

In addition, it will be appreciated by those skilled in the art, that certain compounds of formula (I) where R⁴ or R⁵ are hydrogen, may be converted to compounds of formula (I) where R⁴ or R⁵ are not hydrogen using standard esterification conditions analogous to those described for the preparation of compounds of formula (VII) in scheme 5.

Alternatively it will be appreciated by those skilled in the art, that certain compounds of formula (I) where R⁴ or R⁵ are not hydrogen, may be converted to compounds of formula (I) with alternative R⁴ or R⁵ groups, using standard transesterification conditions.

A pharmaceutically acceptable salt of a compound of the formula (I) may be readily prepared by mixing together solutions of a compound of the formula (I) and the desired acid or base, as appropriate. The salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent.

Procedures for isolating the desired products will be well-known to those skilled in the art with reference to literature precedents and the Examples and Preparations hereto.

25

The compounds of the invention can be administered alone but will generally be administered in admixture with a suitable pharmaceutical excipient, diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical practice.

30

For example, the compounds of the invention can be administered orally, buccally or sublingually in the form of tablets, capsules, multi-particulates, gels, films, ovules, elixirs, solutions or suspensions, which may contain flavouring or colouring agents, for immediate-, delayed-, modified-, sustained-, pulsed- or controlled-release applications.

The compounds of the invention may also be administered as fast-dispersing or fast-dissolving dosage forms or in the form of a high energy dispersion or as coated

35

particles. Suitable formulations of the compounds of the invention may be in coated or uncoated form, as desired.

Such solid pharmaceutical compositions, for example, tablets, may contain excipients
 5 such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate, glycine and starch (preferably corn, potato or tapioca starch), disintegrants such as sodium starch glycollate, croscarmellose sodium and certain complex silicates, and granulation binders such as polyvinylpyrrolidone,
 hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), sucrose, gelatin
 10 and acacia. Additionally, lubricating agents such as magnesium stearate, stearic acid, glyceryl behenate and talc may be included.

General Example

A formulation of the tablet could typically contain between about 0.01mg and 500mg of
 15 active compound whilst tablet fill weights may range from 50mg to 1000mg. An example of a formulation for a 10mg tablet is illustrated below:

Ingredient	%w/w
Free acid, Free base or Salt form	10.000*
20 Lactose	64.125
Starch	21.375
Croscarmellose Sodium	3.000
Magnesium Stearate	1.500

25 * Quantity adjusted in accordance with drug activity.

The tablets are manufactured by a standard process, for example, direct compression or a wet or dry granulation process. The tablet cores may be coated with appropriate overcoats.

30

Solid compositions of a similar type may also be employed as fillers in gelatin or HPMC capsules. Preferred excipients in this regard include lactose, starch, a cellulose, milk sugar or high molecular weight polyethylene glycols. For aqueous suspensions and/or elixirs, the compounds of the invention may be combined with various sweetening or
 35 flavouring agents, colouring matter or dyes, with emulsifying and/or suspending agents

and with diluents such as water, ethanol, propylene glycol and glycerin, and combinations thereof.

Modified release and pulsatile release dosage forms may contain excipients such as those detailed for immediate release dosage forms together with additional excipients that act as release rate modifiers, these being coated on and/or included in the body of the device. Release rate modifiers include, but are not exclusively limited to, hydroxypropylmethyl cellulose, methyl cellulose, sodium carboxymethylcellulose, ethyl cellulose, cellulose acetate, polyethylene oxide, Xanthan gum, Carbomer, ammonio methacrylate copolymer, hydrogenated castor oil, carnauba wax, paraffin wax, cellulose acetate phthalate, hydroxypropylmethyl cellulose phthalate, methacrylic acid copolymer and mixtures thereof. Modified release and pulsatile release dosage forms may contain one or a combination of release rate modifying excipients. Release rate modifying excipients may be present both within the dosage form i.e. within the matrix, and/or on the dosage form, i.e. upon the surface or coating.

Fast dispersing or dissolving dosage formulations (FDDFs) may contain the following ingredients: aspartame, acesulfame potassium, citric acid, croscarmellose sodium, crospovidone, diascorbic acid, ethyl acrylate, ethyl cellulose, gelatin, hydroxypropylmethyl cellulose, magnesium stearate, mannitol, methyl methacrylate, mint flavouring, polyethylene glycol, fumed silica, silicon dioxide, sodium starch glycolate, sodium stearyl fumarate, sorbitol, xylitol. The terms dispersing or dissolving as used herein to describe FDDFs are dependent upon the solubility of the drug substance used i.e. where the drug substance is insoluble a fast dispersing dosage form can be prepared and where the drug substance is soluble a fast dissolving dosage form can be prepared.

The compounds of the invention can also be administered parenterally, for example, intracavernously, intravenously, intra-arterially, intraperitoneally, intrathecally, intraventricularly, intraurethrally, intrasternally, intracranially, intramuscularly or subcutaneously, or they may be administered by infusion or needleless injection techniques. For such parenteral administration they are best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood. The aqueous solutions should be suitably buffered (preferably to a pH of from 3 to 9), if necessary. The preparation of

suitable parenteral formulations under sterile conditions is readily accomplished by standard pharmaceutical techniques well-known to those skilled in the art.

5 The following dosage levels and other dosage levels herein are for the average human subject having a weight range of about 65 to 70 kg. The skilled person will readily be able to determine the dosage levels required for a subject whose weight falls outside this range, such as children and the elderly.

10 For oral and parenteral administration to human patients, the daily dosage level of the compounds of the invention will usually be from 0.01 mg/kg to 10 mg/kg (in single or divided doses).

15 Thus tablets or capsules of the compound of the invention may contain from 1 mg to 500 mg of active compound for administration singly or two or more at a time, as appropriate. The physician in any event will determine the actual dosage which will be most suitable for any individual patient and it will vary with the age, weight and response of the particular patient. The above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited and such are within the scope of this invention.

20 The compounds of the invention can also be administered intranasally or by inhalation and are conveniently delivered in the form of a dry powder inhaler or an aerosol spray presentation from a pressurised container, pump, spray, atomiser or nebuliser, with or without the use of a suitable propellant, e.g. dichlorodifluoromethane,
25 trichlorofluoromethane, dichlorotetrafluoroethane, a hydrofluoroalkane such as 1,1,1,2-tetrafluoroethane (HFA 134A [trade mark]) or 1,1,1,2,3,3,3-heptafluoropropane (HFA 227EA [trade mark]), carbon dioxide or other suitable gas. In the case of a pressurised aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. The pressurised container, pump, spray, atomiser or nebuliser may contain a
30 solution or suspension of the active compound, e.g. using a mixture of ethanol and the propellant as the solvent, which may additionally contain a lubricant, e.g. sorbitan trioleate. Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated to contain a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.

35

Aerosol or dry powder formulations are preferably arranged so that each metered dose or "puff" contains from 1 to 50 mg of a compound of the invention for delivery to the patient. The overall daily dose with an aerosol will be in the range of from 1 to 50 mg which may be administered in a single dose or, more usually, in divided doses
5 throughout the day.

Alternatively, the compounds of the invention can be administered in the form of a suppository or pessary, or they may be applied topically in the form of a gel, hydrogel, lotion, solution, cream, ointment or dusting powder. The compounds of the invention
10 may also be dermally or transdermally administered, for example, by the use of a skin patch. They may also be administered by the pulmonary, vaginal or rectal routes.

They may also be administered by the ocular route, particularly for treating disorders of the eye. For ophthalmic use, the compounds can be formulated as micronised
15 suspensions in isotonic, pH adjusted, sterile saline, or, preferably, as solutions in isotonic, pH adjusted, sterile saline, optionally in combination with a preservative such as a benzylalkonium chloride. Alternatively, they may be formulated in an ointment such as petrolatum.

20 For application topically to the skin, the compounds of the invention can be formulated as a suitable ointment containing the active compound suspended or dissolved in, for example, a mixture with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water. Alternatively, they can be formulated as a suitable lotion or cream,
25 suspended or dissolved in, for example, a mixture of one or more of the following: mineral oil, sorbitan monostearate, a polyethylene glycol, liquid paraffin, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

The compounds of the invention may also be used in combination with a cyclodextrin.
30 Cyclodextrins are known to form inclusion and non-inclusion complexes with drug molecules. Formation of a drug-cyclodextrin complex may modify the solubility, dissolution rate, bioavailability and/or stability property of a drug molecule. Drug-cyclodextrin complexes are generally useful for most dosage forms and administration routes. As an alternative to direct complexation with the drug the cyclodextrin may be
35 used as an auxiliary additive, e.g. as a carrier, diluent or solubiliser. Alpha-, beta- and

gamma-cyclodextrins are most commonly used and suitable examples are described in WO-A-91/11172, WO-A-94/02518 and WO-A-98/55148.

For treating cardiovascular disorders, particular hypertension, the compounds of the invention may be combined with one or more active ingredient selected from the list:

- a) angiotensin receptor blockers (ARB), such as losartan, valsartan, telmisartan, candesartan, irbesartan, eprosartan and olmesartan;
- b) calcium channel blockers (CCB) such as amlodipine;
- c) statins, such as atorvastatin;
- 10 d) PDE5 inhibitors, such as sildenafil, tadalafil, vardenafil, 5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-[2-methoxyethyl]-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; 5-(5-acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidiny)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one and; the pyrazolo[4,3-d]pyrimidin-4-ones disclosed in WO00/27848 particularly N-[[3-(4,7-15 dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]-pyrimidin-5-yl)-4-propoxyphenyl]sulfonyl]-1-methyl-2-pyrrolidinepropanamide [DA-8159 (Example 68 of WO00/27848)];
- e) beta blockers, such as atenolol or carvedilol;
- f) ACE inhibitors, such as quinapril, enalapril and lisinopril;
- 20 g) alpha-blockers such as doxazosin;
- h) selective aldosterone receptor antagonists (SARA), such as eplerenone or spironolactone;
- i) imidazoline I₁ agonists, such as rilmenidine or monoxidine; and
- j) endothelin receptor antagonists and endothelin converting enzyme inhibitors.

25 For treating FSAD, the compounds of the invention may be combined with one or more active ingredient selected from the list:

- a) PDE5 inhibitors, such as sildenafil, tadalafil, vardenafil, 5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-[2-methoxyethyl]-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; 5-(5-acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidiny)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one and; the pyrazolo[4,3-d]pyrimidin-4-ones disclosed in WO00/27848 particularly N-[[3-(4,7-30 dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]-pyrimidin-5-yl)-4-propoxyphenyl]sulfonyl]-1-methyl-2-pyrrolidinepropanamide [DA-8159 (Example 68 of WO00/27848)];

- b) dopaminergic agents, preferably apomorphine or a selective D₂, D₃ or D₂/D₃agonist such as, pramipexole and ropirinol (as claimed in WO-00/23056), PNU95666 (as claimed in WO-00/40226);
- c) melanocortin receptor agonists, such as melanotan II; PT-14; PT-141;
 5 compounds claimed in WO-99/64002, WO-00/74679, WO-99/55679, WO-01/05401, WO-00/58361, WO-01/14879, WO-01/13112 and WO-99/54358; selective MC4 receptor agonists such as those disclosed by Martin *et al* [European Journal of Pharmacology, 454 71-79 (2002)] particularly (N-[(3R)-1,2,3,4-tetrahydroisoquinolinium-3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)-2-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (THIQ);
 10 and selective MC3 receptor agonists
- d) selective estrogen receptor modulators (SERMs) such as lasofoxifene and raloxifene;
- e) tibolone;
- 15 f) an androgen such as androsterone, dehydro-androsterone, testosterone, androstenedione and a synthetic androgen; and
- g) an oestrogen, such as oestradiol, oestrone, oestriol and a synthetic estrogen, such as oestrogen benzoate.
- 20 For treating MED, the compounds of the invention may be combined with one or more active ingredient selected from the list:
- a) PDE5 inhibitors, such as sildenafil, tadalafil, vardenafil, 5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-[2-methoxyethyl]-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; 5-(5-acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidiny)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one and; the
 25 pyrazolo[4,3-d]pyrimidin-4-ones disclosed in WO00/27848 particularly N-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]-pyrimidin-5-yl)-4-propoxyphenyl]sulfonyl]-1-methyl-2-pyrrolidinepropanamide [DA-8159 (Example 68 of WO-00/27848)];
- 30 b) dopaminergic agents, preferably apomorphine or a selective D₂, D₃ or D₂/D₃agonist such as, pramipexole and ropirinol (as claimed in WO-00/23056), PNU95666 (as claimed in WO-00/40226); and
- c) melanocortin receptor agonists, such as melanotan II; PT-14; PT-141;
 35 compounds claimed in WO-99/64002, WO-00/74679, WO-99/55679, WO-01/05401, WO-00/58361, WO-01/14879, WO-01/13112 and WO-99/54358; selective MC4 receptor agonists such as those disclosed by Martin *et al*

[European Journal of Pharmacology, 454 71-79 (2002)] particularly (*N*-[(3*R*)-1,2,3,4-tetrahydroisoquinolinium-3-ylcarbonyl]-(1*R*)-1-(4-chlorobenzyl)-2-[4-cyclohexyl-4-(1*H*-1,2,4-triazol-1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (THIQ); and selective MC3 receptor agonists.

5

If a combination of active agents are administered, then they may be administered simultaneously, separately or sequentially.

The invention also includes the following aspects. The preferred embodiments specified
10 hereinabove for the first aspect extend to these aspects.

The invention additionally includes, but is not limited to:

- (i) A pharmaceutical composition including a compound of the invention, together with a pharmaceutically acceptable excipient, diluent or carrier.
- 15 (ii) A compound of the invention for use as a medicament.
- (iii) The use of a compound of the invention as a medicament for treating or preventing a condition for which a beneficial therapeutic response can be obtained by the inhibition of neutral endopeptidase.
- (iv) The use of a compound of the invention as a medicament for treating or
20 preventing cardiovascular diseases and conditions, preferably essential hypertension, pulmonary hypertension, secondary hypertension, isolated systolic hypertension, hypertension associated with diabetes, hypertension associated with atherosclerosis, renovascular hypertension, congestive heart failure, angina, stroke, glaucoma, impaired renal function, renal failure, obesity, metabolic
25 diseases (including Metabolic Syndrome), diabetes and impaired glucose tolerance, including complications thereof, such as diabetic retinopathy and diabetic neuropathy.
- (v) A method of treating or preventing cardiovascular diseases and conditions (preferably essential hypertension, pulmonary hypertension, secondary
30 hypertension, isolated systolic hypertension, hypertension associated with diabetes, hypertension associated with atherosclerosis, renovascular hypertension, congestive heart failure, angina, stroke, glaucoma, impaired renal function, renal failure, obesity, metabolic diseases (including Metabolic Syndrome), diabetes and impaired glucose tolerance, including complications
35 thereof, such as diabetic retinopathy and diabetic neuropathy) in a mammal

including treating said mammal with an effective amount of a compound of the invention.

- 5 (vi) A cardiovascular disease treating pharmaceutical composition comprising a compound of the invention together with a pharmaceutically acceptable excipient, diluent or carrier.
- (vii) A compound of the invention for use in treating or preventing cardiovascular diseases and conditions.
- (viii) The use of a compound of the invention in the manufacture of a medicament for treating or preventing cardiovascular disease and conditions.

10

The invention is illustrated by the following non-limiting examples in which the following abbreviations and definitions are used:

ES ⁺	electrospray ionisation positive scan
ES ⁻	electrospray ionisation negative scan
HPLC	high pressure liquid chromatography
m/z	mass spectrum peak
MS	mass spectrum
TS ⁺	thermospray ionisation positive scan


15 ¹H Nuclear magnetic resonance (NMR) spectra were in all cases consistent with the proposed structures. Characteristic chemical shifts (δ) are given in parts-per-million downfield from tetramethylsilane using conventional abbreviations for designation of major peaks: e.g. s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad. The following abbreviations have been used for common solvents: CDCl₃, deuteriochloroform;

20 DMSO, dimethylsulphoxide. The abbreviation psi means pounds per square inch and LRMS means low resolution mass spectrometry. Where thin layer chromatography (TLC) has been used it refers to silica gel TLC using silica gel 60 F₂₅₄ plates, R_f is the distance travelled by a compound divided by the distance travelled by the solvent front on a TLC plate. Melting points were determined using a Perkin Elmer DSC7 at a heating

25 rate of 20°C/minute).

Example 1


(2R)-2-[(1-[[[(1S)-2-Carboxy-1-[(3-fluorobenzyl)oxy]methyl]ethyl]amino]-carbonyl]cyclopentyl)methyl]pentanoic acid



- 5 Trifluoroacetic acid (2ml) was added to a solution of the ester from preparation 11 (80mg, 0.16mmol) in dichloromethane (3ml), and the reaction stirred at room temperature for 90 minutes. The solution was concentrated under reduced pressure and the trifluoroacetic acid removed by azeotrope with toluene, ethyl acetate and dichloromethane to afford the title compound as a colourless oil, 44 mg. ¹H NMR (CDCl₃, 400MHz) δ: 0.87 (t, 3H), 1.22-1.70 (m, 10H), 1.77 (dd, 1H), 1.84 (m, 1H), 1.99 (dd, 1H), 2.17 (m, 1H), 2.38 (m, 1H), 2.71 (d, 2H), 3.59 (m, 2H), 4.50 (m, 3H), 6.58 (d, 1H), 6.95-7.08 (m, 3H), 7.26 (m, 1H). LRMS : m/z (ES⁺) 438 [MH⁺]


Examples 2 to 4



- 15 The following examples of general formula:



were obtained quantitatively as colourless oils, from the corresponding *tert*-butyl esters, following a similar procedure to that described in Example 1.


20

Ex. No	R ²	Data
2		¹ H NMR (CDCl ₃ , 400MHz) δ: 0.89 (t, 3H), 1.30 (m, 2H), 1.38-1.76 (m, 8H), 1.84 (m, 2H), 1.99 (dd, 1H), 2.17 (m, 1H), 2.39 (m, 1H), 2.75 (d, 2H), 3.59 (m, 2H), 4.50 (m, 3H), 6.62 (d, 1H), 7.02 (m, 2H), 7.27 (d, 2H). LRMS : m/z (ES ⁺) 438.3 [MH ⁺]

Ex. No	R ²	Data
3		¹ H NMR (CDCl ₃ , 400MHz) δ: 0.85 (t, 3H), 1.22-1.68 (m, 10H), 1.80 (m, 2H), 1.98 (dd, 1H), 2.16 (m, 1H), 2.38 (m, 1H), 2.69 (d, 2H), 3.58 (m, 2H), 4.46 (m, 3H), 6.58 (d, 1H), 7.20-7.34 (m, 4H). LRMS : m/z (ES ⁺) 454 [MH ⁺] Microanalysis found: C, 59.16; H, 6.97; N, 2.95. C ₂₃ H ₃₂ ClNO ₆ ; 0.20CH ₂ Cl ₂ requires C, 59.17; H, 6.93; N, 2.97%.
4		¹ H NMR (CDCl ₃ , 400MHz) δ: 0.86 (t, 3H), 1.22-1.72 (m, 10H), 1.82 (m, 2H), 1.98 (dd, 1H), 2.17 (m, 1H), 2.38 (m, 1H), 2.72 (d, 2H), 3.60 (m, 2H), 4.50 (m, 1H), 4.58 (s, 2H), 6.60 (d, 1H), 7.40 (d, 2H), 7.60 (d, 2H). LRMS : m/z (ES ⁺) 488 [MH ⁺]

Example 5

(2R)-2-[(1-[[[(1R)-2-Carboxy-1-[[4-chlorobenzyl]oxy]methyl]ethyl]amino]-carbonyl]cyclopentyl)methyl]pentanoic acid



5

Trifluoroacetic acid (1ml) was added to a solution of the ester from preparation 15 (125mg, 0.25mmol) in dichloromethane (5ml), and the reaction stirred at room temperature for 18 hours. The solution was concentrated under reduced pressure and the residue azeotroped with dichloromethane (6x). The crude product was purified by

10

column chromatography on silica gel using dichloromethane:methanol:acetic acid

(97:3:0.3) as eluant to afford the title compound, 30mg. ¹H NMR (CDCl₃, 400MHz) δ:

0.84 (t, 3H), 1.18-1.38 (m, 3H), 1.42-1.52 (m, 7H), 1.79 (dd, 1H), 1.96 (m, 2H), 2.10 (m, 1H), 2.38 (m, 1H), 2.68 (m, 2H), 3.60 (m, 2H), 4.44 (m, 3H), 7.04 (d, 1H), 7.24 (m, 4H).


LRMS : m/z (ES⁺) 476 [MNa⁺]; Microanalysis found: C, 58.72; H, 7.05; N, 2.88.

15

C₂₃H₃₂ClNO₆;H₂O requires C, 58.53; H, 7.26; N, 2.97%

Example 6


(2R)-2-[(1-[[[(1R)-2-Carboxy-1-[(4-fluorobenzyl)oxy]methyl]ethyl]amino]-carbonyl]cyclopentyl)methyl]pentanoic acid



- 5 Imidazole (50mg, 0.73mmol) and sodium hydride (60% dispersion in mineral oil, 1.24g, 31mmol) were added to a cooled (-15°C) solution of the alcohol from preparation 7 (1.2g, 3.1mmol) in tetrahydrofuran (70ml), and the mixture stirred for 45 minutes. A solution of 4-fluorobenzylbromide (650mg, 3.4mmol) was added and the reaction stirred for a further 2 hours at -15°C, and then allowed to warm to room temperature. Stirring
- 10 was continued for a further 3 hours, then the flask cooled in an ice-bath. The reaction was quenched by the addition of water, diluted with 1N hydrochloric acid, and the mixture extracted with ethyl acetate. The combined organic solutions were dried (MgSO₄) and evaporated under reduced pressure. The product was purified by column chromatography on silica gel using an elution gradient of dichloromethane:methanol
- 15 (98:2 to 92:8). This intermediate was dissolved in trifluoroacetic acid (2ml) and dichloromethane (4ml), and the reaction stirred at room temperature for 18 hours. The solution was concentrated under reduced pressure and the residue azeotroped with dichloromethane (3x). The crude product was purified by column chromatography on silica gel using dichloromethane:methanol:acetic acid (96:4:0.4) as eluant to afford the
- 20 title compound, 100mg. ¹H NMR (CDCl₃, 400MHz) δ: 0.82 (t, 3H), 1.25 (m, 3H), 1.40-1.81 (m, 8H), 1.96 (m, 2H), 2.15 (m, 1H), 2.38 (m, 1H), 2.58-2.80 (m, 2H), 3.48-3.72 (m, 2H), 4.48 (m, 3H), 6.82 (m, 1H), 7.01 (d, 2H), 7.24 (d, 2H). LRMS : m/z (ES⁻) 436 [M-H]⁻

Example 7


- 25 (2R)-2-[(1-[[[(1R)-2-Carboxy-1-[(3-methoxybenzyl)oxy]methyl]ethyl]amino]-carbonyl]cyclopentyl)methyl]pentanoic acid



The title compound was obtained in 81% yield from the ester from preparation 16, following the procedure described in Example 5. ¹H NMR (CDCl₃, 400MHz) δ: 0.84 (t, 3H), 1.20-1.38 (m, 3H), 1.44-1.70 (m, 7H), 1.79 (dd, 1H), 1.90 (m, 1H), 2.02 (m, 2H), 2.38 (m, 1H), 2.70 (m, 2H), 3.60 (m, 2H), 3.80 (s, 3H), 4.44 (m, 3H), 6.84 (m, 2H), 7.02 (d, 1H), 7.24 (m, 2H), 7.82 (br s, 2H). LRMS : m/z (ES⁺) 472 [MNa⁺].

Example 8

(2R)-2-[(1-[[[(1R)-2-Carboxy-1-[(4-cyanobenzyl)oxy]methyl]ethyl]amino]-carbonyl]cyclopentyl)methyl]pentanoic acid




10

A solution of the ester from preparation 52 (60mg, 0.13mmol) and 1M sodium hydroxide (2ml) in dioxan (6ml) was stirred at room temperature for 3 hours. The reaction was concentrated under reduced pressure the residue suspended in water (3ml), the pH adjusted to 1 using 2N hydrochloric acid, and the solution extracted with ethyl acetate (3x3ml). The combined organic extracts were washed with brine, dried (MgSO₄) and evaporated under reduced pressure to afford the title compound as a colourless gum, 55mg. ¹H NMR (CDCl₃, 400MHz) δ: 0.82 (t, 3H), 1.18-1.38 (m, 3H), 1.42-1.72 (m, 7H), 1.79 (d, 1H), 1.98 (m, 2H), 2.18 (m, 1H), 2.40 (m, 1H), 2.62 (dd, 1H), 2.79 (dd, 1H), 3.62 (m, 2H), 4.52 (m, 1H), 4.59 (s, 2H), 6.94 (d, 1H), 7.40 (d, 2H), 7.62 (d, 2H). LRMS : m/z (ES⁻) 443 [M-H]⁻

20

Example 9

Sodium (2R)-2-[(1-[[[(1R)-1-[(5-methyl-2-pyridinyl)methoxy]methyl]-3-oxido-3-oxopropyl]amino]carbonyl]cyclopentyl)methyl]pentanoate




25

A solution of the ester from preparation 53 (40mg, 0.07mmol) and 1N sodium hydroxide solution (210μl, 0.21mmol) in dioxan (0.6ml) was stirred at room temperature for 2

hours. The mixture was evaporated under reduced pressure and the residue azeotroped with toluene to afford the title compound, 40mg. ^1H NMR (CD_3OD , 400MHz) δ : 0.82 (t, 3H), 1.25 (m, 3H), 1.42-1.64 (m, 7H), 1.76 (dd, 1H), 1.98 (m, 2H), 2.08 (m, 1H), 2.18 (m, 1H), 2.42 (m, 2H), 2.50 (s, 3H), 3.60 (m, 2H), 4.41 (m, 1H), 4.58 (q, 2H), 7.25 (d, 1H), 7.78 (d, 1H), 8.38 (s, 1H). HRMS : m/z (ES^+) 435.2488 [MH^+] $\text{C}_{23}\text{H}_{34}\text{N}_2\text{O}_6$ requires 435.2490.

Example 10


(2S)-2-[(1-[[[(1S)-2-Carboxy-1-[(3-methoxybenzyl)oxy]methyl]ethyl]amino]-carbonyl]cyclopentyl)methyl]-4-methoxybutanoic acid








Trifluoroacetic acid (1ml) was added to a solution of the *tert*-butyl ester from preparation 17 (26mg, 0.05mmol) in dichloromethane (4ml), and the reaction stirred at room temperature for 18 hours. The solution was concentrated under reduced pressure and the trifluoroacetic acid removed by azeotrope with toluene, ethyl acetate and dichloromethane to afford the title compound as a colourless oil, 17mg. ^1H NMR (CDCl_3 + drop D_2O , 400MHz, rotamers) δ : 1.23-2.15 (m, 12H), 2.48 (m, 1H), 2.63 (m, 2H), 3.30 (2xs, 3H), 3.39 (m, 2H), 3.57 (m, 2H), 3.79 (m, 3H), 4.21 (m, 1H), 4.47 (m, 2H), 6.57, 6.60 (2xd, 1H), 6.82 (m, 3H), 7.22 (m, 1H). HRMS : m/z (ES^+) 466.2450 [MH^+] $\text{C}_{24}\text{H}_{35}\text{NO}_8$ requires 466.2436

Examples 11 to 15

The following examples of general formula:




were obtained quantitatively from the corresponding tert-butyl esters, following a similar procedure to that described in Example 10.

Ex. No	R	Data
11		$^1\text{H NMR}$ ($\text{CDCl}_3 + \text{D}_2\text{O}$, 400MHz, rotamers) δ : 1.45-1.76 (m, 6H), 1.79-2.14 (m, 6H), 2.48 (m, 1H), 2.63 (m, 2H), 3.30 (d, 3H), 3.33-3.60 (m, 4H), 4.48 (m, 3H), 6.45, 6.56 (2xd, 1H), 7.23 (m, 2H), 7.32 (m, 2H). HRMS : m/z (ES) 470.1956 [MH^+] $\text{C}_{23}\text{H}_{32}\text{ClNO}_7$ requires 470.1940 [MH^+]
12		$^1\text{H NMR}$ ($\text{CDCl}_3 + \text{D}_2\text{O}$, 400MHz) δ : 1.48-1.76 (m, 7H), 1.79-1.97 (m, 3H), 2.00-2.16 (m, 2H), 2.52 (m, 1H), 2.75 (d, 2H), 3.34 (s, 3H), 3.40 (m, 2H), 3.62 (m, 2H), 4.57 (m, 1H), 4.61 (s, 2H), 7.22 (m, 2H), 7.39 (m, 2H). HRMS : m/z (ES) 470.1947 [MH^+] $\text{C}_{23}\text{H}_{32}\text{ClNO}_7$ requires 470.1940 [MH^+]
13		$^1\text{H NMR}$ ($\text{CDCl}_3 + \text{D}_2\text{O}$, 400MHz) δ : 1.45-1.77 (m, 7H), 1.83 (m, 3H), 2.00-2.17 (m, 2H), 2.50 (m, 1H), 2.68 (d, 2H), 3.32 (s, 3H), 3.40 (m, 2H), 3.58 (m, 2H), 4.50 (m, 3H), 7.18 (m, 1H), 7.26 (m, 3H); HRMS : m/z (ES) 470.1944 [MH^+] $\text{C}_{23}\text{H}_{32}\text{ClNO}_7$ requires 470.1940 [MH^+]
14		$^1\text{H NMR}$ (CDCl_3 , 400MHz) δ : 1.44-1.74 (m, 6H), 1.78-1.93 (m, 4H), 1.99-2.16 (m, 2H), 2.48 (m, 1H), 2.70 (d, 2H), 3.30 (s, 3H), 3.40 (m, 2H), 3.57 (m, 2H), 4.46 (m, 3H), 6.62 (d, 1H), 6.99 (m, 1H), 7.12 (m, 2H), 8.36 (br, s, 2H). HRMS : m/z (ES) 472.2144 [MH^+] $\text{C}_{23}\text{H}_{31}\text{F}_2\text{NO}_7$ requires 472.2142 [MH^+]
15		$^1\text{H NMR}$ (CDCl_3 , 400MHz) δ : 1.42-1.76 (m, 8H), 1.84 (m, 2H), 1.99-2.18 (m, 2H), 2.46 (m, 1H), 2.62 (m, 2H), 3.26 (s, 3H), 3.39 (m, 2H), 3.57 (m, 2H), 4.50 (m, 3H), 6.58 (d, 1H), 6.76-6.86 (m, 2H), 7.30 (m, 1H). HRMS : m/z (ES) 472.2143 [MH^+] $\text{C}_{23}\text{H}_{31}\text{F}_2\text{NO}_7$ requires 472.2142 [MH^+]

5 Example 16

(2S)-2-[(1-[[[(1R)-2-Carboxy-1-[[4-chlorobenzyl]oxy]methyl]ethyl]amino]-carbonyl]cyclopentyl)methyl]-4-methoxybutanoic acid




A solution of the ester from preparation 23 (100mg, 0.19mmol) and trifluoroacetic acid
 10 (1ml) in dichloromethane (5ml) was stirred at room temperature for 18 hours. The mixture was concentrated under reduced pressure and azeotroped with toluene. The

residue was partitioned between dichloromethane and water, the layers separated, and the organic phase dried (MgSO₄) and evaporated under reduced pressure to afford the title compound as a colourless oil, 73mg. ¹H NMR (CDCl₃, 400MHz) δ: 1.45-1.78 (m, 7H), 1.81-2.02 (m, 4H), 2.18 (m, 1H), 2.47-2.75 (m, 3H), 3.38 (m, 4H), 3.57 (m, 3H),
 5 4.46 (s, 2H), 4.73 (m, 1H), 6.40, 6.58 (2xd, 1H), 7.21 (d, 2H), 7.30 (d, 2H).

Example 17

(2R)-2-({1-[(1S)-1-[(Benzyloxy)methyl]-3-ethoxy-3-oxopropyl]amino}carbonyl)cyclopentyl)methyl]pentanoic acid




10

A solution of the ester from preparation 46 (110mg, 0.22mmol) in trifluoroacetic acid (0.5ml) and dichloromethane (5ml) was stirred at room temperature for 72 hours. The reaction was concentrated under reduced pressure and the residue azeotroped with toluene and dichloromethane to afford the title compound, 95mg. ¹H NMR (CDCl₃,
 15 400MHz) δ: 0.90 (t, 3H), 1.20-1.43 (m, 6H), 1.50-1.78 (m, 7H), 2.00 (m, 3H), 2.39 (m, 2H), 2.62 (m, 2H), 3.59 (m, 2H), 4.10 (q, 2H), 4.50 (m, 3H), 6.77 (d, 1H), 7.35 (m, 5H).
 LRMS : m/z (ES⁺) 448.5 [MH⁺]

Example 18

(2R)-2-[(1-[(1S)-3-Ethoxy-1-[(3-methoxybenzyl)oxy]methyl]-3-oxopropyl]amino]carbonyl)cyclopentyl)methyl]pentanoic acid




Trifluoroacetic acid (1ml) was added to a solution of the ester from preparation 24 (280mg, 0.53mmol) in dichloromethane (5ml), and the solution stirred at room
 25 temperature for 4 hours. The reaction was concentrated under reduced pressure and the

residue azeotroped with ethyl acetate. The crude product was purified by column chromatography on silica gel using dichloromethane:methanol (98:2) to afford the title compound as a colourless oil. $^1\text{H NMR}$ (CDCl_3 , 400MHz) δ : 0.86 (t, 3H), 1.23 (t, 3H), 1.34 (m, 3H), 1.50-1.76 (m, 8H), 2.00 (m, 3H), 2.38 (m, 1H), 2.62 (m, 2H), 3.58 (m, 2H), 3.81 (s, 3H), 4.14 (q, 2H), 4.45 (m, 3H), 6.62 (d, 1H), 6.84 (m, 3H), 7.24 (m, 1H). $[\alpha]_D = -2.13^\circ$ (c = 0.3, methanol) Microanalysis found: C, 65.10; H, 8.29; N, 3.01. $\text{C}_{26}\text{H}_{39}\text{NO}_7$ requires C, 65.39; H, 8.23; N, 2.93%

Example 19

10 (2R)-2-[(1-(((1S)-1-[(4-Chlorobenzyl)oxy]methyl)-3-ethoxy-3-oxopropyl)amino)-carbonyl]cyclopentyl)methyl]pentanoic acid




Trifluoroacetic acid (1.2ml) was added to a solution of the ester from preparation 25 (175mg, 0.33mmol) in dichloromethane (10ml), and the solution stirred at room temperature for 18 hours. The mixture was concentrated under reduced pressure and the residue azeotroped with toluene (3x20ml), ethyl acetate (20ml), and dichloromethane (20ml). The crude product was purified by column chromatography on silica gel using an elution gradient of dichloromethane:methanol (98:2 to 95:5) to give the title compound as a colourless oil. $^1\text{H NMR}$ (CDCl_3 , 400MHz) δ : 0.87 (t, 3H), 1.21-1.41 (m, 6H), 1.49-1.78 (m, 8H), 2.00 (m, 3H), 2.38 (m, 1H), 2.62 (m, 2H), 3.57 (m, 2H), 4.14 (q, 2H), 4.45 (m, 3H), 6.60 (d, 1H), 7.23 (m, 2H), 7.35 (d, 2H). HRMS : m/z (ES^+) 482.2314 [MH^+] $\text{C}_{25}\text{H}_{36}\text{ClNO}_6$ requires 482.2306; $[\alpha]_D = -13.2^\circ$ (c = 0.1, methanol)

Examples 20 to 24

25 The following examples of general formula:

39




were obtained, from the corresponding *tert*-butyl esters, following a similar procedure to that described in Example 19.

Ex. No	R	Data
20		$^1\text{H NMR}$ (CDCl_3 , 400MHz) δ : 1.22 (t, 3H), 1.52-1.75 (m, 8H), 1.99 (m, 3H), 2.10 (dd, 1H), 2.56 (m, 1H), 2.61 (m, 2H), 3.26 (s, 3H), 3.38 (m, 2H), 3.57 (m, 2H), 4.10 (q, 2H), 4.45 (m, 3H), 6.63 (d, 1H), 7.22 (d, 2H), 7.32 (d, 2H); LRMS : m/z (APCI) 498 [MH^+]
21		$^1\text{H NMR}$ (CDCl_3 , 400MHz) δ : 1.22 (t, 3H), 1.50-1.75 (m, 8H), 1.88-2.10 (m, 4H), 2.54 (m, 1H), 2.64 (m, 2H), 3.26 (s, 3H), 3.38 (m, 2H), 3.62 (m, 2H), 4.09 (q, 2H), 4.48 (m, 1H), 4.60 (s, 2H), 6.74 (d, 1H), 7.22 (m, 2H), 7.38 (d, 1H), 7.40 (d, 1H); HRMS : m/z (ES^+) 498.2261 [MH^+] $\text{C}_{25}\text{H}_{36}\text{ClNO}_7$ requires 498.2253
22		$^1\text{H NMR}$ (CDCl_3 , 400MHz) δ : 1.22 (t, 3H), 1.54-1.76 (m, 8H), 1.88-2.14 (m, 4H), 2.52 (m, 1H), 2.62 (m, 2H), 3.24 (s, 3H), 3.38 (m, 2H), 3.58 (m, 2H), 4.18 (q, 2H), 4.44 (m, 3H), 6.74 (d, 1H), 7.18 (m, 1H), 7.25 (m, 3H). HRMS : m/z (ES^+) 498.2255 [MH^+] $\text{C}_{25}\text{H}_{36}\text{ClNO}_7$ requires 498.2253
23 ^a		$^1\text{H NMR}$ (CDCl_3 , 400MHz) δ : 1.22 (t, 3H), 1.52-1.76 (m, 8H), 1.98 (m, 3H), 2.05 (m, 1H), 2.50 (m, 1H), 2.60 (m, 2H), 3.26 (s, 3H), 3.38 (m, 2H), 3.58 (m, 2H), 4.07 (q, 2H), 4.43 (m, 1H), 4.52 (s, 2H), 6.68 (d, 1H), 6.78-6.90 (m, 2H), 7.35 (m, 1H); HRMS : m/z (ES^+) 500.2451 [MH^+] $\text{C}_{25}\text{H}_{35}\text{F}_2\text{NO}_7$ requires 500.2455
24		$^1\text{H NMR}$ (CDCl_3 , 400MHz) δ : 1.22 (t, 3H), 1.50-1.74 (m, 8H), 1.98 (m, 3H), 2.07 (dd, 1H), 2.56 (m, 1H), 2.61 (m, 2H), 3.26 (s, 3H), 3.38 (m, 2H), 3.58 (m, 2H), 4.12 (q, 2H), 4.43 (m, 3H), 6.66 (d, 1H), 7.00 (m, 1H), 7.14 (m, 2H); HRMS : m/z (ES^+) 500.2458 [MH^+] $\text{C}_{25}\text{H}_{35}\text{F}_2\text{NO}_7$ requires 500.2455

5 a-isolated without column chromatography

Example 25

(2R)-2-[(1-[[[(1R)-1-[(4-Chlorobenzyl)oxy]methyl]-3-ethoxy-3-oxopropyl]amino]-carbonyl]cyclopentyl)methyl]pentanoic acid




5

A solution of the ester from preparation 99 (98mg, 0.18mmol) and trifluoroacetic acid (2ml) in dichloromethane (4ml) was stirred at room temperature for 18 hours. The mixture was concentrated under reduced pressure and the residue azeotroped with dichloromethane to afford the title compound, 73mg. ¹H NMR (CDCl₃, 400MHz) δ: 0.87 (t, 3H), 1.21-1.41 (m, 6H), 1.50-1.78 (m, 8H), 1.96 (m, 1H), 2.02 (m, 2H), 2.38 (m, 1H), 2.60 (m, 2H), 3.57 (m, 2H), 4.10 (q, 2H), 4.45 (m, 3H), 6.58 (d, 1H), 7.23 (m, 2H), 7.35 (d, 2H); HRMS : m/z (ES⁺) 504 [MNa⁺]; [α]_D = +10.00 (c =0.11, methanol).

10

Example 26

(2R)-2-[[1-[[[(1S)-1-[(Benzyloxy)methyl]-3-(2-butoxyethoxy)-3-oxopropyl]amino]-carbonyl]cyclopentyl]methyl]pentanoic acid




20

A solution of the ester from preparation 50 (100mg, 0.17mmol) in trifluoroacetic acid (0.3ml) and dichloromethane (3ml) was stirred at room temperature for 18 hours, and then evaporated under reduced pressure to afford the title compound. ¹H NMR (CDCl₃, 400MHz) δ: 0.88 (m, 6H), 1.30 (m, 5H), 1.48-1.74 (m, 9H), 1.93 (m, 1H), 1.99-2.16 (m,

2H), 2.38 (m, 1H), 2.68 (d, 2H), 3.45 (m, 3H), 3.58 (m, 2H), 3.61 (m, 2H), 4.17 (m, 1H), 4.23 (m, 1H), 4.50 (m, 3H), 6.59 (d, 1H), 7.22 (m, 5H); LRMS : m/z (ES⁻) 518 [M-H]⁻.

Example 27


- 5 (2R)-2-({1-[(1S)-1-(Benzyloxy)methyl]-3-oxo-3-[2-oxo-2-(1-piperidinyl)ethoxy]propyl}amino)carbonyl]cyclopentyl)methyl}pentanoic acid



- 10 A solution of the ester from preparation 51 (100mg, 0.16mmol) in trifluoroacetic acid (0.3ml) and dichloromethane (3ml) was stirred at room temperature for 18 hours, and concentrated under reduced pressure. The residue was azeotroped with toluene, and the crude product then purified by column chromatography on silica gel using dichloromethane:methanol (98:2 to 95:5) to afford the title compound, 30mg. ¹H NMR (CDCl₃, 400MHz) δ: 0.85 (t, 3H), 1.24-1.78 (m, 17H), 1.90 (m, 1H), 1.99 (dd, 1H), 2.18 (m, 1H), 2.37 (m, 1H), 2.80 (d, 2H), 3.25 (m, 2H), 3.50 (m, 1H), 3.60 (m, 3H), 4.50 (s, 15 2H), 4.61 (m, 2H), 4.78 (d, 1H), 6.63 (d, 1H), 7.28 (m, 5H); LRMS : m/z (ES⁻) 543 [M-H]⁻.

Example 28

- (2R)-2-({1-[(1R)-3-Ethoxy-3-oxo-1-(2-phenoxyethyl)propyl]amino}carbonyl)-cyclopentyl)methyl}pentanoic acid




20

Trifluoroacetic acid (1ml) was added to a solution of the ester from preparation 67 (60mg, 0.12mmol) in dichloromethane (5ml), and the solution stirred at room temperature for 18 hours. The mixture was concentrated under reduced pressure, the



residue dissolved in dichloromethane, washed with water, dried (MgSO_4) and evaporated under reduced pressure to afford the title compound, 40mg. $^1\text{H-NMR}$ (CDCl_3 , 400MHz) δ : 0.83 (t, 3H), 1.26 (m, 8H), 1.55-1.77 (m, 7H), 2.00 (m, 2H), 2.10 (m, 2H), 2.35 (m, 1H), 2.65 (m, 2H), 4.02 (m, 2H), 4.17 (q, 2H), 4.48 (m, 1H), 6.86 (m, 3H), 6.99 (m, 1H),
 5 7.25 (m, 2H).

Examples 29 to 30

The compounds of the following general formula:




10 were prepared from the corresponding *tert*-butyl esters, following a similar procedure to that described in Example 28.

Ex. No	R	Data
29		$^1\text{H-NMR}$ (CDCl_3 , 400MHz) δ : 0.85 (t, 3H), 1.26 (m, 6H), 1.48-1.75 (m, 8H), 1.95-2.22 (m, 5H), 2.37 (m, 1H), 2.62 (m, 2H), 3.99 (m, 2H), 4.18 (q, 2H), 4.45 (m, 1H), 6.77 (d, 1H), 6.80 (m, 2H), 6.98 (dd, 2H). LRMS : m/z (ES^+) 488 [MNa^+]
30		$^1\text{H-NMR}$ (CDCl_3 , 400MHz) δ : 0.85 (t, 3H), 1.28 (m, 6H), 1.50-1.77 (m, 8H), 1.92-2.14 (m, 5H), 2.34 (m, 1H), 2.64 (d, 2H), 4.00 (t, 2H), 4.18 (q, 2H), 4.42 (m, 1H), 6.80 (d, 2H), 6.96 (d, 1H), 7.22 (d, 2H). LRMS : m/z (ES^+) 504 [MNa^+]

Example 31

15 (2R)-2-[[1-({[(1S)-2-(Benzyloxy)-1-(carboxymethyl)ethyl]amino}carbonyl)-cyclopentyl]methyl]pentanoic acid




A solution of the ethyl ester from example 17 (70mg, 0.16mmol) in sodium hydroxide solution (1ml, 1N) and methanol (5ml) was stirred at room temperature for 18 hours. The

reaction was concentrated under reduced pressure to remove the methanol, and the residue was partitioned between ethyl acetate (10ml) and hydrochloric acid (2N, 10ml). The phases were separated, the aqueous layer extracted with ethyl acetate (4x10ml), the combined organic solutions washed with brine (10ml), dried (MgSO₄) and evaporated under reduced pressure to afford the title compound, 50mg; ¹H NMR (CDCl₃, 400MHz) δ: 0.92 (t, 3H), 1.23-2.39 (m, 15H), 2.74 (d, 2H), 3.60 (m, 2H), 4.52 (m, 3H), 6.66 (d, 1H), 7.35 (m, 5H); HRMS: m/z (ES⁺) 420.2374 [MH⁺]; C₂₃H₃₃NO₆ calculated 420.2381.

Example 32


(2R)-2-[(1-[[[(1S)-2-Carboxy-1-[(3-methoxybenzyl)oxy]methyl]ethyl)amino]carbonyl]-cyclopentyl)methyl]pentanoic acid



Sodium hydroxide solution (1ml, 1N, 1mmol) was added to a solution of the ethyl ester from example 18 (50mg, 0.11mmol) in dioxan (3ml), and the reaction stirred at room temperature for 2 hours. The reaction was concentrated under reduced pressure, the residue dissolved in water, acidified using 2N hydrochloric acid, and extracted into ethyl acetate. The combined organic extracts were dried (MgSO₄) and evaporated under reduced pressure to afford the title compound, 30mg; ¹H NMR (CDCl₃, 400MHz) δ: 0.86 (t, 3H), 1.23-1.66 (m, 10H), 1.78 (m, 1H), 1.85 (m, 1H), 1.98 (dd, 1H), 2.14 (m, 1H), 2.39 (m, 1H), 2.72 (d, 2H), 3.58 (m, 2H), 3.80 (s, 3H), 4.46 (m, 3H), 6.58 (d, 1H), 6.84 (m, 3H), 7.23 (m, 1H); LRMS : m/z (ES⁻) 448 [M-H]⁻.









Examples 33 to 40


The compounds of the following general structure:




25

were prepared from the corresponding ethyl esters, following a similar procedure to that described in Example 32.

Ex. No	R	Data
33		$^1\text{H-NMR}$ (CDCl_3 , 400MHz) δ : 0.84 (t, 3H), 1.30-1.74 (m, 9H), 1.90 (m, 3H), 2.17 (m, 4H), 2.37 (m, 1H), 2.78 (m, 2H), 4.02 (m, 2H), 4.56 (m, 1H), 6.59 (d, 1H), 6.90 (m, 2H), 6.99 (m, 1H), 7.24 (m, 2H). LRMS : m/z (ES^-) 418 [M-H^-]
34		$^1\text{H-NMR}$ (CDCl_3 , 400MHz) δ : 0.84 (t, 3H), 1.24-1.70 (m, 9H), 1.86 (m, 3H), 2.16 (m, 4H), 2.34 (m, 1H), 2.70 (dd, 1H), 2.80 (dd, 1H), 3.99 (dd, 2H), 4.50 (m, 1H), 6.68 (d, 1H), 6.81 (m, 2H), 6.98 (m, 2H). LRMS : m/z (ES^+) 460 [MNa^+]
35		$^1\text{H-NMR}$ (CDCl_3 , 400MHz) δ : 0.86 (t, 3H), 1.21-1.74 (m, 9H), 1.86 (m, 3H), 2.16 (m, 4H), 2.27 (m, 1H), 2.70 (dd, 1H), 2.82 (dd, 1H), 3.98 (dd, 2H), 4.54 (m, 1H), 6.72 (d, 1H), 6.81 (d, 2H), 7.22 (d, 2H). LRMS : m/z (ES^+) 454 [MH^+]
36		$^1\text{H-NMR}$ (CDCl_3 , 400MHz) δ : 0.85 (t, 3H), 1.22-1.77 (m, 9H), 1.84 (m, 3H), 2.17 (m, 4H), 2.29 (m, 1H), 2.70 (dd, 1H), 2.81 (dd, 1H), 4.00 (dd, 2H), 4.55 (m, 1H), 6.76 (m, 2H), 6.86 (s, 1H), 6.94 (d, 1H), 7.18 (dd, 1H). LRMS : m/z (ES^-) 452 [M-H^-]
37		$^1\text{H-NMR}$ (CDCl_3 , 400MHz) δ : 0.84 (t, 3H), 1.20-1.99 (m, 13H), 2.16 (m, 3H), 2.34 (m, 1H), 2.74 (m, 2H), 3.77 (s, 3H), 4.02 (m, 2H), 4.40 (m, 1H), 6.76 (d, 1H), 6.80 (s, 4H).
38		$^1\text{H-NMR}$ (CDCl_3 , 400MHz) δ : 0.85 (t, 3H), 1.22-1.74 (m, 10H), 1.96 (m, 3H), 2.17 (m, 3H), 2.32 (m, 1H), 2.70 (dd, 1H), 2.80 (dd, 1H), 3.79 (s, 3H), 4.00 (m, 2H), 4.50 (m, 1H), 6.46 (m, 3H), 6.78 (d, 1H), 7.18 (dd, 1H); HRMS : m/z (ES^+) 450.2488 [MH^+]; $\text{C}_{24}\text{H}_{35}\text{NO}_7$ gives 450.2487
39		$^1\text{H-NMR}$ (CDCl_3 , 400MHz) δ : 0.83 (t, 3H), 1.22-1.39 (m, 3H), 1.41-1.65 (m, 7H), 1.76 (dd, 1H), 1.90-2.21 (m, 5H), 2.37 (m, 1H), 2.71 (dd, 1H), 2.79 (dd, 1H), 3.83 (s, 3H), 4.08 (m, 2H), 4.50 (m, 1H), 6.90 (m, 4H), 7.02 (d, 1H), 8.84 (br s, 2H); HRMS : m/z (ES^+) 450.2490 [MH^+]; $\text{C}_{24}\text{H}_{35}\text{NO}_7$ gives 450.2487
40		$^1\text{H-NMR}$ (CDCl_3 , 400MHz) δ : 0.83 (t, 3H), 1.22-1.72 (m, 10H), 1.86 (m, 4H), 2.17 (m, 4H), 2.30 (m, 4H), 2.75 (m, 2H), 4.00-4.50 (m, 1H), 6.78 (m, 3H), 7.05 (d, 2H); LRMS : m/z (ES^+) 456 [MNa^+]

Example 41(3S)-3-[(1-[(2R)-2-Carboxypentyl]cyclopentyl)carbonyl]amino]-5-(4-chlorophenoxy)pentanoic acid

- 5 A mixture of the ethyl ester from preparation 86 (180mg, 0.37mmol) and sodium hydroxide solution (2N, 2ml) in dioxan (5ml) was stirred at 50°C for 5 hours, then at room temperature for a further 18 hours. The mixture was concentrated under reduced pressure, the residue acidified using 2N hydrochloric acid, and extracted with ethyl acetate (2x20ml). The combined organic solutions were dried (MgSO₄), concentrated
- 10 under reduced pressure and the residue purified by column chromatography on silica gel using an elution gradient of dichloromethane:methanol:acetic acid (95:5:0 to 90:10:0 to 90:10:1) to afford the title compound as a colourless oil, 150mg. ¹H-NMR (CDCl₃, 400MHz) δ: 0.84 (t, 3H), 1.26 (m, 3H), 1.40-1.80 (m, 6H), 1.97 (m, 2H), 2.10 (m, 5H), 2.37 (m, 1H), 2.61 (dd, 1H), 2.78 (dd, 1H), 4.00 (m, 2H), 4.42 (m, 1H), 6.80 (d, 2H), 6.98
- 15 (d, 1H), 7.20 (d, 2H). LRMS : m/z (ES⁻) 452 [M-H⁻]

Example 42(3S)-3-[(1-[(2R)-2-Carboxypentyl]cyclopentyl)carbonyl]amino]-5-(4-fluorophenoxy)pentanoic acid


20

- A mixture of the ester from preparation 87 (130mg, 0.28mmol) in sodium hydroxide solution (3ml, 2N) and dioxan (6ml) was stirred at 50°C for 3 hours. The reaction mixture was concentrated under reduced pressure, the residue acidified using 2N hydrochloric acid and extracted with ethyl acetate (3x50ml). The crude product was purified by
- 25 column chromatography on silica gel using an elution gradient of methanol:dichloromethane (5:95 to 10:90) to afford the title compound as a colourless

oil, 58mg; $^1\text{H-NMR}$ (CDCl_3 +1 drop TFAc, 400MHz) δ : 0.83 (t, 3H), 1.23 (m, 2H), 1.39 (m, 1H), 1.55-1.78 (m, 8H), 1.82 (m, 1H), 1.98 (m, 1H), 2.16 (m, 3H), 2.38 (m, 1H), 2.79 (m, 2H), 4.05 (t, 2H), 4.58 (m, 1H), 6.82 (m, 2H), 7.00 (m, 2H), 7.18 (d, 1H); LRMS : m/z (ES^-) 436 [M-H^-]; Microanalysis found: C, 59.87; H, 7.11; N, 3.02. $\text{C}_{23}\text{H}_{32}\text{FNO}_6$; 0.4 CH_2Cl_2 requires C, 59.61; H, 7.01; N, 2.97%.

Examples 43 to 45


The following examples of general formula:



10 were prepared from the corresponding ethyl esters following a similar procedure to that described in Example 42.

Ex. No	R	Data
43		$^1\text{H-NMR}$ (CDCl_3 , 400MHz) δ : 0.82 (t, 3H), 1.24 (m, 3H), 1.40-1.80 (m, 8H), 1.98 (m, 2H), 2.16 (m, 3H), 2.37 (m, 1H), 2.62 (m, 1H), 2.79 (m, 1H), 4.02 (m, 2H), 4.43 (m, 1H), 6.62 (m, 3H), 7.01 (m, 1H), 7.20 (m, 1H); LRMS : m/z (ES^+) 460 [MNa^+]; $[\alpha]_D = -17.15$ (c = 0.07, methanol)
44 ^a		$^1\text{H-NMR}$ (CDCl_3 , 400MHz) δ : 0.84 (t, 3H), 1.26 (m, 3H), 1.42-1.70 (m, 7H), 1.78 (dd, 1H), 1.98 (m, 2H), 2.16 (m, 3H), 2.26 (s, 3H), 2.39 (m, 1H), 2.60 (dd, 1H), 2.80 (dd, 1H), 4.02 (m, 2H), 4.42 (m, 1H), 6.78 (d, 2H), 7.04 (m, 3H); LRMS : m/z (ES^-) 432 [M-H^-]
45 ^a		$^1\text{H-NMR}$ (CDCl_3 , 400MHz) δ : 0.84 (t, 3H), 1.26 (m, 3H), 1.42-1.80 (m, 8H), 1.98 (m, 3H), 2.18 (m, 2H), 2.38 (m, 1H), 2.62 (dd, 1H), 2.80 (dd, 1H), 4.04 (m, 2H), 4.42 (m, 1H), 6.85 (d, 2H), 6.97 (m, 1H), 7.04 (d, 1H), 7.25 (d, 2H); LRMS : m/z (ES^+) 420 [MH^+]; $[\alpha]_D = -19.20$ (c = 0.10, methanol)


a-product purified by reverse phase HPLC using acetonitrile:water:trifluoroacetic acid as eluant

Example 46(3R)-3-[(1-[(2S)-2-Carboxy-4-methoxybutyl]cyclopentyl)carbonyl]amino]-5-(4-chlorophenoxy)pentanoic acid

- 5 A solution of the ester from preparation 80 (295mg, 0.51mmol) in trifluoroacetic acid (1ml) and dichloromethane (4ml) was stirred at room temperature for 4 hours. The solution was concentrated under reduced pressure and then azeotroped with toluene. The residue was partitioned between saturated sodium bicarbonate solution and dichloromethane, the layers separated and the aqueous extracted with dichloromethane.
- 10 The pH of the aqueous solution was adjusted to 1 using hydrochloric acid (2N), and this was then extracted with dichloromethane (3x). These combined organic extracts were dried (MgSO_4) and evaporated under reduced pressure to afford the title compound as a colourless solid, 134mg; $^1\text{H-NMR}$ (CDCl_3 , 400MHz) δ : 1.40-1.74 (m, 7H), 1.80-1.99 (m, 4H), 2.08 (m, 3H), 2.41 (m, 1H), 2.63 (dd, 1H), 2.78 (dd, 1H), 3.24 (s, 3H), 3.38 (m, 2H),
- 15 3.98 (s, 2H), 4.55 (m, 1H), 6.62 (m, 1H), 6.78 (d, 2H), 7.20 (d, 2H); LRMS : m/z (ES^-) 468 [M-H^-]; Microanalysis found: C, 57.76; H, 6.88; N, 3.03. $\text{C}_{23}\text{H}_{32}\text{ClNO}_7 \cdot 0.5\text{H}_2\text{O}$ requires C, 57.68; H, 6.94; N, 2.92%.

Example 47

- 20 Ethyl (3S)-3-[(1-[(2S)-2-Carboxy-4-methoxybutyl]cyclopentyl)carbonyl]amino]-5-(4-chlorophenoxy)pentanoate




A solution of the ester from preparation 81 (300mg, 0.54mmol) and trifluoroacetic acid (5ml) in dichloromethane (5ml) was stirred at room temperature for 2 hours. The mixture

was concentrated under reduced pressure and the residue azeotroped with toluene. The crude product was purified by column chromatography on reverse phase silica gel using an elution gradient of acetonitrile:water:trifluoroacetic acid (5:95:0.1 to 95:5:0) to afford the title compound as a colourless oil, 109mg; $^1\text{H NMR}$ (CDCl_3 , 400MHz) δ : 1.28 (t, 3H), 1.54-1.75 (m, 8H), 1.98 (m, 3H), 2.06 (m, 3H), 2.50 (m, 1H), 2.63 (m, 2H), 3.25 (s, 3H), 3.38 (m, 2H), 4.00 (t, 2H), 4.18 (q, 2H), 4.43 (m, 1H), 6.81 (m, 3H), 7.22 (d, 2H); LRMS : m/z (ES^-) 496 [M-H] $^-$.

Example 48


10 (3S)-3-[(1-[(2S)-2-Carboxy-4-methoxybutyl]cyclopentyl)carbonyl]amino]-5-(4-chlorophenoxy)pentanoic acid



A solution of the ethyl ester from example 47 (100mg, 0.20mmol) and 2N sodium hydroxide solution (2ml) in dioxan (4ml) was stirred at 50°C for 3 hours, then concentrated under reduced pressure. The residue was suspended in 2N hydrochloric acid (2ml), extracted with ethyl acetate (3x20ml), and the combined organic solutions dried (MgSO_4) and evaporated under reduced pressure. The crude product was purified by column chromatography on silica gel using an elution gradient of ethyl acetate:methanol:acetic acid (90:10:0 to 90:10:1) to afford the title compound as a colourless oil, 50mg; $^1\text{H NMR}$ (CDCl_3 , 400MHz) δ : 1.45-1.78 (m, 8H), 1.85-2.19 (m, 6H), 2.56 (m, 1H), 2.62 (m, 2H), 3.37 (m, 4H), 3.46 (m, 1H), 4.00 (t, 2H), 4.62 (m, 1H), 6.64 (d, 1H), 6.81 (d, 2H), 7.22 (d, 2H); LRMS : m/z (ES^-) 468 [M-H] $^-$.

Example 49

(2S)-2-({1-[(1S)-3-Butoxy-1-[2-(4-chlorophenoxy)ethyl]-3-oxopropyl]amino}carbonyl)-cyclopentyl)methyl)-4-methoxybutanoic acid




- 5 A solution of the ester from preparation 92 (278mg, 0.48mmol) and trifluoroacetic acid (3ml) in dichloromethane (5ml) was stirred at room temperature for 2 hours. The mixture was concentrated under reduced pressure and the residue azeotroped with toluene. The crude product was purified by column chromatography on silica gel using an elution gradient of ethyl acetate:pentane (30:70 to 50:50) to afford the title compound as a
- 10 colourless oil, 229mg; ¹H NMR (CDCl₃, 400MHz) δ: 0.95 (t, 3H), 1.40 (m, 2H), 1.45-1.75 (m, 10H), 1.95 (m, 3H), 2.05 (m, 3H), 2.50 (m, 1H), 2.65 (m, 2H), 3.25 (s, 3H), 3.35 (m, 2H), 4.00 (t, 2H), 4.05 (t, 2H), 4.45 (m, 1H), 6.80 (m, 3H), 7.20 (d, 2H); Microanalysis found: C, 60.39; H, 7.50; N, 2.49. C₂₇H₄₀ClNO₇·0.6H₂O requires C, 60.40; H, 7.74; N, 2.61%; [α]_D = -14.8 (c = 0.17, methanol)

15

Example 50

(3S)-3-[(1-[(2R)-2-(Ethoxycarbonyl)pentyl]cyclopentyl]carbonyl)amino]-4-[(3-methoxybenzyl)oxy]butanoic acid




- 20 Pyrrolidine (39μl, 0.46mmol) and tetrakis(triphenylphosphine)palladium(0) (10mg) were added to a solution of the allyl ester from preparation 35 (60mg, 0.116mmol) in tetrahydrofuran (2ml), and the reaction stirred at room temperature for 2 hours. The mixture was partitioned between hydrochloric acid (1N) and ethyl acetate, the layers


separated, and the organic phase dried (MgSO_4) and concentrated under reduced pressure. The residual orange oil was purified by column chromatography on silica gel using an elution gradient of dichloromethane:methanol:acetic acid (99:1:0 to 97:3:0.3) to afford the title compound as a colourless solid, 15mg; $^1\text{H NMR}$ (CDCl_3 , 400MHz) δ : 0.84 (t, 3H), 1.22 (m, 5H), 1.30-1.63 (m, 8H), 1.75 (dd, 1H), 1.84 (m, 1H), 1.96-2.07 (m, 2H), 2.35 (m, 1H), 2.70 (m, 2H), 3.56 (m, 1H), 3.60 (m, 1H), 3.80 (s, 3H), 4.09 (m, 2H), 4.40 (m, 1H), 4.50 (s, 2H), 6.42 (d, 1H), 6.83 (m, 3H), 7.24 (m, 1H); LRMS : m/z (ES^+) 500 [MNa^+].

10 Example 51

(3S)-4-[(4-Chlorobenzyl)oxy]-3-[(1-[(2S)-2-(ethoxycarbonyl)-4-methoxybutyl]-cyclopentyl}carbonyl)amino]butanoic acid




Pyrrolidine (53mg, 0.74mmol) and tetrakis(triphenylphosphine)paladium(0) (20mg) were added to a solution of the allyl ester from preparation 36 (100mg, 0.186mmol) in tetrahydrofuran (4ml), and the reaction stirred at room temperature for 3 hours. The mixture was diluted with hydrochloric acid (1N, 30ml), the aqueous solution extracted with dichloromethane (3x30ml), the combined organic solutions washed with water (50ml), and dried (MgSO_4) and concentrated under reduced pressure. The residual yellow oil was purified by column chromatography on silica gel using an elution gradient of dichloromethane:methanol (98:2 to 92:8) to afford the title compound as a colourless oil, 42mg; $^1\text{H NMR}$ (CDCl_3 , 400MHz) δ : 1.22 (t, 3H), 1.41-1.72 (m, 7H), 1.82 (m, 3H), 1.95-2.05 (m, 2H), 2.46 (m, 1H), 2.64 (m, 2H), 3.28 (m, 4H), 3.38 (m, 1H), 3.46-3.59 (m, 2H), 4.08 (m, 2H), 4.46 (s, 3H), 6.38 (d, 1H), 7.22 (d, 2H), 7.30 (d, 2H); LRMS : m/z (APCI) 498 [MH^+]

Example 52Ethyl (3S)-3-[(1-[(2S)-2-carboxy-4-methoxybutyl]cyclopentyl)carbonyl]amino]-6-(4-chlorophenyl)hexanoate

- 5 A solution of the diester from preparation 97 (200mg, 0.36mmol) in dichloromethane (15ml) and trifluoroacetic acid (6ml) was stirred at room temperature for 18 hours. The mixture was concentrated under reduced pressure and the residue partitioned between dichloromethane (75ml) and water (75ml). The layers were separated, the organic phase dried (MgSO₄) and evaporated under reduced pressure to afford the title compound, as
- 10 a colourless oil, 180mg; ¹H NMR (CDCl₃, 400MHz) δ: 1.22 (t, 3H), 1.44-1.78 (m, 13H), 1.90-2.00 (m, 3H), 2.42-2.62 (m, 5H), 3.22 (s, 3H), 3.37 (m, 2H), 4.15 (q, 2H), 4.26 (m, 1H), 6.80 (d, 1H), 7.08 (d, 2H), 7.22 (d, 2H).

Example 53

- 15 (3S)-3-[(1-[(2S)-2-carboxy-4-methoxybutyl]cyclopentyl)carbonyl]amino]-6-(4-chlorophenyl)hexanoic acid




- 20 A solution of the ester from example 52 (60mg, 0.12mmol) in dioxan (4ml) and 1N sodium hydroxide (4ml) was stirred at room temperature for 5 hours. The mixture was concentrated under reduced pressure and the residue partitioned between water (20ml) and ethyl acetate (20ml). The layers were separated, the aqueous acidified to pH 1 using hydrochloric acid, and this solution then re-extracted with ethyl acetate (2x20ml). These combined organic extracts were dried (MgSO₄) and evaporated under reduced

pressure to afford the title compound, 49mg; $^1\text{H NMR}$ (CDCl_3 , 400MHz) δ : 1.42-1.78 (m, 10H), 1.97 (m, 3H), 2.16 (m, 1H), 2.40-2.70 (m, 6H), 3.37 (m, 5H), 3.44 (m, 1H), 4.42 (m, 1H), 6.38 (d, 1H), 7.07 (d, 2H), 7.21 (d, 2H).

5 Example 54


(3S)-3-[(1-[(2S)-2-carboxy-4-methoxybutyl]cyclopentyl)carbonyl]amino]-6-(4-methoxyphenyl)hexanoic acid



A solution of the ester from preparation 98 (17mg, 0.03mmol) in trifluoroacetic acid
 10 (0.5ml) and dichloromethane (2ml) was stirred at room temperature for 18 hours. The
 reaction was concentrated under reduced pressure and the residue partitioned between
 dichloromethane and water, and the layers separated. The organic phase was dried
 (MgSO_4) and evaporated under reduced pressure. The product was purified by Fraction-
 Lynx® reverse phase HPLC using a Phenomenex Luna C18 column and
 15 acetonitrile:water:trifluoroacetic acid (5:95:0.1 to 95.25:4.75:0.005) as eluant to give the
 title compound; $^1\text{H NMR}$ (CD_3OD , 400MHz) δ : 1.40-1.86 (m, 12H), 1.97-2.16 (m, 4H),
 2.38-2.62 (m, 5H), 3.22 (s, 3H), 3.50 (m, 2H), 3.76 (s, 3H), 4.30 (m, 1H), 6.80 (d, 2H),
 7.06 (d, 2H); LRMS: m/z (ES^-) 462 [$\text{M}-\text{H}$] $^-$.

20 Preparation 1

1-[(2S)-2-(*tert*-Butoxycarbonyl)-4-methoxybutyl]cyclopentanecarboxylic acid




To a solution of 1-[2-(*tert*-butoxycarbonyl)-4-methoxybutyl]cyclopentane carboxylic acid
 (WO 0202513) (3.90 kg, 13.0 mol) in heptane (58.5 L, total solution weight 44.0 kg) was
 25 added (1S, 2S)-(+)-pseudoephedrine (2.13 kg, 12.9 mol) under an atmosphere of
 nitrogen at 20 °C. The suspension was then heated to 70 °C with stirring until a clear

solution was obtained. The solution was then cooled to 40 °C and a sample of authentic crystallised title compound (0.8 g) was added to seed the crystallisation. The temperature of the mixture was maintained at 40 °C for 2 hours and then the slurry was cooled to 20 °C over 6 hours. The product was then collected by filtration and was washed with heptane (2 x 2.3 L) then dried under vacuum for 22 hours at 50 °C to give (1*S*, 2*S*)-1-hydroxy-*N*-methyl-1-phenyl-2-propanaminium 1-[(2*S*)-2-(*tert*-butoxy carbonyl)-4-methoxybutyl]cyclopentane carboxylate (3.20 kg, 6.87 mol, 53% yield as an 86:14 mixture of diastereoisomeric salts as measured by ¹H NMR). The product (3.20 kg, 6.87 mol) was then suspended in heptane (30 L) and heated to 70 °C until a clear solution was obtained. The resultant solution was then cooled to 58 °C and a sample of authentic crystallised title compound (1.0 g) was added to seed the crystallisation. The solution was then held at 58 °C for 1 hour and was then cooled to 20 °C over 6 hours. The slurry was then granulated at 20 °C for 12 hours. The product was collected by filtration and was washed with heptane (2 x 2 L). Drying in a vacuum oven at 50 °C for 22.5 hours gave (1*S*, 2*S*)-1-hydroxy-*N*-methyl-1-phenyl-2-propanaminium 1-[(2*S*)-2-(*tert*-butoxycarbonyl)-4-methoxybutyl]cyclopentane carboxylate as a white crystalline solid (2.35 kg, 5.0 mol, 73% yield). m.p. (heptane); 95 °C; ¹H-NMR (CDCl₃, 300 MHz), δ : 1.08 (d, 3 H), 1.48 (s, 10 H), 1.56-1.74 (m, 4 H), 1.74-1.90 (m, 2 H), 1.90-2.03 (m, 2 H), 2.03-2.27 (m, 2 H), 2.4-2.53 (m, 1 H), 2.66 (s, 3 H), 3.08 (dq, 1 H), 3.24 (s, 3 H), 3.38 (q, 2 H), 4.58 (d, 1 H), 7.27-7.45 (m, 5 H), 7.70 (s, br, 3 H); Anal. found C, 67.06; H, 9.35; N, 3.04; C₂₆H₄₃NO₆ requires C, 67.07; H, 9.31; N, 3.01%. The title compound was obtained by breaking the salt as follows. To a stirred suspension of (1*S*, 2*S*)-1-hydroxy-*N*-methyl-1-phenyl-2-propanaminium 1-[(2*S*)-2-(*tert*-butoxycarbonyl)-4-methoxybutyl]cyclopentane carboxylate (210 g, 0.45 mol) in deionised water (1.26 L) and isopropyl acetate (1.47 L) was added aqueous hydrochloric acid (99.5 ml of a 5 M solution, 0.50 mol) until the pH of the aqueous layer was between pH 2 and 3. The layers were then separated, and the aqueous phase was extracted with isopropyl acetate (630 ml). The organic extracts were then combined and washed with saturated brine solution (420 ml). The organic phase was then concentrated by distillation at atmospheric pressure (to remove 1.4 L of isopropyl acetate) to the title compound as a solution in isopropyl acetate which was used directly in the next step. An aliquot can be taken and the solvent removed to give an analytical sample; ¹H NMR (CDCl₃ 300MHz) δ : 1.44 (s, 9 H), 1.48-1.59 (m, 2 H), 1.59-1.72 (m, 5 H), 1.72-1.93 (m, 2 H), 2.03-2.18 (m, 3 H), 2.35-2.46 (m, 1 H), 3.31 (s, 3 H), 3.38 (t, 2 H); LRMS (EI): m/z 244 [M-C₄H₈]⁺, 227 [M-C₄H₉O]⁺, 199 [M-C₄H₉O₂C]⁺; GC (injector program: initial temp. 0 °C, rate 150 °C/min, final temp. 230 °C; oven program: initial temp. 100 °C, rate 10 °C/min, final temp. 230 °C, final time 20 min; column, BP-21


25 m x 0.25mm ID x 0.25um FT; detection FID) Retention Time 16.0 min; HPLC (column: ChiralPak AD (25 x 0.46 cm); mobile phase: hexane/IPA/acetic acid (98/2/0.1 v/v/v); Rinsing mobile phase: hexane/IPA/DEA (80/20/.5 v/v/v); flow rate: 1.0 ml/min; temperature: ambient; injection volume: 20 µl; detection: ELSD) Run time: 20 mins
 5 followed by 10 mins rinse with hexane/IPA/DEA (80/20/.5 v/v/v), followed by 10 mins rinse with hexane/IPA/acetic acid (98/2/0.1 v/v/v); Retention Time: minor enantiomer 15.5 min (3.3%), major enantiomer 17.5 min (96.7%).

Preparation 2

10 *tert*-Butyl (2*R*)-2-([1-({[(3*S*)-5-oxotetrahydro-3-furanyl]amino}carbonyl)-cyclopentyl]methyl}pentanoate




A mixture of 3(*S*)-amino-γ-butyrolactone hydrobromide (J.A.C.S; 1986; 108(16), 4943) (7g, 38mmol), 1-[(2*R*)-2-(*tert*-butyloxycarbonyl-pentyl)]-cyclopentanecarboxylic acid (WO
 15 0202513) (11.4g, 40mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (7.7g, 40mmol), 1-hydroxybenzotriazole hydrate (5.4g, 40mmol) and 4-methylmorpholine (22ml, 200mmol) in dichloromethane (200ml) was stirred at room temperature for 18 hours. The mixture was washed with water, hydrochloric acid (2N), then dried (MgSO₄) and concentrated under reduced pressure. The crude product was purified by column
 20 chromatography on silica gel using an elution gradient of dichloromethane:methanol (99:1 to 98:2) to afford the title compound as a colourless oil, 12.6g; ¹H NMR (CDCl₃, 400MHz) δ: 0.85 (t, 3H), 1.27 (m, 3H), 1.40-1.68 (m, 17H), 1.88-2.14 (m, 3H), 2.19 (m, 1H), 2.54 (dd, 1H), 2.84 (dd, 1H), 4.19 (dd, 1H), 4.54 (dd, 1H), 4.66 (m, 1H), 6.43 (d, 1H); LRMS : m/z (ES⁺) 390 [MNa⁺]; Microanalysis found: C, 62.28; H, 9.26; N, 3.54.
 25 C₂₀H₃₃NO₅ requires C, 62.31; H, 9.15; N, 3.63%.

Preparation 3*tert*-Butyl (2*R*)-2-[1-({[(3*R*)-5-oxotetrahydro-3-furanyl]amino}carbonyl)cyclopentyl]-methyl}pentanoate

5 3(*R*)-Amino- γ -butyrolactone hydrobromide (US 5252747, compound 25) (6.2g, 34mmol) was added to a solution of 1-[(2*R*)-2-(*tert*-butyloxycarbonyl-pentyl)]-cyclopentanecarboxylic acid (WO 0202513, preparation 2) (9.9g, 34.8mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (8.65g, 44.3mmol), 1-hydroxybenzotriazole hydrate (6.22g, 41.8mmol) and 4-methylmorpholine (14g, 138mmol) in dichloromethane (200ml) and the reaction was stirred at room temperature for 72 hours. The mixture was concentrated under reduced pressure and the residue partitioned between ethyl acetate and brine. The organic phase was dried (MgSO₄) and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel using an elution gradient of dichloromethane:methanol (99:1 to 90:10). The product was triturated with a solution of ether:pentane (20:80) and the resulting precipitate filtered and dried to afford the title compound, 6.3g.


15 ¹H NMR (CDCl₃, 400MHz) δ : 0.86 (t, 3H), 1.20-1.39 (m, 3H), 1.40-1.75 (m, 17H), 1.90 (m, 1H), 1.99 (dd, 1H), 2.06 (m, 1H), 2.20 (m, 1H), 2.44 (dd, 1H), 2.84 (dd, 1H), 4.22 (dd, 1H), 4.56 (dd, 1H), 4.66 (m, 1H), 6.22 (d, 1H); LRMS : m/z (ES⁺) 390 [MNa⁺]; [α]_D = 20 +21.9 (c = 0.104, methanol).

Preparation 4*tert*-Butyl (2*S*)-4-methoxy-2-[1-({[(3*S*)-5-oxotetrahydro-3-furanyl]amino}carbonyl)-cyclopentyl]methyl}butanoate

The title compound was obtained as a colourless oil in 82% yield, from the acid from preparation 1 and 3-(*S*)-amino- γ -butyrolactone hydrobromide (J.A.C.S; 1986; 108(16), 4943) following a similar procedure to that described in preparation 2; $^1\text{H-NMR}$ (CDCl_3 , 400MHz) δ : 1.41 (m, 11H), 1.50-1.80 (m, 7H), 2.01 (m, 3H), 2.35 (m, 1H), 2.55 (m, 1H), 2.82 (m, 1H), 3.26 (s, 3H), 3.35 (m, 2H), 4.10 (dd, 1H), 4.52 (m, 1H), 4.65 (m, 1H), 6.46 (br d, 1H); LRMS : m/z (APCI) 384 [MH^+]; Microanalysis found: C, 61.30; H, 8.55; N, 3.60. $\text{C}_{20}\text{H}_{33}\text{NO}_6 \cdot 0.1\text{CH}_2\text{Cl}_2$ requires C, 61.60; H, 8.40; N, 3.57%.

Preparation 5

10 *tert*-Butyl (2*S*)-4-methoxy-2-[[1-(((3*R*)-5-oxotetrahydro-3-furanyl)amino)carbonyl]-cyclopentyl]methyl]butanoate




The title compound was obtained as a colourless oil from 3(*R*)-amino- γ -butyrolactone hydrobromide (US 5252747, compound 25) and the acid from preparation 1, following a similar procedure to that described in preparation 4, except the compound was purified by column chromatography on silica gel using an elution gradient of ethyl acetate:pentane (50:50 to 75:25); $^1\text{H-NMR}$ (CDCl_3 , 400MHz) δ : 1.42 (m, 11H), 1.58-1.82 (m, 7H), 1.92-2.08 (m, 3H), 2.35 (m, 1H), 2.46 (m, 1H), 2.82 (dd, 1H), 3.34 (m, 5H), 4.22 (dd, 1H), 4.54 (m, 1H), 4.65 (m, 1H), 6.44 (br d, 1H); LRMS : m/z (ES^+) 406 [MNa^+].

20

Preparation 6


(3*S*)-3-[[1-[(2*R*)-2-(*tert*-Butoxycarbonyl)pentyl]cyclopentyl]carbonyl]amino]-4-hydroxybutanoic acid



Sodium hydroxide solution (60ml, 1M, 60mmol) was added to a solution of the lactone from preparation 2 (12.5g, 34mmol) in methanol (200ml), and the solution stirred at room temperature for 18 hours. The mixture was concentrated under reduced pressure and the residue diluted with water. The aqueous solution was washed with ethyl acetate, acidified with hydrochloric acid (2N), and this solution extracted with ethyl acetate. The combined organic extracts were dried (MgSO₄), and evaporated under reduced pressure to give a colourless oil. This was triturated with ether, the solid filtered and dried, to afford the title compound as a white solid, 7.55g; ¹H NMR (CDCl₃, 400MHz) δ: 0.90 (t, 3H), 1.23-1.40 (m, 3H), 1.42-1.76 (m, 16H), 1.92-2.16 (m, 4H), 2.24 (m, 1H), 2.75 (m, 2H), 3.78 (d, 2H), 4.21 (m, 1H), 6.62 (d, 1H); LRMS : m/z (ES⁺) 386 [MH⁺]

Preparation 7

(3R)-3-[(1-[(2R)-2-(*tert*-Butoxycarbonyl)pentyl]cyclopentyl)carbonyl]amino]-4-hydroxybutanoic acid




15

The title compound was obtained from the lactone from preparation 3, following a similar procedure to that described in preparation 6; ¹H NMR (CDCl₃, 400MHz) δ: 0.86 (t, 3H), 1.20-1.38 (m, 3H), 1.40-1.79 (m, 16H), 1.90 (m, 2H), 2.14 (m, 2H), 2.21 (m, 1H), 2.62 (d, 2H), 3.68 (dd, 1H), 3.79 (dd, 1H), 4.32 (m, 1H), 6.60 (d, 1H).

20

Preparation 8

(3S)-3-[(1-[(2S)-2-(*tert*-Butoxycarbonyl)-4-methoxybutyl]cyclopentyl)carbonyl]amino]-4-hydroxybutanoic acid




The title compound was obtained from the compound from preparation 4, following a similar procedure to that described in preparation 6; $^1\text{H-NMR}$ (CDCl_3 , 400MHz) δ : 1.44 (m, 11H), 1.58-1.82 (m, 7H), 2.00 (m, 3H), 2.38 (m, 1H), 2.65 (m, 2H), 3.34 (s, 3H), 3.42 (m, 2H), 3.72 (m, 2H), 4.26 (m, 1H), 6.60 (br d, 1H); LRMS : m/z (APCI) 402 [MH^+]

5 Microanalysis found: C, 59.71; H, 8.81; N, 3.47. $\text{C}_{20}\text{H}_{35}\text{NO}_7$ requires C, 59.85; H, 8.73; N, 3.49%.

Preparation 9


10 (3S)-3-[(1-[(2R)-2-(tert-Butoxycarbonyl)-4-methoxybutyl]cyclopentyl]carbonyl)amino]-4-hydroxybutanoic acid



The title compound was obtained as a colourless oil in 64% yield from the lactone from preparation 5, following a similar procedure to that described in preparation 6; $^1\text{H-NMR}$ (CDCl_3 , 400MHz) δ : 1.42 (m, 11H), 1.58-1.82 (m, 7H), 1.92-2.03 (m, 3H), 2.38 (m, 1H), 2.62 (m, 2H), 3.30 (m, 4H), 3.42 (m, 1H), 3.64 (dd, 1H), 3.78 (dd, 1H), 4.38 (m, 1H), 6.54 (d, 1H); LRMS : m/z (ES^+) 424 [MNa^+].

Preparation 10

20 (3S)-3-[(1-[(2R)-2-(tert-Butoxycarbonyl)pentyl]cyclopentyl]carbonyl)amino]-4-[(3-methoxybenzyl)oxy]butanoic acid




Sodium hydride (60% dispersion in mineral oil, 935mg, 24mmol) was added to a cooled (-15°C) solution of the alcohol from preparation 6 (1g, 2.6mmol) in tetrahydrofuran (20ml), and the mixture stirred for 1 hour. 3-Methoxybenzyl bromide (862mg, 4.29mmol) and imidazole (52mg, 0.79mmol) were added and the reaction stirred for a further hour

at -15°C, and then allowed to warm to room temperature, and stirred for a further 3 hours. The reaction was quenched by the addition of water, tetrahydrofuran was removed *in vacuo* and the residue acidified with 1N hydrochloric acid. This aqueous mixture was extracted with ethyl acetate (3x), the combined organic solutions were dried (MgSO₄) and evaporated under reduced pressure. The crude product was purified by column chromatography on silica gel using an elution gradient of dichloromethane:methanol (99:1 to 96:4) to afford the title compound as a clear oil; ¹H NMR (CDCl₃, 400MHz) δ: 0.84 (t, 3H), 1.20-1.37 (m, 3H), 1.44 (m, 12H), 1.56-1.75 (m, 5H), 1.85-2.03 (m, 3H), 2.20 (m, 1H), 2.70 (m, 2H), 3.54 (m, 1H), 3.60 (m, 1H), 3.80 (m, 3H), 4.42 (m, 1H), 4.48 (d, 2H), 6.42 (bd, 1H), 6.64 (m, 3H), 7.23 (m, 1H); LRMS : m/z (ES⁺) 528 [MNa⁺].

Preparations 11 to 14


The following preparations of general formula:



15

were prepared from the alcohol from preparation 6 and the corresponding benzyl bromides, following a similar procedure to that described in preparation 10.


Prep. No	R	Data
11		¹ H NMR (CDCl ₃ , 400MHz) δ: 0.81 (t, 3H), 1.18-1.70 (m, 20H), 1.88 (m, 2H), 2.00 (m, 1H), 2.19 (m, 1H), 2.65 (m, 2H), 3.52 (dd, 1H), 3.59 (dd, 1H), 4.40 (m, 1H), 4.45 (s, 2H), 6.40 (d, 1H), 6.74-7.04 (m, 3H), 7.24 (m, 1H). LRMS : m/z (ES ⁺) 494 [MH ⁺]
12		¹ H NMR (CDCl ₃ , 400MHz) δ: 0.84 (t, 3H), 1.20-1.77 (m, 20H), 1.98 (m, 3H), 2.21 (m, 1H), 2.65 (m, 2H), 3.58 (m, 2H), 4.46 (m, 3H), 6.43 (d, 1H), 7.02 (d, 2H), 7.24 (d, 2H). LRMS : m/z (ES ⁺) 494.57 [MH ⁺]
13 ^a		¹ H NMR (CDCl ₃ , 400MHz) δ: 0.82 (t, 3H), 1.18-1.70 (m, 19H), 1.82-2.02 (m, 3H), 2.18 (m, 1H), 2.64 (d, 2H), 3.55 (m, 3H), 4.42 (m, 3H), 6.40 (d, 1H), 7.24 (m, 4H); LRMS : m/z (ES ⁺) 532 [MNa ⁺]; [α] _D = -17.8 (c = 0.1, methanol)

Prep. No	R	Data
14		$^1\text{H NMR}$ (CDCl_3 , 400MHz) δ : 0.83 (t, 3H), 1.18-1.74 (m, 20H), 1.84-2.03 (m, 3H), 2.20 (m, 1H), 2.70 (d, 2H), 3.58 (m, 1H), 3.62 (m, 1H), 4.44 (m, 1H), 4.58 (s, 2H), 6.46 (d, 1H), 7.41 (d, 2H), 7.60 (d, 2H). LRMS : m/z (ES^+) 566 [MNa^+]

a= no imidazole was added to the reaction

Preparation 15


5 (3R)-3-[(1-[(2R)-2-(*tert*-Butoxycarbonyl)pentyl]cyclopentyl)carbonyl]amino]-4-[(4-chlorobenzyl)oxy]butanoic acid




The title compound was obtained in 13% yield from the alcohol from preparation 7 and 4-chlorobenzyl bromide, following a similar procedure to that described in preparation 10; $^1\text{H NMR}$ (CDCl_3 , 400MHz) δ : 0.83 (t, 3H), 1.20-1.38 (m, 3H), 1.40-1.75 (m, 17H),
10 1.84-2.02 (m, 3H), 2.20 (m, 1H), 2.64 (m, 2H), 3.58 (m, 2H), 4.40-4.56 (m, 3H), 6.45 (d, 1H), 7.23 (d, 2H), 7.30 (d, 2H); LRMS : m/z (ES^+) 532 [MNa^+].

Preparation 16

15 (3R)-3-[(1-[(2R)-2-(*tert*-Butoxycarbonyl)pentyl]cyclopentyl)carbonyl]amino]-4-[(3-methoxybenzyl)oxy]butanoic acid



The title compound was obtained in 10% yield from the alcohol from preparation 7 and 3-methoxybenzyl bromide, following a similar procedure to that described in preparation 10; $^1\text{H NMR}$ (CDCl_3 , 400MHz) δ : 0.83 (t, 3H), 1.20-1.36 (m, 3H), 1.40-1.74 (m, 17H),
20 1.88-2.02 (m, 3H), 2.20 (m, 1H), 2.70 (m, 2H), 3.59 (m, 2H), 3.80 (s, 3H), 4.40 (m, 1H), 4.50 (s, 2H), 6.45 (d, 1H), 6.84 (m, 3H), 7.24 (m, 1H); LRMS : m/z (ES^+) 528 [MNa^+].

Preparation 17(3S)-3-[(1-[(2S)-2-(*tert*-Butoxycarbonyl)-4-methoxybutyl]cyclopentyl)carbonyl]amino]-4-[(3-methoxybenzyl)oxy]butanoic acid


5

Imidazole (13mg, 0.19mmol) and sodium hydride (60% dispersion in mineral oil, 400mg, 10mmol) were added to a cooled (-15°C) solution of the alcohol from preparation 8 (400mg, 1.0mmol) in tetrahydrofuran (20ml), and the mixture stirred for 45 minutes. A solution of 3-methoxybenzyl bromide (221mg, 1.1mmol) was added and the reaction stirred for a further 2 hours at -15°C, and then allowed to warm to room temperature. Stirring was continued for a further 3 hours, then the flask cooled in an ice-bath. The reaction was quenched by the addition of water, diluted with 1N hydrochloric acid, and the mixture extracted with ethyl acetate. The combined organic solutions were dried (MgSO₄) and evaporated under reduced pressure. The crude product was purified by column chromatography on silica gel using an elution gradient of dichloromethane:methanol (98:2 to 92:8) to afford the title compound as a colourless oil, 66mg; ¹H NMR (CDCl₃, 400MHz, rotamers) δ: 1.40 (s, 9H), 1.45-2.05 (m, 13H), 2.35 (m, 1H), 2.62 (m, 2H), 3.30 (s, 3H), 3.32-3.60 (m, 3H), 3.78 (s, 3H), 4.45 (s, 2H), 4.47 (m, 1H), 6.20, 6.40 (2xd, 1H), 6.83 (m, 3H), 7.22 (d, 1H); LRMS : m/z (APCI) 522 [MH⁺].

20






Preparations 18 to 22

The following preparations of general formula:




were prepared from the alcohol from preparation 8 and the corresponding benzyl bromides, following a similar procedure to that described in preparation 17.

25

Prep. No	R	Data
18		$^1\text{H NMR}$ (CDCl_3 , 400MHz, rotamers) δ : 1.37-1.90 (m, 20H), 2.00 (m, 1H), 2.38 (m, 1H), 2.62 (m, 2H), 3.32 (m, 4H), 3.40-3.59 (m, 3H), 4.48 (s, 2H), 4.58 (m, 1H), 6.02, 6.26 (2xd, 1H), 7.22 (d, 2H), 7.32 (d, 2H); LRMS : m/z (APCI) 526 [MH^+]
19		$^1\text{H NMR}$ (CDCl_3 , 400MHz) δ : 1.41 (s, 9H), 1.43-1.80 (m, 8H), 1.86 (m, 3H), 2.01 (m, 1H), 2.38 (m, 1H), 2.70 (d, 2H), 3.35 (m, 4H), 3.40 (m, 1H), 3.61 (m, 2H), 4.59 (m, 3H), 6.36 (d, 1H), 7.23 (m, 2H), 7.37 (m, 1H), 7.40 (m, 1H); LRMS : m/z (APCI) 526 [MH^+]
20		$^1\text{H NMR}$ (CDCl_3 , 400MHz) δ : 1.42 (s, 9H), 1.43-1.78 (m, 8H), 1.83 (m, 3H), 2.00 (m, 1H), 2.38 (m, 1H), 2.64 (d, 2H), 3.30 (m, 4H), 3.40 (m, 1H), 3.54 (m, 2H), 4.46 (d, 2H), 4.56 (m, 1H), 6.24 (d, 1H), 7.17 (m, 1H), 7.23 (m, 3H); LRMS : m/z (APCI) 526 [MH^+]
21		$^1\text{H NMR}$ (CDCl_3 , 400MHz) δ : 1.42 (s, 9H), 1.45-1.80 (m, 9H), 1.85 (m, 3H), 2.01 (m, 1H), 2.39 (m, 1H), 2.65 (d, 2H), 3.35 (s, 3H), 3.40 (m, 1H), 3.57 (m, 2H), 4.45 (s, 2H), 4.57 (m, 1H), 6.28 (d, 1H), 7.00 (m, 1H), 7.15 (m, 2H); LRMS : m/z (ES^-) 526 [M-H^-]
22		$^1\text{H NMR}$ (CDCl_3 , 400MHz, rotamers) δ : 1.41-1.88 (m, 21H), 2.00 (m, 1H), 2.38 (m, 1H), 2.62 (d, 2H), 3.34, 3.40 (2xm, 4H), 3.56 (m, 2H), 4.56 (m, 3H), 6.00, 6.23 (2xd, 1H), 6.81 (m, 2H), 7.32 (m, 1H); LRMS : m/z (ES^-) 526 [M-H^-]

Preparation 23


(3R)-3-[(1-[(2S)-2-(tert-Butoxycarbonyl)-4-methoxybutyl]cyclopentyl)carbonyl]amino]-4-[(4-chlorobenzyl)oxy]butanoic acid



The title compound was obtained as a colourless oil in 30% yield from the alcohol from preparation 9 and 4-chlorobenzyl bromide, following the procedure described in preparation 17; $^1\text{H NMR}$ (CDCl_3 , 400MHz) (rotamers) δ : 1.36 (m, 1H), 1.41-1.88 (m, 18H), 2.01 (m, 1H), 2.18 (m, 1H), 2.40 (m, 1H), 2.62 (m, 2H), 3.34 (m, 4H), 3.50 (m, 3H), 4.47 (s, 2H), 4.59 (m, 1H), 6.00, 6.24 (2xd, 1H), 7.22 (d, 2H), 7.30 (d, 2H); LRMS : m/z (ES^+) 548 [MNa^+].

Preparation 24


tert-Butyl (2*R*)-2-[(1-[[[(1*S*)-3-ethoxy-1-[(3-methoxybenzyl)oxy]methyl]-3-oxopropyl]-amino]carbonyl]cyclopentyl)methyl]pentanoate



- 5 Potassium carbonate (61mg, 0.45mmol) and iodoethane (40 μ l, 0.49mmol) were added to a solution of the acid from preparation 10 (275mg, 0.45mmol) in N,N-dimethylformamide (5ml), and the reaction stirred at room temperature for 18 hours. The mixture was diluted with ethyl acetate (20ml), washed with water (x4) and brine, then dried (MgSO₄) and concentrated under reduced pressure. The residue was purified by
- 10 column chromatography on silica gel using an elution gradient of dichloromethane:methanol (100:0 to 99:1). The residue was azeotroped with xylene, ethyl acetate and dichloromethane to afford the title compound as a colourless oil, 250mg; ¹H NMR (CDCl₃, 400MHz) δ : 0.84 (t, 3H), 1.20-1.27 (m, 6H), 1.44 (m, 11H), 1.57-1.76 (m, 6H), 1.97 (m, 3H), 2.21 (m, 1H), 2.63 (m, 2H), 3.48 (m, 1H), 3.59 (m, 1H),
- 15 3.80 (s, 3H), 4.10 (q, 2H), 4.44 (m, 3H), 6.56 (br d, 1H), 6.84 (m, 3H), 7.24 (m, 1H); LRMS : m/z (ES⁺) 556 [MNa⁺].

Preparation 25

- 20 *tert*-Butyl (2*R*)-2-[(1-[[[(1*S*)-1-[(4-chlorobenzyl)oxy]methyl]-3-ethoxy-3-oxopropyl]amino]-carbonyl]cyclopentyl)methyl]pentanoate




A mixture of the acid from preparation 13 (190mg, 0.37mmol), iodoethane (13mg, 0.84mmol) and potassium carbonate (158.5mg, 1.15mmol) in N,N-dimethylformamide

(3ml) was stirred at room temperature for 72 hours. The mixture was poured into water (100ml), and extracted with ethyl acetate (3x100ml). The combined organic extracts were washed with brine (3x100ml), dried (MgSO₄) and evaporated under reduced pressure to afford the title compound as a pale yellow oil, 190mg; ¹H NMR (CDCl₃, 400MHz) δ: 0.82 (t, 3H), 1.18-1.78 (m, 23H), 1.98 (m, 3H), 2.20 (m, 1H), 2.61 (m, 2H), 3.50 (dd, 1H), 3.58 (dd, 1H), 4.10 (q, 2H), 4.42 (m, 3H), 6.54 (d, 1H), 7.24 (d, 2H), 7.30 (d, 2H); HRMS : m/z 538.2942 [MH⁺] C₂₉H₄₄ClNO₆ requires 538.2930; [α]_D = -15.8 (c =0.1, methanol).

10 Preparation 26


tert-Butyl (2*R*)-2-[(1-[(1*S*)-3-(allyloxy)-1-[(3-methoxybenzyl)oxy]methyl]-3-oxopropyl)amino]carbonyl]cyclopentyl)methyl]pentanoate



Potassium carbonate (38mg, 0.27mmol) and allyl bromide (27μl, 0.28mmol) were added to a solution of the acid from preparation 10 (140mg, 0.28mmol) in N,N-dimethylformamide (3ml), and the reaction stirred at room temperature for 18 hours. The mixture was partitioned between ethyl acetate and water, the layers separated, and the organic phase washed with water, dried (MgSO₄) and evaporated under reduced pressure to afford the title compound as a colourless oil, 120mg; ¹H NMR (CDCl₃, 400MHz) δ: 0.83 (t, 3H), 1.20-1.37 (m, 3H), 1.44 (m, 11H), 1.58-1.75 (m, 6H), 1.96 (m, 3H), 2.20 (m, 1H), 2.68 (m, 2H), 3.50 (m, 1H), 3.59 (m, 1H), 3.80 (s, 3H), 4.45 (m, 3H), 4.56 (m, 2H), 5.20-5.34 (m, 2H), 5.87 (m, 1H), 6.52 (m, 1H), 6.83 (m, 3H), 7.24 (m, 1H); LRMS : m/z (ES⁺) 568 [MNa⁺].

Preparation 27


tert-Butyl (2*S*)-2-[(1-[[[(1*S*)-1-[(4-chlorobenzyl)oxy]methyl]-3-ethoxy-3-oxopropyl]amino]-carbonyl]cyclopentyl)methyl]-4-methoxybutanoate



- 5 A mixture of the acid from preparation 18 (30mg, 0.06mmol), iodoethane (19mg, 0.12mmol) and potassium carbonate (24mg, 0.17mmol) in N,N-dimethylformamide (2ml) was stirred at room temperature for 18 hours. TLC showed starting material remaining, so additional iodoethane (19mg, 0.12mmol) was added and the reaction stirred at room temperature for a further 3 hours. The reaction was poured into water (30ml), potassium carbonate (50mg) added, and this mixture extracted with ethyl acetate (3x20ml). The combined organic extracts were washed with brine (20ml), dried (MgSO₄) and evaporated under reduced pressure to afford the title compound as a pale yellow oil, 31mg; ¹H NMR (CDCl₃, 400MHz) δ: 1.22 (t, 3H), 1.40-1.82 (m, 18H), 1.97 (m, 3H), 2.38 (m, 1H), 2.61 (m, 2H), 3.26 (m, 5H), 3.54 (m, 2H), 4.08 (m, 2H), 4.43 (m, 3H), 6.57 (m, 1H), 7.21 (d, 2H), 7.29 (d, 2H); HRMS : m/z (ESI) 554.2887 [MH⁺]; C₂₉H₄₄ClNO₇ requires 554.2879 [MH⁺].

Preparation 28


20 *tert*-Butyl (2*S*)-2-[(1-[[[(1*S*)-1-[(3-chlorobenzyl)oxy]methyl]-3-ethoxy-3-oxopropyl]amino]-carbonyl]cyclopentyl)methyl]-4-methoxybutanoate



The title compound was obtained as a pale yellow oil, from the acid from preparation 19 and iodoethane, following the procedure described in preparation 27; ^1H NMR (CDCl_3 , 400MHz, rotamers) δ : 1.22 (t, 3H), 1.40-1.80 (m, 18H), 1.97 (m, 3H), 2.38, 2.54 (2xm, 1H), 2.63 (m, 2H), 3.30 (m, 5H), 3.62 (m, 2H), 4.10 (m, 2H), 4.48 (m, 1H), 4.60 (m, 2H),
5 6.60, 6.70 (2xm, 1H), 7.21 (m, 2H), 7.36 (m, 1H), 7.40 (m, 1H); LRMS : m/z (APCI) 554 [MH^+].

Preparation 29


10 *tert*-Butyl (2*S*)-2-[(1-[[[(1*S*)-1-[(2-chlorobenzyl)oxy]methyl]-3-ethoxy-3-oxopropyl]amino]-carbonyl]cyclopentyl)methyl]-4-methoxybutanoate



The title compound was obtained as a pale yellow oil, from the acid from preparation 20 and iodoethane, following the procedure described in preparation 27; ^1H NMR (CDCl_3 , 400MHz) δ : 1.22 (t, 3H), 1.40 (m, 10H), 1.60 (m, 5H), 1.78 (m, 3H), 1.98 (m, 3H), 2.37
15 (m, 1H), 2.63 (m, 2H), 3.30 (m, 5H), 3.58 (m, 2H), 4.10 (q, 2H), 4.44 (m, 3H), 6.58 (d, 1H), 7.17-7.39 (m, 4H); HRMS : m/z (ESI) 554.2888 [MH^+] $\text{C}_{29}\text{H}_{44}\text{ClNO}_7$ requires 554.2879 [MH^+].

Preparation 30

20 *tert*-Butyl (2*S*)-2-[(1-[[[(1*S*)-1-[(3,4-difluorobenzyl)oxy]methyl]-3-ethoxy-3-oxopropyl]-amino]carbonyl]cyclopentyl)methyl]-4-methoxybutanoate




A mixture of the acid from preparation 21 (58mg, 0.11mmol), iodoethane (21mg, 0.13mmol) and potassium carbonate (36mg, 0.26mmol) in N,N-dimethylformamide (2ml) was stirred at room temperature for 18 hours. The mixture was diluted with water and extracted with ethyl acetate (3x). The combined organic extracts were washed with
 5 brine, dried (MgSO₄) and evaporated under reduced pressure to afford the title compound, 39mg; ¹H NMR (CDCl₃, 400MHz) δ: 1.23 (t, 3H), 1.40-1.82 (m, 18H), 1.98 (m, 3H), 2.37 (m, 1H), 2.63 (m, 2H), 3.24 (s, 3H), 3.32 (m, 2H), 3.50 (m, 1H), 3.58 (m, 1H), 4.10 (q, 2H), 4.42 (m, 3H), 6.58 (d, 1H), 7.00 (m, 1H), 7.13 (m, 2H); LRMS : m/z (APCI) 578 [MNa⁺].

10

Preparation 31

tert-Butyl (2*S*)-2-[(1-[[[(1*S*)-1-[(2,4-difluorobenzyl)oxy]methyl]-3-ethoxy-3-oxopropyl]-amino]carbonyl]cyclopentyl)methyl]-4-methoxybutanoate




15 A mixture of the acid from preparation 22 (53mg, 0.1mmol), iodoethane (24mg, 0.15mmol) and potassium carbonate (28mg, 0.2mmol) in N,N-dimethylformamide (2ml) was stirred at room temperature for 18 hours. The reaction was diluted with water and extracted with dichloromethane. The combined organic solutions were dried (MgSO₄) and concentrated under reduced pressure. The residue was purified by column
 20 chromatography on silica gel using dichloromethane:methanol (99:1 to 97.5:2.5) to afford the title compound as a colourless oil, 42mg; ¹H NMR (CDCl₃, 400MHz) δ: 1.22 (t, 3H), 1.40-1.80 (m, 18H), 1.98 (m, 3H), 2.35 (m, 1H), 2.63 (m, 2H), 3.26 (s, 3H), 3.32 (m, 2H), 3.50 (m, 1H), 3.60 (m, 1H), 4.08 (q, 2H), 4.43 (m, 1H), 4.52 (s, 2H), 6.58 (d, 1H), 6.78-6.88 (m, 2H), 7.36 (m, 1H); LRMS : m/z (ES⁺) 578 [MNa⁺].

25

Preparation 32


tert-Butyl (2*S*)-2-[(1-[[[(1*S*)-3-(allyloxy)-1-[[[4-chlorobenzyl]oxy]methyl]-3-oxopropyl]-amino]carbonyl]cyclopentyl)methyl]-4-methoxybutanoate



- 5 The title compound was obtained as a pale yellow oil in 86% yield, from the acid from preparation 18 and allyl bromide, following the procedure described in preparation 26. ¹H NMR (CDCl₃, 400MHz) δ: 1.40-1.82 (m, 18H), 1.98 (m, 3H), 2.38 (m, 1H), 2.68 (m, 2H), 3.27 (m, 5H), 3.50 (m, 1H), 3.58 (m, 1H), 4.44 (s, 3H), 4.57 (d, 2H), 5.22 (d, 1H), 5.30 (d, 1H), 5.85 (m, 1H), 6.58 (d, 1H), 7.22 (d, 2H), 7.30 (d, 2H); LRMS : m/z (APCI)
- 10 566 [MH⁺]; [α]_D = -18.8 (c = 0.1, methanol); Microanalysis found: C, 63.44; H, 7.91; N, 2.43. C₃₀H₄₄ClNO₇ requires C, 63.70; H, 7.78; N, 2.47%.

Preparation 33

- 15 (2*R*)-2-[(1-[[[(1*S*)-3-(Allyloxy)-1-[[[3-methoxybenzyl]oxy]methyl]-3-oxopropyl]amino]-carbonyl]cyclopentyl)methyl]pentanoic acid




- Trifluoroacetic acid (1ml) was added to a solution of the ester from preparation 26 (120mg, 0.20mmol) in dichloromethane (5ml) and the reaction stirred at room temperature for 3 hours. The mixture was concentrated under reduced pressure and the residue azeotroped with dichloromethane and ethyl acetate to afford the title compound, 110mg; ¹H NMR (CDCl₃, 400MHz) δ: 0.85 (t, 3H), 1.50 (m, 4H), 1.50-1.76 (m, 7H), 1.92-2.04 (m, 3H), 2.38 (m, 1H), 2.64 (m, 2H), 3.58 (m, 2H), 3.80 (s, 3H), 4.45 (m, 3H), 4.57
- 20

(d, 2H), 5.22 (d, 1H), 5.30 (d, 1H), 5.86 (m, 1H), 6.75 (d, 1H), 6.84 (m, 3H), 7.26 (m, 1H); LRMS : m/z (ES⁺) 490 [MH⁺].

Preparation 34

- 5 (2S)-2-[(1-[[[(1S)-3-(Allyloxy)-1-[[[(4-chlorobenzyl)oxy]methyl]-3-oxopropyl]amino]-carbonyl]cyclopentyl)methyl]-4-methoxybutanoic acid




The title compound was obtained as an orange oil, from the ester from preparation 32, following the procedure described in preparation 33; ¹H NMR (CDCl₃, 400MHz) δ: 1.55-1.74 (m, 8H), 1.97 (m, 3H), 2.10 (m, 1H), 2.56 (m, 1H), 2.62 (m, 2H), 3.26 (s, 3H), 3.38
10 (m, 2H), 3.57 (m, 2H), 4.43 (m, 3H), 4.56 (m, 2H), 5.21 (d, 1H) 5.27 (d, 1H), 5.84 (m, 1H), 6.64 (d, 1H), 7.21 (m, 2H), 7.30 (d, 2H); LRMS : m/z (ES⁺) 510 [MH⁺]; [α]_D = -16.67° (c = 0.06, methanol); Microanalysis found: C, 59.06; H, 6.96; N, 2.56. C₂₆H₃₆ClNO₇·H₂O requires C, 59.20; H, 7.21; N, 2.65%.

15

Preparation 35

- Ethyl (2R)-2-[(1-[[[(1S)-3-(allyloxy)-1-[[[(3-methoxybenzyl)oxy]methyl]-3-oxopropyl]-amino]carbonyl]cyclopentyl)methyl]pentanoate




20 The title compound was obtained as a pale yellow solid, from the acid from preparation 33 and iodoethane, following the procedure described in preparation 26; ¹H NMR (CDCl₃, 400MHz) δ: 0.82 (t, 3H), 1.21 (m, 6H), 1.30-1.65 (m, 7H), 1.78 (dd, 1H), 1.84-2.04 (m, 3H), 2.35 (m, 1H), 2.66 (m, 2H), 3.50 (m, 1H), 3.59 (m, 1H), 3.79 (s, 3H), 4.08

(m, 2H), 4.44 (m, 3H), 4.56 (d, 2H), 5.21 (d, 1H), 5.32 (d, 1H), 5.87 (m, 1H), 6.50 (d, 1H), 6.82 (m, 3H), 7.22 (m, 1H); LRMS : m/z (ES⁺) 540 [MNa⁺].

Preparation 36


5 Ethyl (2S)-2-[(1-[[[(1S)-3-(allyloxy)-1-[[4-(4-chlorobenzyl)oxy]methyl]-3-oxopropyl]amino]-carbonyl]cyclopentyl)methyl]-4-methoxybutanoate



A mixture of the acid from preparation 34 (280mg, 0.55mmol), iodoethane (200mg, 1.29mmol) and potassium carbonate (228mg, 1.65mmol) in N,N-dimethylformamide
 10 (3ml) was stirred at room temperature for 18 hours. The reaction was diluted with water (50ml) and extracted with ethyl acetate (3x50ml). The combined organic solutions were washed with brine (2x50ml), dried (MgSO₄) and evaporated under reduced pressure, to afford the title compound as a pale yellow oil, 241mg; ¹H NMR (CDCl₃, 400MHz) δ: 1.22 (t, 3H), 1.40-1.70 (m, 7H), 1.78-1.95 (m, 3H), 2.00 (m, 2H), 2.44 (m, 1H), 2.68 (m, 2H),
 15 3.28 (m, 5H), 3.50 (dd, 1H), 3.59 (dd, 1H), 4.10 (m, 2H), 4.44 (s, 3H), 4.56 (d, 2H), 5.22 (d, 1H), 5.30 (d, 1H), 5.88 (m, 1H), 6.57 (d, 1H), 7.22 (d, 2H), 7.31 (d, 2H); Microanalysis found: C, 62.12; H, 7.58; N, 2.68. C₂₈H₄₀ClNO₇ requires C, 62.45; H, 7.43; N, 2.60%.

Preparation 37

20 Sodium (3R)-3-[(*tert*-butoxycarbonyl)amino]-4-hydroxybutanoate




A solution of *N*^α-(*tert*-butyloxycarbonyl)-D-aspartic anhydride (J. Med. Chem. 1996; 3842) (19g, 88mmol) in tetrahydrofuran (150ml) was added dropwise to an ice-cooled suspension of sodium borohydride (3.4g, 88mmol) in tetrahydrofuran (75ml), and once
 25 addition was complete, the mixture was stirred for a further 2 hours. Acetic acid (30ml) was added dropwise and the mixture then evaporated under reduced pressure. The


residue was partitioned between water (150ml) and ether (150ml) and 2N hydrochloric acid (20ml) carefully added. The layers were separated, the aqueous phase further extracted with ether (2x150ml), and the combined organic solutions dried (MgSO₄) and evaporated under reduced pressure. The product was dissolved in 2N sodium hydroxide (50ml), and the solution stirred for 1 hour. The mixture was washed with ether (2x50ml), acidified with 2N hydrochloric acid (50ml) and extracted with dichloromethane (4x100ml). The combined dichloromethane extracts were dried (MgSO₄) and evaporated under reduced pressure. The acid product (7.8g, 35.6mmol) was dissolved in methanol (100ml) sodium hydroxide (1.42g, 35.6mmol) added, and the reaction stirred at room temperature for 1 hour. The mixture was evaporated under reduced pressure the residue azeotroped with toluene and then triturated with diisopropyl ether to afford the title compound as a white solid, 8.6g; ¹H NMR (DMSO-d₆, 400MHz) δ: 1.38 (s, 9H), 2.17 (m, 2H), 3.21-3.50 (m, 3H), 6.74 (d, 1H).

15 Preparation 38

Ethyl (3S)-4-(benzyloxy)-3-[(*tert*-butoxycarbonyl)amino]butanoate




A solution of cesium carbonate (3.53g, 10.9mmol) in water (22ml) was added to an ice-cooled solution of (3S)-4-(benzyloxy)-3-[(*tert*-butoxycarbonyl)amino]butanoic acid (3.36g, 10.9mmol) in methanol (70ml) and water (7ml), and the reaction stirred for 20 minutes. The mixture was concentrated under reduced pressure and azeotroped with N,N-dimethylformamide and dichloromethane. The residual oil was dissolved in N,N-dimethylformamide (70ml), ethyl iodide (1.64g, 10.9mmol) added, and the reaction stirred at room temperature for 18 hours. The mixture was concentrated under reduced pressure, suspended in ethyl acetate (300ml), washed with water (4x), brine, then dried (MgSO₄) and evaporated under reduced pressure. The residual oil was purified by column chromatography on silica gel using hexane:ethyl acetate (85:15) to afford the title compound as a pale yellow oil, 2.86g; ¹H NMR (CDCl₃, 400MHz) δ: 1.26 (t, 3H), 1.45 (s, 9H), 2.65 (d, 2H), 3.58 (m, 2H), 4.17 (m, 3H), 4.55 (s, 2H), 5.20 (bs, 1H), 7.36 (m, 5H).

Preparation 39(3R)-3-[(*tert*-Butoxycarbonyl)amino]-4-[(4-cyanobenzyl)oxy]butanoic acid


Sodium hydride (650mg, 60% in mineral oil, 16.25mmol), followed by imidazole (34mg,
 5 0.49mmol) were added portionwise to a cooled (-15°C) suspension of the acid from
 preparation 37 (600mg, 2.49mmol) in tetrahydrofuran (20ml), and the mixture then
 stirred for a further hour. 4-Cyanobenzyl bromide (540mg, 2.74mmol) was added, the
 mixture stirred at -15°C for 2 hours and then allowed to warm to room temperature and
 stirred for a further 18 hours. The reaction mixture was cooled in an ice-bath, water
 10 added carefully, followed by 1M hydrochloric acid, and the mixture extracted with ethyl
 acetate (3x100ml). The combined organic extracts were washed with brine (150ml),
 dried (MgSO₄) and evaporated under reduced pressure. The residual oil was purified by
 column chromatography on silica gel using dichloromethane:methanol (94:6) as eluant
 to afford the title compound as a yellow oil, 442mg; ¹H NMR (CDCl₃, 400MHz) δ: 1.42 (s,
 15 9H), 2.68 (d, 2H), 3.59 (m, 2H), 4.18 (m, 1H), 4.59 (s, 2H), 5.17 (m, 1H), 7.41 (d, 2H),
 7.62 (d, 2H); HRMS : m/z (ESI⁺) 357.1414 [MNa⁺] C₁₇H₂₂N₂O₅ requires C, 357.1421.

Preparation 405-(Bromomethyl)-2-methylpyridine hydrobromide

20 A solution of (6-methylpyridin-3-yl)methanol (J. Med. Chem. 43; 18; 2000; 3386)
 (492mg, 4mmol) and thionyl bromide (4.16g, 20mmol) in dichloromethane (20ml) was
 stirred at room temperature for 3 hours. The reaction was concentrated under reduced
 pressure and the residue azeotroped with dichloromethane. The residual red oil was
 triturated well with ether to afford the title compound as an orange powder, 1.39g; ¹H
 25 NMR (DMSO-d₆, 400MHz) δ: 2.64 (s, 3H), 4.81 (s, 2H), 7.81 (d, 1H), 8.42 (d, 1H), 8.84
 (s, 1H).

Preparation 41Ethyl (3*R*)-3-[(*tert*-butoxycarbonyl)amino]-4-[(4-cyanobenzyl)oxy]butanoate

A mixture of the acid from preparation 39 (410mg, 1.13mmol), potassium carbonate
 5 (468mg, 3.40mmol) and iodoethane (529mg, 3.40mmol) in N,N-dimethylformamide (5ml)
 was stirred at room temperature for 6 hours. The mixture was evaporated under reduced
 pressure, the residue suspended in brine (100ml) and extracted with ethyl acetate
 (3x80ml). The combined organic extracts were washed with brine (150ml), dried
 (MgSO₄) and evaporated under reduced pressure to afford the title compound as a
 10 yellow oil, 385mg; ¹H NMR (CDCl₃, 400MHz) δ: 1.22 (t, 3H), 1.42 (s, 9H), 2.62 (d, 2H),
 3.58 (m, 2H), 4.05-4.22 (m, 3H), 4.58 (m, 2H), 5.18 (m, 1H), 7.40 (d, 2H), 7.62 (d, 2H).
 HRMS : m/z (ESI⁺) 385.1726 [MNa⁺] C₁₉H₂₆N₂O₅ requires 385.1726.


Preparation 4215 (3*R*)-3-[(*tert*-Butoxycarbonyl)amino]-4-[(6-methylpyridin-3-yl)methoxy]butanoic acid

Sodium hydride (800mg, 60% dispersion in mineral oil, 20mmol) and imidazole (54mg,
 0.8mmol) were added portionwise to a cooled (-15°C) solution of the acid from
 20 preparation 37 (960mg, 4mmol) in tetrahydrofuran (40ml) and the solution stirred for 1
 hour. A suspension of the bromide from preparation 40 (1.28g, 4.8mmol) and N-methyl
 morpholine (535mg, 5.3mmol) in tetrahydrofuran (10ml) was added so as to maintain the
 temperature below -15°C, and the reaction then stirred for a further 2 hours. The
 reaction was allowed to warm to room temperature and stirred for a further 18 hours.
 25 The mixture was then basified to pH 11, washed with ethyl acetate, carefully acidified to
 pH 5 and extracted with ethyl acetate. These combined organic solutions were washed
 with brine, dried (MgSO₄) and evaporated under reduced pressure. The crude product

was purified by column chromatography on silica gel using dichloromethane:methanol (94:6) as eluant, and the product triturated with ether to afford the title compound, 177mg; $^1\text{H NMR}$ (CDCl_3 , 400MHz) δ : 1.42 (s, 9H), 2.62-2.80 (m, 5H), 3.64 (m, 2H), 4.18 (m, 1H), 4.60 (s, 2H), 5.50 (d, 1H), 7.40 (d, 1H), 7.83 (d, 1H), 8.62 (s, 1H); LRMS : m/z (ES $^-$) 323 [M-H] $^-$.

Preparation 43


Ethyl (3S)-3-amino-4-(benzyloxy)butanoate hydrochloride



10 Hydrogen chloride was bubbled through an ice-cooled solution of the protected amine from preparation 38 (2.8g, 8.3mmol) in ethyl acetate (40ml) for 15 minutes. The solution was evaporated under reduced pressure and azeotroped with diethyl ether to afford the title compound as an oil, 2.0g; $^1\text{H NMR}$ (CDCl_3 , 400MHz) δ : 1.20 (t, 3H), 2.84 (dd, 1H), 3.00 (dd, 1H), 3.58 (m, 2H), 3.90 (m, 1H), 4.10 (q, 2H), 4.58 (s, 2H), 7.30 (m, 5H), 8.60 (bs, 2H).

Preparation 44

Ethyl (3R)-3-amino-4-(4-cyanobenzyloxy)butanoate




20 A solution of the protected amine from preparation 41 (375mg, 1mmol) and trifluoroacetic acid (2ml) in dichloromethane (8ml) was stirred at room temperature for 3 hours. The reaction was concentrated under reduced pressure and the residue azeotroped with dichloromethane. The product was partitioned between ethyl acetate and saturated sodium bicarbonate solution, the layers separated, and the organic phase washed with brine, dried (MgSO_4) and evaporated under reduced pressure to give a yellow oil, 260mg. The crude product was purified by column chromatography on silica gel using dichloromethane:methanol (97.5:2.5) to afford the title compound as a

colourless oil, 180mg; $^1\text{H NMR}$ (CDCl_3 , 400MHz) δ : 1.22 (t, 3H), 2.65 (d, 2H), 3.57-3.70 (m, 3H), 4.16 (m, 2H), 4.60 (m, 2H), 7.43 (d, 2H), 7.63 (d, 2H); LRMS : m/z (ESI^+) 285 [MNa^+].

5 Preparation 45


Ethyl (3*R*)-3-amino-4-[(6-methylpyridin-3-yl)methoxy]butanoate dihydrochloride



A solution of the protected amine from preparation 42 (175mg, mmol) in ethanolic hydrogen chloride (6ml) was heated under reflux for 2 hours. The solution was concentrated under reduced pressure, the residue azeotroped with toluene and dried *in vacuo* to give the title compound as a colourless gum, 176mg; $^1\text{H NMR}$ (CD_3OD , 400MHz) δ : 1.27 (t, 3H), 2.80 (m, 5H), 3.79 (m, 1H), 3.86 (m, 2H), 4.20 (q, 2H), 4.82 (s, 2H), 7.97 (d, 1H), 8.54 (d, 1H), 8.78 (s, 1H); LRMS : m/z (ES^+) 275 [MNa^+].

15 Preparation 46

tert-Butyl (2*R*)-2-({1-[(*S*)-1-[(benzyloxy)methyl]-3-ethoxy-3-oxopropyl]amino)carbonyl-cyclopentyl}methyl)pentanoate




A solution of 1-[(2*R*)-2-(*tert*-butyloxycarbonyl-pentyl)]cyclopentanecarboxylic acid (WO 0202513, preparation 2) (156mg, 0.55mmol) in dichloromethane (1ml) was added to a solution of the amine from preparation 43 (150mg, 0.55mmol), 1-hydroxybenzotriazole hydrate (74mg, 0.55mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (105mg, 0.55mmol) and *N*-methyl morpholine (120 μl , 1.1mmol) in dichloromethane (5ml), and the reaction stirred at room temperature for 20 hours. The mixture was diluted with dichloromethane (20ml), washed with 1N hydrochloric acid (10ml), then water

(10ml), dried (MgSO_4) and evaporated under reduced pressure. The crude product was purified by column chromatography on silica gel using dichloromethane:methanol (100:0 to 95:5) to afford the title compound, 110mg; ^1H NMR (CDCl_3 , 300MHz) δ : 0.86 (t, 3H), 1.20-1.78 (m, 22H), 1.96-2.30 (m, 5H), 2.63 (m, 2H), 3.56 (dd, 1H), 3.60 (dd, 1H), 4.10 (q, 2H), 4.50 (m, 3H), 6.58 (d, 1H), 7.37 (m, 5H); LRMS : m/z (ES^+) 526 [MNa^+].

Preparation 47

tert-Butyl (2*R*)-2-[(1-[[[(1*R*)-1-[(4-cyanobenzyl)oxy]methyl]-3-ethoxy-3-oxopropyl]amino]-carbonyl]cyclopentyl)methyl]pentanoate




10

The amine from preparation 44 (160mg, 0.61mmol), was added to a solution of 1-[(2*R*)-2-(*tert*-butyloxycarbonyl-pentyl)]-cyclopentanecarboxylic acid (WO 0202513, preparation 2) (191mg, 0.67mmol), 1-hydroxybenzotriazole hydrate (108mg, 0.80mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (141mg, 0.74mmol) and *N*-methyl morpholine (169mg, 1.7mmol) in dichloromethane (6ml), and the reaction stirred at room temperature for 18 hours. The reaction was diluted with ethyl acetate, washed with water (2x), then brine, dried (MgSO_4) and evaporated under reduced pressure. The residual gum was purified by column chromatography on silica gel using an elution gradient of dichloromethane:methanol (100:0 to 99:1) to afford the title compound as a viscous oil, 240mg; ^1H NMR (CDCl_3 , 400MHz) δ : 0.83 (t, 3H), 1.22 (m, 6H), 1.40-1.77 (m, 17H), 1.97 (m, 3H), 2.20 (m, 1H), 2.62 (m, 2H), 3.60 (m, 2H), 4.10 (q, 2H), 4.50 (m, 1H), 4.60 (s, 2H), 6.59 (d, 1H), 7.41 (d, 2H), 7.62 (d, 2H); LRMS : m/z (ES^+) 551 [MNa^+].

20

Preparation 48


tert-Butyl (2*R*)-2-[(1-[[[(1*R*)-3-ethoxy-1-[(6-methyl-3-pyridinyl)methoxy]methyl]-3-oxopropyl]amino]carbonyl]cyclopentyl)methyl]pentanoate



- 5 The title compound was obtained as a colourless oil in 67% yield from 1-[(2*R*)-2-(*tert*-butyloxycarbonyl-pentyl)]-cyclopentanecarboxylic acid (WO 0202513, preparation 2) and the amine from preparation 45, following the procedure described in preparation 47.
- ¹H NMR (CDCl₃, 400MHz) δ: 0.83 (t, 3H), 1.24 (m, 6H), 1.40-1.78 (m, 17H), 1.98 (m, 3H), 2.21 (m, 1H), 2.60 (m, 5H), 3.55 (m, 1H), 3.61 (m, 1H), 4.08 (q, 2H), 4.50 (m, 3H),
- 10 6.55 (d, 1H), 7.19 (d, 1H), 7.62 (d, 1H), 8.83 (s, 1H); LRMS : m/z (ES⁺) 519 [MH⁺].

Preparation 49

(3*S*)-4-(Benzyloxy)-3-[[[1-[(2*R*)-2-(*tert*-butoxycarbonyl)pentyl]cyclopentyl]-carbonyl]amino]butanoic acid




15

- The title compound was prepared, from the alcohol from preparation 6 and benzyl bromide, following the procedure described for preparation 10; ¹H NMR (CDCl₃, 400MHz) δ: 0.83 (t, 3H), 1.22-1.74 (m, 20H), 1.90-2.02 (m, 3H), 2.21 (m, 1H), 2.67 (m, 2H), 3.56 (dd, 1H), 3.60 (dd, 1H), 4.40-4.58 (m, 3H), 6.48 (d, 1H), 7.17-7.40 (m, 5H);
- 20 LRMS : m/z (ES⁻) 474 [M-H].

Preparation 50


tert-Butyl (2*R*)-2-([1-([[(1*S*)-1-[(benzyloxy)methyl]-3-(2-butoxyethoxy)-3-oxopropyl]amino]carbonyl)cyclopentyl]methyl]pentanoate



- 5 4-Dimethylaminopyridine (30mg) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (48mg, 0.25mmol) were added to a solution of the acid from preparation 49 (120mg, 0.25mmol) and 2-butoxyethanol (30mg, 0.25mmol) in dichloromethane (5ml), and the reaction stirred at room temperature for 18 hours. The mixture was evaporated under reduced pressure and the residue purified by column chromatography
- 10 on silica gel using an elution gradient of dichloromethane:methanol (100:0 to 98:2) to afford the title compound, 100mg; ¹H NMR (CDCl₃, 400MHz) δ: 0.82 (t, 3H), 0.94 (t, 3H), 1.21-1.76 (m, 24H), 1.98 (m, 3H), 2.20 (m, 1H), 2.68 (m, 2H), 3.41 (d, 2H), 3.52 (m, 1H), 3.60 (m, 3H), 4.19 (m, 2H), 4.44 (m, 3H), 6.50 (d, 1H), 7.30 (m, 5H).

15 Preparation 51

tert-Butyl (2*R*)-2-([1-([[(1*S*)-1-[(benzyloxy)methyl]-3-oxo-3-[2-oxo-2-(1-piperidinyl)ethoxy]propyl]amino]carbonyl)cyclopentyl]methyl]pentanoate




- 20 1-(Bromoacetyl)piperidine (EP 580402) (58mg, 0.28mmol) was added to a suspension of the acid from preparation 49 (120mg, 0.25mmol) and potassium carbonate (35mg,


0.25mmol) in N,N-dimethylformamide (3ml), and the reaction stirred at room temperature for 18 hours. The mixture was concentrated under reduced pressure and the residue purified by column chromatography on silica gel using an elution gradient of dichloromethane:methanol (100:0 to 98.5:1.5) to afford the title compound, 100mg; ¹H NMR (CDCl₃, 400MHz) δ: 0.82 (t, 3H), 1.20-1.68 (m, 25H), 1.78 (m, 1H), 2.00 (m, 3H), 2.22 (m, 1H), 2.78 (dd, 2H), 3.25 (m, 2H), 3.56 (m, 2H), 3.60 (m, 2H), 4.58 (m, 3H), 4.62 (d, 1H), 4.78 (d, 1H), 6.98 (d, 1H), 7.26 (m, 5H); LRMS : m/z (ES⁺) 623 [MNa⁺].

Preparation 52


10 (2R)-2-[(1-[[[(1R)-1-[(4-Cyanobenzyl)oxy]methyl]-3-ethoxy-3-oxopropyl)amino]carbonyl]-cyclopentyl)methyl]pentanoic acid



A solution of the ester from preparation 47 (220mg, 0.42mmol) and trifluoroacetic acid (2ml) in dichloromethane (8ml) was stirred at room temperature for 3 hours. The mixture was concentrated under reduced pressure and the residue azeotroped with dichloromethane. The product was suspended in ethyl acetate, washed with water and brine, then dried (MgSO₄) and evaporated under reduced pressure to afford the title compound as a colourless gum, 189mg; ¹H NMR (CDCl₃, 400MHz) δ: 0.84 (t, 3H), 1.26 (m, 6H), 1.46-1.78 (m, 8H), 1.98 (m, 1H), 2.02 (m, 2H), 2.38 (m, 1H), 2.62 (m, 2H), 3.60 (m, 2H), 4.10 (q, 2H), 4.44-4.62 (m, 3H), 6.70 (d, 1H), 7.41 (d, 2H), 7.62 (d, 2H); LRMS : m/z (ES⁺) 495 [MNa⁺].

Preparation 53(2R)-2-[(1-[[[(1R)-3-Ethoxy-1-[(6-methyl-3-pyridinyl)methoxy]methyl]-3-oxopropyl]-amino]carbonyl]cyclopentyl)methyl]pentanoic acid

- 5 A solution of the ester from preparation 48 (94mg, 0.18mmol) and trifluoroacetic acid (1ml) in dichloromethane (4ml) was stirred at room temperature for 18 hours. The mixture was concentrated under reduced pressure and the residue azeotroped with dichloromethane. The product was dissolved in water, the pH adjusted to 6 and the mixture extracted with ethyl acetate. The combined organic extracts were dried (MgSO₄)
- 10 and evaporated under reduced pressure. The crude product was purified by column chromatography on silica gel using dichloromethane:methanol (90:10) as eluant to afford the title compound as a colourless gum, 63mg; HRMS : m/z (ES⁺) 463.2801 [MH⁺] C₂₅H₃₈N₂O₆ requires 463.2803.


15 Preparation 54Ethyl 5-[[tert-butyl(dimethyl)silyl]oxy]-2-pentenoate

- Methyl sulphoxide (1.9ml, 26.8mmol) was added to a cooled (-78°C) solution of oxalyl chloride (2.16ml, 24.7mmol) in dichloromethane (100ml), and after 10 minutes, a
- 20 solution of 3-(tert-butyl-dimethyl-silanyloxy)-propan-1-ol (3g, 15.8mmol) in dichloromethane (25ml) was added dropwise. Once addition was complete, the solution was stirred for a further 15 minutes. Triethylamine (8ml, 57.5mmol) was added, followed by dropwise addition of a solution of (ethoxycarbonylmethylene)triphenylphosphorane (10g, 29.9mmol) in dichloromethane (50ml), and the reaction mixture allowed to warm to
- 25 room temperature. The mixture was washed with water (4x), dried (MgSO₄) and concentrated under reduced pressure. The residue was pre-adsorbed onto silica gel and purified by column chromatography using diethyl ether:pentane (2.5:97.5) as eluant to


afford the title compound, 1.3g; $^1\text{H NMR}$ (CDCl_3 , 400MHz) δ : 0.02 (s, 6H), 0.87 (s, 9H), 1.26 (t, 3H), 2.40 (m, 2H), 3.74 (t, 2H), 4.18 (q, 2H), 5.84 (d, 1H), 6.95 (m, 1H).

Preparation 55


5 Ethyl (3*R*)-3-{benzyl[(1*R*)-1-phenylethyl]amino}-5-{[*tert*-butyl(dimethyl)silyl]oxy}-pentanoate



n-Butyl lithium (21.4ml, 53.5mmol) was added to a cooled (-78°C) solution of (*R*)-(+)-*N*-benzyl- α -methylbenzylamine (12.0g, 57.06mmol) in tetrahydrofuran (100ml), and the solution stirred for 1 hour. A solution of the compound from preparation 54 (9.2g, 35.7mmol) in tetrahydrofuran (50ml) was added, and the reaction stirred for a further 2 hours at -78°C . Saturated ammonium chloride solution (40ml) was added, and the mixture then allowed to warm to room temperature. The mixture was concentrated under reduced pressure, the residue partitioned between ether and water and the layers separated. The organic phase was dried (MgSO_4) and evaporated under reduced pressure. The residual yellow oil was purified by column chromatography on silica gel using diethyl ether:pentane (1.5:98.5) as eluant to afford the title compound as a pale yellow oil, 8.6g; $^1\text{H NMR}$ (CDCl_3 , 400MHz) δ : 0.07 (s, 6H), 0.88 (s, 9H), 1.18 (t, 3H), 1.38 (d, 3H), 1.55 (m, 1H), 1.80 (m, 1H), 2.02 (m, 2H), 3.58 (m, 1H), 3.76 (m, 3H), 3.83 (m, 1H), 3.94-4.06 (m, 2H), 7.20-7.42 (m, 10H); LRMS : m/z (ES^+) 470 [MH^+].

Preparation 56Ethyl (3S)-3-{benzyl[(1S)-1-phenylethyl]amino}-5-{[*tert*-butyl(dimethyl)silyl]oxy}pentanoate

- 5 The title compound was obtained as a colourless oil in 56% yield from (*S*)-(-)-*N*-benzyl- α -methylbenzylamine and the compound from preparation 54, following the procedure described in preparation 55; $^1\text{H NMR}$ (CDCl_3 , 400MHz) δ : 0.05 (s, 6H), 0.88 (s, 9H), 1.18 (t, 3H), 1.38 (d, 3H), 1.55 (m, 1H), 1.80 (m, 1H), 2.02 (m, 2H), 3.58 (m, 2H), 3.70-3.88 (m, 4H), 3.99 (m, 2H), 7.19-7.37 (m, 8H), 7.40 (d, 2H); $[\alpha]_D = -4.6$ (c = 0.096 in methanol).
- 10


Preparation 57Ethyl (3*R*)-3-amino-5-{[*tert*-butyl(dimethyl)silyl]oxy}pentanoate

- 15 A mixture of the compound from preparation 55 (8.6g, 18.34mmol), and 10% palladium on charcoal (2.5g) in acetic acid (100ml) was hydrogenated at 6 atm and room temperature for 72 hours. The mixture was filtered through Arbocel® and the filtrate evaporated under reduced pressure. The residue was purified by column chromatography on silica gel using an elution gradient of
- 20 dichloromethane:methanol:0.88 ammonia (98:2:0.2 to 95:5:0.5) to give an orange oil. The product was dissolved in ethyl acetate, the solution washed with sodium carbonate


solution, dried (MgSO_4) and evaporated under reduced pressure. The residual oil was further purified by column chromatography on silica gel using an elution gradient of dichloromethane:methanol:0.88 ammonia (99:1:0.1 to 97:3:0.3) to afford the title compound, 3g; ^1H NMR (CDCl_3 , 400MHz) δ : 0.05 (s, 6H), 0.88 (s, 9H), 1.25 (t, 3H), 1.56-1.68 (m, 2H), 2.34 (dd, 1H), 2.50 (dd, 1H), 3.39 (m, 1H), 3.77 (m, 2H), 4.15 (q, 2H).

Preparation 58

Ethyl (3S)-3-amino-5-([*tert*-butyl(dimethyl)silyl]oxy)pentanoate




- 10 A mixture of the compound from preparation 56 (10.0g, 21.3mmol), and 10% palladium on charcoal (2.9g) in acetic acid (150ml) was hydrogenated at 6 atm and room temperature for 42 hours. The mixture was filtered through Arbocel®, and the filtrate concentrated under reduced pressure. The residue was partitioned between ethyl acetate and saturated aqueous sodium bicarbonate solution and the layers separated.
- 15 The aqueous phase was further extracted with ethyl acetate (200ml), and the combined organic solutions dried (MgSO_4) and evaporated under reduced pressure. The crude product was purified by column chromatography on silica gel using an elution gradient of dichloromethane:methanol:0.88 ammonia (95:5:0.5 to 90:10:1) to afford the title compound as a yellow oil, 4.27g; ^1H NMR (CDCl_3 , 400MHz) δ : 0.05 (s, 6H), 0.88 (s, 9H), 1.25 (t, 3H), 1.64 (m, 2H), 2.40 (dd, 1H), 2.56 (m, 1H), 3.42 (m, 1H), 3.77 (m, 2H), 4.15 (q, 2H); LRMS : m/z (ES^+) 275.6 [MH^+]
- 20

Preparation 59Ethyl (3R)-3-[(1-[(2R)-2-(*tert*-butoxycarbonyl)pentyl]cyclopentyl)carbonyl]amino]-5-[(*tert*-butyl(dimethyl)silyl]oxy}pentanoate

- 5 A mixture of the amine from preparation 57 (1.5g, 5.45mmol), 1-[(2*S*)-2-(*tert*-butyloxycarbonyl-pentyl)]-cyclopentanecarboxylic acid (WO 0202513, preparation 2) (1.7g, 6.0mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.15g, 6.00mmol), 1-hydroxybenzotriazole hydrate (811mg, 6.0mmol) and N-methylmorpholine (1.15ml, 10.45mmol) in dichloromethane (30ml) was stirred at room temperature for 18
- 10 hours. The reaction was washed with water, dried (MgSO₄) and concentrated under reduced pressure. The residual yellow oil was purified by column chromatography on silica gel using dichloromethane:methanol:0.88 ammonia (99.5:0.5:0.05) as eluant to afford the title compound as a colourless oil, 2.3g; ¹H NMR (CDCl₃, 400MHz) δ: 0.05 (s, 6H), 0.90 (m, 15H), 1.24-1.55 (m, 15H), 1.58-1.74 (m, 6H), 1.80 (m, 2H), 1.98 (m, 3H),
- 15 2.21 (m, 1H), 2.57 (dd, 1H), 2.70 (dd, 1H), 3.70 (m, 1H), 4.16 (q, 2H), 4.37 (m, 1H), 6.65 (d, 1H); LRMS : m/z (ES⁺) 542 [MH⁺].

Preparation 60

20 Ethyl (3*S*)-3-[(1-[(2*R*)-2-(*tert*-butoxycarbonyl)pentyl]cyclopentyl)carbonyl]amino]-5-[(*tert*-butyl(dimethyl)silyl]oxy}pentanoate




The title compound was obtained as a colourless oil in 56% yield from 1-[(2*S*)-2-(*tert*-butyloxycarbonyl-pentyl)]-cyclopentanecarboxylic acid (WO 0202513, preparation 2) and the amine from preparation 58, following a similar procedure to that described in


preparation 59, except the compound was purified by column chromatography on silica gel using pentane:ethyl acetate (90:10) and re-columned using an elution gradient of toluene:ethyl acetate (94:4 to 88:12); ^1H NMR (CDCl_3 , 400MHz) δ : 0.05 (s, 6H), 0.86 (m, 12H), 1.26 (t, 3H), 1.43 (m, 13H), 1.59-1.85 (m, 8H), 1.98 (m, 3H), 2.20 (m, 1H), 2.56 (dd, 1H), 2.63 (dd, 1H), 3.70 (m, 1H), 4.14 (q, 2H), 4.37 (m, 1H), 6.60 (d, 1H).
 5 LRMS : m/z (ES^+) 542 [MH^+]; $[\alpha]_D = -19.88$ ($c = 0.156$ in methanol).

Preparation 61

tert-Butyl (3*R*)-3-[(1-[(2*S*)-2-(*tert*-butoxycarbonyl)-4-methoxybutyl]cyclopentyl)carbonyl]-amino]-5-[(*tert*-butyl(dimethyl)silyl]oxy)pentanoate
 10




The title compound was obtained as a viscous oil in 84% yield, from (*R*) *tert*-butyl-3-amino-5-(*tert*-butyl-dimethylsilyloxy)-pentanoate (J. Org. Chem. 57(7); 1992; 2120) and the acid from preparation 1, following the procedure described in preparation 59; ^1H
 15 NMR (CDCl_3 , 400MHz) δ : 0.03 (s, 6H), 0.90 (s, 9H), 1.42 (2xs, 18H), 1.61 (m, 7H), 1.80 (m, 4H), 1.98 (m, 3H), 2.35 (m, 1H), 2.44 (dd, 1H), 2.60 (dd, 1H), 3.26 (s, 3H), 3.36 (m, 2H), 3.68 (m, 2H), 4.26 (m, 1H), 6.65 (d, 1H); LRMS : m/z (ES^+) 608 [MNa^+];
 Microanalysis found: C, 63.55; H, 10.15; N, 2.39. $\text{C}_{31}\text{H}_{59}\text{NO}_7\text{Si}$ requires C, 63.36; H, 10.05; N, 2.57%.

Preparation 62Ethyl (3S)-3-[(1-[(2S)-2-(tert-butoxycarbonyl)-4-methoxybutyl]cyclopentyl)carbonyl]amino]-5-[[tert-butyl(dimethyl)silyl]oxy]pentanoate


- 5 The title compound was obtained as a colourless oil in 87% yield from the acid from preparation 1 and the amine from preparation 58, following a similar procedure to that described in preparation 59, except the compound was purified by column chromatography on silica gel using pentane:ethyl acetate (90:10 to 75:25); ¹H NMR (CDCl₃, 400MHz) δ: 0.05 (s, 6H), 0.90 (s, 9H), 1.25 (t, 3H), 1.40 (s, 9H), 1.45 (m, 1H),
- 10 1.66 (m, 6H), 1.80 (m, 4H), 1.95 (m, 3H), 2.20 (m, 1H), 2.55 (m, 1H), 2.65 (m, 1H), 3.25 (s, 3H), 3.30 (m, 2H), 3.70 (m, 2H), 4.10 (q, 2H), 4.35 (m, 1H), 6.60 (d, 1H);

Preparation 63

- 15 Ethyl (3R)-3-[(1-[(2R)-2-(tert-butoxycarbonyl)pentyl]cyclopentyl)carbonyl]amino]-5-hydroxypentanoate




- A mixture of the protected alcohol from preparation 59 (1g, 1.85mmol), and acetic acid (10ml) in water (5ml) and tetrahydrofuran (5ml) was stirred at room temperature for 2 hours. The reaction was concentrated under reduced pressure, the residue dissolved in ethyl acetate, washed with saturated sodium carbonate solution, dried (MgSO₄) and
- 20 concentrated under reduced pressure. The residue was purified by column chromatography on silica gel using dichloromethane:methanol:0.88 ammonia (99:1:0.1) to afford the title compound as a colourless oil, 550mg; LRMS : m/z (ES⁺) 450 [MNa⁺].

Preparation 64Ethyl (3S)-3-[(1-[(2R)-2-(*tert*-butoxycarbonyl)pentyl]cyclopentyl)carbonyl]amino]-5-hydroxypentanoate

5

The title compound was obtained in 91% yield from the compound from preparation 60, following a similar procedure to that described in preparation 63; $^1\text{H NMR}$ (CDCl_3 , 400MHz) δ : 0.87 (m, 3H), 1.28 (m, 5H), 1.40-1.84 (m, 19H), 1.98 (m, 3H), 2.22 (m, 1H), 2.59 (m, 2H), 2.98 (m, 1H), 3.60 (m, 2H), 4.18 (m, 2H), 4.40 (m, 1H), 6.94 (d, 1H);


10 LRMS : m/z (ES^+) 450 [MNa^+].

Preparation 65*tert*-Butyl (3R)-3-[(1-[(2S)-2-(*tert*-butoxycarbonyl)-4-methoxybutyl]cyclopentyl)-carbonyl]amino]-5-hydroxypentanoate

15


The title compound was obtained as a viscous oil, from the compound from preparation 61, following a similar procedure to that described in preparation 63, but without chromatography; $^1\text{H NMR}$ (CDCl_3 , 400MHz) δ : 1.43 (2xs, 18H), 1.46-1.83 (m, 9H), 1.95-2.08 (m, 3H), 2.38 (m, 1H), 2.44 (dd, 1H), 2.62 (dd, 1H), 2.72 (m, 2H), 3.28 (s, 3H), 3.35 (q, 2H), 3.50 (m, 1H), 3.60 (m, 1H), 4.36 (m, 1H), 7.15 (d, 1H).

20

Preparation 66Ethyl- (3S)-3-[(1-[(2S)-2-(tert-butoxycarbonyl)-4-methoxybutyl]cyclopentyl)-carbonyl]amino]-5-hydroxypentanoate

- 5 The title compound was obtained as a colourless oil, from the compound from preparation 62, following a similar procedure to that described in preparation 63, but without chromatography; ¹H NMR (CDCl₃, 400MHz) δ: 1.25 (t, 3H), 1.42 (s, 9H), 1.50-2.01 (m, 14H), 2.38 (m, 1H), 2.56 (dd, 1H), 2.62 (dd, 1H), 3.30 (s, 3H), 3.37 (m, 2H), 3.62 (m, 2H), 4.15 (q, 2H), 4.41 (m, 1H), 6.96 (d, 1H); LRMS : m/z (ES⁺) 466 [MNa⁺].

10


Preparation 67Ethyl (3R)-3-[(1-[(2R)-2-(tert-butoxycarbonyl)pentyl]cyclopentyl)carbonyl]amino]-5-phenoxy pentanoate

- 15 Diisopropyl azodicarboxylate (60μl, 0.30mmol) was added to a solution of triphenylphosphine (79mg, 0.30mmol), phenol (28mg, 0.30mmol) and the alcohol from preparation 63 (100mg, 0.23mmol) in tetrahydrofuran (5ml), and the mixture stirred at room temperature for 18 hours. The mixture was concentrated under reduced pressure, the residue dissolved in dichloromethane and washed with saturated sodium carbonate
- 20 solution. The organic solution was then dried (MgSO₄) and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel using an elution gradient of ethyl acetate:pentane (87.5:12.5 to 80:20) to afford the title compound as a colourless residue, 60mg; ¹H NMR (CDCl₃, 400MHz) δ : 0.84 (t, 3H), 1.24 (m, 6H),

1.40-1.78 (m, 17H), 1.99 (m, 3H), 2.14 (m, 2H), 2.22 (m, 1H), 2.62 (dd, 1H), 2.78 (dd, 1H), 4.02 (m, 2H), 4.19 (q, 2H), 4.44 (m, 1H), 6.78 (d, 1H), 6.90 (d, 2H), 6.98 (m, 1H), 7.25 (m, 2H); LRMS : m/z (ES⁺) 526 [MNa⁺].

5 Preparations 68 to 74



The following compounds of general formula:



were prepared from the alcohol from preparation 63 and the corresponding alcohols, following a similar procedure to that described in preparation 67.

10


Prep. No	R	Data
68		¹ H NMR (CDCl ₃ , 400MHz) δ: 0.83 (t, 3H), 1.25 (m, 7H), 1.40-1.77 (m, 15H), 1.98 (m, 3H), 2.05 (m, 3H), 2.21 (m, 1H), 2.60 (dd, 1H), 2.72 (dd, 1H), 3.99 (m, 2H), 4.16 (q, 2H), 4.43 (m, 1H), 6.68 (d, 1H), 6.82 (m, 2H), 6.97 (m, 2H); LRMS : m/z (ES ⁺) 544 [MNa ⁺]
69		¹ H NMR (CDCl ₃ , 400MHz) δ: 0.83 (t, 3H), 1.25 (m, 7H), 1.40-1.75 (m, 16H), 1.98 (m, 3H), 2.05 (m, 2H), 2.20 (m, 1H), 2.60 (dd, 1H), 2.68 (dd, 1H), 4.00 (m, 2H), 4.16 (q, 2H), 4.43 (m, 1H), 6.68 (d, 1H), 6.80 (d, 2H), 7.20 (d, 2H); LRMS : m/z (ES ⁺) 560 [MNa ⁺]; Microanalysis found: C 64.49; H, 8.22; N, 2.57. C ₂₉ H ₄₄ ClNO ₆ requires C, 64.73; H, 8.24; N, 2.60%.
70		¹ H NMR (CDCl ₃ , 400MHz) δ: 0.83 (t, 3H), 1.18-2.10 (m, 28H), 2.22 (m, 1H), 2.57 (dd, 1H), 2.70 (dd, 1H), 3.46 (m, 1H), 3.60 (m, 1H), 4.18 (q, 2H), 4.38 (m, 1H), 7.03 (d, 1H), 7.40-7.74 (m, 4H); LRMS : m/z (ES ⁺) 538.4 [MH ⁺]
71a		¹ H NMR (CDCl ₃ , 400MHz) δ: 0.84 (t, 3H), 1.23 (m, 7H), 1.40-1.77 (m, 16H), 1.98 (m, 3H), 2.04 (m, 2H), 2.20 (m, 1H), 2.58 (dd, 1H), 2.72 (dd, 1H), 3.77 (s, 3H), 4.00 (m, 2H), 4.17 (q, 2H), 4.42 (m, 1H), 6.68 (d, 1H), 6.81 (s, 4H).
72		¹ H NMR (CDCl ₃ , 400MHz) δ: 0.82 (t, 3H), 1.20-1.78 (m, 23H), 1.98 (m, 3H), 2.05 (m, 2H), 2.20 (m, 1H), 2.60 (dd, 1H), 2.74 (dd, 1H), 3.79 (s, 3H), 4.00 (m, 2H), 4.16 (q, 2H), 4.42 (m, 1H), 6.43 (m, 3H), 6.72 (d, 1H), 7.18 (dd, 1H); LRMS : m/z (APCI ⁺) 534 [MH ⁺]

Prep. No	R	Data
73		$^1\text{H NMR}$ (CDCl_3 , 400MHz) δ : 0.81 (t, 3H), 1.22-1.62 (m, 22H), 1.75 (dd, 1H), 1.90-2.02 (m, 3H), 2.10-2.24 (m, 3H), 2.59 (dd, 1H), 2.77 (dd, 1H), 3.84 (s, 3H), 4.01-4.18 (m, 4H), 4.50 (m, 1H), 6.79 (d, 1H), 6.84-6.98 (m, 4H); LRMS : m/z (ES^+) 556 [MNa^+]
74		LRMS : m/z (ES^+) 540 [MNa^+]

a = the product was further triturated with pentane to remove impurities




Preparations 75 to 79



The following compounds of general formula:



5

were prepared from the alcohol from preparation 64 and the corresponding alcohols, following a similar procedure to that described in preparation 67.


Prep. No	R	Data
75		$^1\text{H-NMR}$ (CDCl_3 , 400MHz) δ : 0.81 (t, 3H), 1.15-1.34 (m, 7H), 1.40-1.78 (m, 15H), 1.84-2.20 (m, 7H), 2.60 (m, 2H), 4.00 (m, 2H), 4.16 (q, 2H), 4.43 (m, 1H), 6.62 (d, 1H), 6.80 (d, 2H), 7.20 (d, 2H); HRMS : m/z (ES^+) 538.2924 [MH^+]
76		$^1\text{H-NMR}$ (CDCl_3 , 400MHz) δ : 0.81 (t, 3H), 1.18-1.38 (m, 7H), 1.40-1.78 (m, 17H), 1.86-2.14 (m, 4H), 2.20 (m, 1H), 2.60 (m, 2H), 4.00 (t, 2H), 4.18 (q, 2H), 4.45 (m, 1H), 6.60 (d, 1H), 6.80 (dd, 2H), 7.20 (dd, 2H). LRMS : m/z (ES^+) 544 [MNa^+]
77 ^a		$^1\text{H-NMR}$ (CDCl_3 , 400MHz) δ : 0.80 (t, 3H), 1.15-1.30 (m, 7H), 1.38-1.78 (m, 17H), 1.82-2.20 (m, 5H), 2.60 (m, 2H), 4.00 (t, 2H), 4.16 (q, 2H), 4.42 (m, 1H), 6.60 (m, 4H), 7.18 (m, 1H). LRMS : m/z (ES^+) 544 [MNa^+]

Prep. No	R	Data
78 ^a		¹ H-NMR (CDCl ₃ , 400MHz) δ: 0.82 (t, 3H), 1.22 (m, 6H), 1.40-1.68 (m, 16H), 1.74 (dd, 1H), 1.86-2.00 (m, 3H), 2.08 (m, 2H), 2.19 (m, 1H), 2.24 (s, 3H), 2.58 (dd, 1H), 2.64 (dd, 1H), 4.00 (t, 2H), 4.16 (q, 2H), 4.44 (m, 1H), 6.64 (d, 1H), 6.78 (d, 2H), 7.03 (d, 2H). LRMS : m/z (ES ⁺) 540 [MNa ⁺]
79 ^a		¹ H-NMR (CDCl ₃ , 400MHz) δ: 0.82 (t, 3H), 1.16-1.36 (m, 6H), 1.40-1.68 (m, 16H), 1.75 (dd, 1H), 1.86-2.21 (m, 6H), 2.59 (dd, 1H), 2.65 (dd, 1H), 4.00 (t, 2H), 4.16 (q, 2H), 4.46 (m, 1H), 6.68 (m, 1H), 6.84 (d, 2H), 6.95 (m, 1H), 7.22 (d, 2H). LRMS : m/z (ES ⁺) 526 [MNa ⁺]


a= dichloromethane was used instead of ethyl acetate in the work-up

Preparation 80

tert-Butyl (3*R*)-3-[(1-[(2*S*)-2-(*tert*-butoxycarbonyl)-4-methoxybutyl]cyclopentyl]-
 5 carbonyl)amino]-5-(4-chlorophenoxy)pentanoate




The title compound was obtained as an oil from the alcohol from preparation 65 and p-chlorophenol, following the procedure described in preparation 67; ¹H-NMR (CDCl₃, 400MHz) δ: 1.24 (2xs, 18H), 1.55-1.80 (m, 9H), 1.98 (m, 3H), 2.03 (m, 2H), 2.37 (m, 1H), 2.53 (dd, 1H), 2.60 (dd, 1H), 3.26 (m, 5H), 4.00 (m, 2H), 4.39 (m, 1H), 6.70 (d, 1H), 6.80 (d, 2H), 7.20 (d, 2H); LRMS : m/z (ES⁺) 604 [MNa⁺].

Preparation 81Ethyl (3S)-3-[(1-[(2S)-2-(tert-butoxycarbonyl)-4-methoxybutyl]cyclopentyl)-carbonyl]amino]-5-(4-chlorophenoxy)pentanoate

- 5 The title compound was obtained as an oil from the alcohol from preparation 66 and p-chlorophenol, following the procedure described in preparation 67, except the crude product was purified by column chromatography on silica gel using an elution gradient of toluene:methanol (99:1 to 98:2) and re-columned using an elution gradient of ether:pentane (25:75 to 80:20); ¹H-NMR (CDCl₃, 400MHz) δ: 1.25 (t, 3H), 1.40-1.70 (m, 16H), 1.80 (m, 2H), 1.98 (m, 3H), 2.08 (m, 2H), 2.30 (m, 1H), 2.62 (m, 2H), 3.25 (m, 5H),
 10 4.01 (m, 2H), 4.18 (q, 2H), 4.44 (m, 1H), 6.63 (d, 1H), 6.82 (d, 2H), 7.20 (d, 2H); LRMS : m/z (APCI⁺) 554 [MH⁺]; [α]_D = -9.67 (c = 0.12, methanol).

Preparation 82


- 15 (2R)-2-({1-[(1R)-1-[2-(3-Chlorophenoxy)ethyl]-3-ethoxy-3-oxopropyl]amino}carbonyl)-cyclopentyl)methyl)pentanoic acid






- A solution of the ester from preparation 69 (45mg, 0.08mmol) and trifluoroacetic acid (0.5ml) in dichloromethane (2ml) was stirred at room temperature for 18 hours. The
 20 reaction was concentrated under reduced pressure, and the residue azeotroped with toluene to afford the title compound, 40mg; LRMS : m/z (ES⁺) 482 [MH⁺].

Preparations 83 to 85

The following compounds of general formula:




5 were prepared as colourless oils, from the corresponding *tert*-butyl esters following a similar procedure to that described in preparation 82.

Prep. no	R	Data
83		LRMS : m/z (ES ⁻) 476 [M-H] ⁻
84		LRMS : m/z (ES ⁻) 476 [M-H] ⁻
85 ^a		

a = The product was additionally dissolved in ethyl acetate, washed with water, dried (MgSO₄) and evaporated under reduced pressure.

10 Preparation 86


(2R)-2-({1-[(1S)-1-[2-(4-Chlorophenoxy)ethyl]-3-ethoxy-3-oxopropyl]amino}carbonyl)-cyclopentyl)methyl)pentanoic acid



A solution of the ester from preparation 81 (390mg, 0.72mmol) in dichloromethane (4ml) and trifluoroacetic acid (2ml) was stirred at room temperature for 3 hours. The mixture was concentrated under reduced pressure and the residue purified by column chromatography on silica gel using an elution gradient of dichloromethane:methanol (99:1 to 95:5) to afford the title compound as a colourless oil, 249mg; $^1\text{H NMR}$ (CDCl_3 , 400MHz) δ : 0.84 (t, 3H), 1.19-1.39 (m, 6H), 1.44-1.80 (m, 7H), 1.93-2.14 (m, 6H), 2.30 (m, 1H), 2.62 (m, 2H), 3.99 (t, 2H), 4.16 (q, 2H), 4.44 (m, 1H), 6.76 (d, 1H), 6.80 (d, 2H), 7.20 (d, 2H); LRMS : m/z (ES^+) 482 [MH^+].

10 Preparations 87 to 90


The following compounds of general formula:



were prepared from the corresponding esters, following the procedure described in preparation 86.

15


Prep. no	R	Data
87		$^1\text{H NMR}$ (CDCl_3 , 400MHz) δ : 0.82 (t, 3H), 1.22-1.39 (m, 7H), 1.46-1.70 (m, 6H), 1.78 (dd, 1H), 1.96-2.12 (m, 5H), 2.32 (m, 1H), 2.62 (m, 2H), 4.00 (t, 2H), 4.16 (q, 2H), 4.44 (m, 1H), 6.76 (d, 1H), 6.80 (dd, 2H), 6.97 (dd, 1H); LRMS : m/z (ES^+) 488 [MNa^+]
88		$^1\text{H NMR}$ (CDCl_3 , 400MHz) δ : 0.82 (t, 3H), 1.20-1.39 (m, 7H), 1.43-1.70 (m, 6H), 1.78 (dd, 1H), 1.96-2.12 (m, 5H), 2.30 (m, 1H), 2.62 (m, 2H), 4.00 (t, 2H), 4.16 (q, 2H), 4.44 (m, 1H), 6.00 (m, 3H), 6.74 (d, 1H), 7.19 (dd, 1H); LRMS : m/z (ES^+) 488 [MNa^+]; $[\alpha_D] = -19.27$ (c = 0.136, methanol)
89		$^1\text{H NMR}$ (CDCl_3 , 400MHz) δ : 0.84 (t, 3H), 1.28 (m, 7H), 1.48-1.78 (m, 7H), 1.96-2.12 (m, 5H), 2.26 (s, 3H), 2.36 (m, 1H), 2.62 (m, 2H), 4.00 (t, 2H), 4.16 (q, 2H), 4.44 (m, 1H), 6.79 (m, 3H), 7.04 (d, 2H). LRMS : m/z (ES^-) 460 [M-H^-]

Prep. no	R	Data
90 ^a		¹ H NMR (CDCl ₃ , 400MHz) δ: 0.82 (t, 3H), 1.25 (m, 6H), 1.43-1.80 (m, 8H), 1.96-2.10 (m, 5H), 2.37 (m, 1H), 2.63 (m, 2H), 4.02 (t, 2H), 4.16 (q, 2H), 4.44 (m, 1H), 6.78 (d, 1H), 6.85 (d, 2H), 6.95 (dd, 1H), 7.25 (m, 2H); LRMS : m/z (ES ⁻) 446 [M-H] ⁻


a = the product was additionally purified by reverse phase HPLC using acetonitrile:water:trifluoroacetic acid as gradient eluant.

Preparation 91


- 5 (3S)-3-[(1-[(2S)-2-(*tert*-Butoxycarbonyl)-4-methoxybutyl]cyclopentyl)carbonyl]amino]-5-(4-chlorophenoxy)pentanoic acid



- Sodium hydroxide solution (3ml, 2N) was added to a solution of the ester from preparation 81 (500mg, 0.90mmol) in tetrahydrofuran (3ml) and the reaction stirred
 10 under reflux for 5 hours. The cooled mixture was partitioned between ethyl acetate (30ml) and 2M hydrochloric acid (10ml), and the layers separated. The aqueous phase was extracted with further ethyl acetate (30ml), and the combined organic solutions washed with brine (20ml), dried (MgSO₄) and evaporated under reduced pressure. The
 15 crude product was purified by column chromatography on silica gel using an elution gradient of dichloromethane:methanol (96:4 to 90:10) to afford the title compound as a colourless oil, 298mg; ¹H NMR (CDCl₃, 400MHz) δ: 1.30-1.65 (m, 15H), 1.75 (m, 2H), 1.88 (m, 1H), 2.00-2.16 (m, 5H), 2.40 (m, 1H), 2.58 (dd, 1H), 2.75 (dd, 1H), 3.30 (m, 1H), 3.38 (s, 3H), 3.45 (m, 1H), 4.00 (m, 2H), 4.58 (m, 1H), 6.08 (d, 1H), 6.80 (d, 2H), 7.20 (d, 2H); LRMS : m/z (APCI⁺) 526 [MH⁺].

Preparation 92Butyl (3S)-3-[(1-[(2S)-2-(*tert*-butoxycarbonyl)-4-methoxybutyl]cyclopentyl)-carbonylamino]-5-(4-chlorophenoxy)pentanoate

- 5 A mixture of the acid from preparation 91 (280mg, 0.53mmol), potassium carbonate (74mg, 0.53mmol) and n-butyl iodide (67 μ l, 0.59mmol) in N,N-dimethylformamide (2ml) was stirred at room temperature for 18 hours. The mixture was concentrated under reduced pressure and the residue partitioned between ether (50ml) and water (25ml) and the layers separated. The organic phase was washed with 2N sodium hydroxide
- 10 solution (15ml), then brine (20ml), dried (MgSO₄) and evaporated under reduced pressure. The residual orange oil was dissolved in a minimum volume of dichloromethane and the solution filtered through silica gel washing through with dichloromethane:methanol solution (25ml, 97.5:2.5), and the filtrate evaporated under reduced pressure to afford the title compound as a colourless oil, 289mg; ¹H NMR
- 15 (CDCl₃, 400MHz) δ : 0.94 (t, 3H), 1.36-1.58 (m, 19H), 1.61 (m, 4H), 1.79 (m, 1H), 1.96-2.03 (m, 2H), 2.08 (m, 1H), 2.30 (m, 1H), 2.62 (m, 2H), 3.23 (m, 5H), 4.01 (t, 2H), 4.09 (t, 2H), 4.45 (m, 1H), 6.66 (d, 1H), 6.81 (d, 2H), 7.20 (d, 2H); LRMS : m/z (ES⁺) 604 [MNa⁺].


20 Preparation 93*tert*-Butyl (3S)-6-(4-chlorophenyl)-3-[(benzyloxycarbonyl)amino]hexanoate

Triethylamine (1.2ml, 8.9mmol) followed by diphenylphosphoryl azide (1.6ml, 7.4mmol) was added to a solution of 4-*tert*-butyl hydrogen 2-(4-chlorophenylpropyl)succinate (WO

9504033 intermediate 2f) (2.4g, 7.4mmol) in toluene (250ml), and the solution stirred at room temperature for 30 minutes, then under reflux for a further 3 hours. The mixture was cooled to 50°C, benzyl alcohol (2.3ml, 22.3mmol) added, and the reaction heated under reflux for 18 hours. The cooled mixture was concentrated under reduced pressure and the residue dissolved in ethyl acetate (125ml). This solution was washed with saturated ammonium chloride solution (100ml), brine (100ml) and water (100ml), then dried (MgSO₄) and concentrated under reduced pressure. The product was purified by column chromatography on silica gel using ethyl acetate :pentane (6:94) as eluant to afford the title compound as a colourless oil 1.59g; ¹H NMR (CDCl₃, 400MHz) δ: 1.41 (s, 9H), 1.46-1.70 (m, 4H), 2.40 (m, 2H), 2.58 (m, 2H), 3.98 (m, 1H), 5.10 (s, 2H), 5.20 (d, 1H), 7.05 (d, 2H), 7.22 (m, 3H), 7.32 (m, 4H); LRMS : m/z (ES⁺) 454 [MNa⁺].

Preparation 94

(3S)-3-Amino-6-(4-chlorophenyl)hexanoic acid hydrobromide




15

Hydrogen bromide in acetic acid (30wt.%, 50ml) was added to a solution of the protected amino acid from preparation 93 (1.5g, 3.47mmol) in acetic acid (100ml), and the reaction stirred at room temperature for 5 hours. The mixture was concentrated under reduced pressure and the residue azeotroped with dichloromethane to afford the title compound as an orange powder, 1.13g; ¹H NMR (CD₃OD, 400MHz) δ: 1.68 (m, 4H), 2.55-2.78 (m, 4H), 3.57 (m, 1H), 7.18 (d, 2H), 7.25 (d, 2H); LRMS : m/z (ES⁺) 242 [MH⁺].

20

Preparation 95

tert-Butyl (3S)-3-amino-5-(4-methoxyphenyl)hexanoate



25

tert-Butyl (3S)-3-[[benzyloxy]carbonyl]amino-5-(4-methoxyphenyl)hexanoate was prepared as a colourless oil in 32% yield from 4-*tert*-butyl hydrogen 2-(4-methoxyphenylpropyl)succinate (WO 9504033 intermediate 4), following the procedure described in preparation 93. A mixture of this compound (110mg, 0.26mmol), 10% palladium on charcoal (20mg) and ethanol (10ml) was hydrogenated at room


30

temperature for 18 hours. The reaction was filtered, and the filtrate concentrated under reduced pressure. The residue was purified by column chromatography on silica gel twice using dichloromethane:methanol:0.88 ammonia (98:2:0.2) to afford the title compound; $^1\text{H NMR}$ (CDCl_3 , 400MHz) δ : 1.42 (s, 9H), 1.60-1.80 (m, 4H), 2.20 (dd, 1H), 2.39 (dd, 1H), 2.58 (t, 2H), 3.18 (m, 1H), 3.79 (s, 3H), 6.82 (d, 2H), 7.07 (d, 2H); LRMS : m/z (ES^+) 294 [MH^+].

Preparation 96

Ethyl (3S)-3-amino-6-(4-chlorophenyl)hexanoate hydrochloride

10




Ethanol hydrogen chloride (45ml) was added to a solution of the acid from preparation 94 (1.06g, 3.29mmol) in ethanol (45ml), and the reaction stirred at room temperature for 6 hours. The mixture was evaporated under reduced pressure to afford the title compound as an orange oil, 1.1g; $^1\text{H NMR}$ (CD_3OD , 400MHz) δ : 1.24 (t, 3H), 1.68 (m, 4H), 2.58-2.80 (m, 4H), 3.58 (m, 1H), 4.19 (q, 2H), 7.20 (d, 2H), 7.25 (d, 2H).

15

Preparation 97

Ethyl (3S)-3-[(1-[(2S)-2-(tert-butoxycarbonyl)-4-methoxybutyl]cyclopentyl]-carbonyl)amino]-6-(4-chlorophenyl)hexanoate

20



1-Hydroxybenzotriazole hydrate (486mg, 3.60mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (690mg, 3.60mmol) and N-methyl morpholine (1.32g, 13.08mmol) were added to a solution of the amine from preparation 96 (1.0g, 3.27mmol), and the acid from preparation 1 (980mg, 3.27mmol) in dichloromethane (50ml), and the reaction stirred at room temperature for 18 hours. The reaction was diluted with dichloromethane (100ml), washed with brine (2x100ml), dried (MgSO_4) and


25

evaporated under reduced pressure. The residual gum was purified by column chromatography on silica gel using pentane:ethyl acetate (85:15) to give the title compound, 1.31g; ^1H NMR (CDCl_3 , 400MHz) δ : 1.24 (t, 3H), 1.44-1.70 (m, 21H), 1.79 (m, 2H), 1.98 (m, 3H), 2.36 (m, 2H), 2.60 (m, 2H), 3.24 (m, 5H), 4.12 (q, 2H), 4.26 (m, 1H), 6.42 (d, 1H), 7.10 (d, 2H), 7.21 (d, 2H).

Preparation 98

tert-butyl (3*S*)-3-[(1-[(2*S*)-2-(*tert*-butoxycarbonyl)-4-methoxybutyl]cyclopentyl)-carbonyl]amino]-6-(4-methoxyphenyl)hexanoate


10



The title compound was obtained in 67% yield from the amine from preparation 95 and the acid from preparation 1, following the procedure described in preparation 97; ^1H NMR (CDCl_3 , 400MHz) δ : 1.42 (2xs, 18H), 1.44-1.70 (m, 12H), 1.80 (m, 2H), 1.98 (m, 2H), 2.37 (m, 1H), 2.40 (m, 2H), 2.58 (m, 2H), 3.22 (s, 3H), 3.27 (m, 2H), 3.78 (s, 3H), 4.23 (m, 1H), 6.44 (d, 1H), 6.80 (d, 2H), 7.08 (d, 2H); LRMS : m/z (ES^+) 598 [MNa^+].

Preparation 99

tert-Butyl (2*R*)-2-[(1-[[[(1*R*)-1-[(4-chlorobenzyl)oxy]methyl]-3-ethoxy-3-oxopropyl]-amino]carbonyl]cyclopentyl)methyl]pentanoate



- 5 The title compound was prepared as a colourless oil in 77% yield, from the acid from preparation 15 and ethyl iodide, following the procedure described in preparation 24. ¹H NMR (CDCl₃, 400MHz) δ: 0.83 (t, 3H), 1.19-1.78 (m, 23H), 2.98 (m, 3H), 2.21 (m, 1H), 2.61 (m, 2H), 3.58 (m, 2H), 4.06 (t, 2H), 4.45 (s, 3H), 6.50 (m, 1H), 7.25 (m, 4H). LRMS : m/z (ES⁺) 560 [MNa⁺].

10

Biological Assays

- 15 IC₅₀ values of the compounds of the invention against NEP and ACE were determined using methods described in published patent application EP1097719-A1, paragraphs [0368] to [0376]. The IC₅₀ values presented below were determined using NEP (EC.3.4.24.11) from human kidney.

The compounds of the invention are potent inhibitors of NEP and are selective against ACE.

- 20 The title compounds of all diacid examples showed an IC₅₀ against NEP of less than 250 nM.


- 25 The title compounds of Examples 1-5, 7, 10-16, 31-42, 44, 46, 48, 53 and 54 showed an IC₅₀ against NEP of less than or equal to 50 nM and a selectivity over ACE of greater than 300 fold.

- 30 In particular, the title compound of Example 16 showed an IC₅₀ against NEP of 8.2 nM; the title compound of Example 41 showed an IC₅₀ against NEP of 6.3 nM; the title compound of Example 48 showed an IC₅₀ against NEP of 2.4 nM; the title compound of Example 53 showed an IC₅₀ against NEP of 0.7 nM; and the title compound of Example

54 showed an IC_{50} against NEP of 4.7 nM. The title compounds of all these Examples were greater than 300 fold selective against ACE.

Claims

1. A compound of formula (I), a pharmaceutically acceptable salt or solvate thereof



5

wherein

R^1 is C_1 - C_6 alkyl, C_1 - C_6 alkoxy C_1 - C_3 alkyl or C_1 - C_6 alkoxy C_1 - C_6 alkoxy C_1 - C_3 alkyl;

R^2 is hydrogen or C_1 - C_6 alkyl;

10 L is a three atom linkage selected from $-CH_2-X-CH_2-$ and $-CH_2-CH_2-X-$ where the right hand side of the linkage is attached to R^3 and where X is oxygen, sulfur or methylene;

15 R^3 is phenyl or aromatic heterocyclyl, either of which may be independently substituted by one or more groups selected from: C_1 - C_6 alkyl, halo, halo C_1 - C_6 alkyl, C_1 - C_6 alkoxy, halo C_1 - C_6 alkoxy, C_1 - C_6 alkylthio, halo C_1 - C_6 alkylthio and nitrile; and

R^4 and R^5 are either both hydrogen, or one of R^4 and R^5 is hydrogen and the other is a biolabile ester-forming group that in the body of a patient is replaced by hydrogen.

- 20 2. A compound according to claim 1 wherein R^1 is C_1 - C_6 alkyl or C_1 - C_6 alkoxy C_1 - C_3 alkyl.

3. A compound according to claim 2 wherein R^1 is propyl or methoxyethyl.

25 4. A compound according to any preceding claim wherein R^2 is hydrogen.

5. A compound according to any preceding claim wherein L is a three atom linkage selected from $-CH_2-O-CH_2-$, $-CH_2-CH_2-O-$ and $CH_2-CH_2-CH_2-$, where the right hand side of the linkage is attached to R^3 .

30

6. A compound according to claim 5 wherein L is $-CH_2-CH_2-O-$ or $CH_2-CH_2-CH_2-$.


7. A compound according to any preceding claim wherein R³ is phenyl which may be independently substituted by one or more groups selected from: C₁-C₆alkyl, halo, haloC₁-C₆alkyl, C₁-C₆alkoxy, haloC₁-C₆alkoxy, C₁-C₆alkylthio, haloC₁-C₆alkylthio and nitrile.
- 5
8. A compound according to claim 7 wherein R³ is phenyl which may be independently substituted by one or more groups selected from: C₁-C₆alkyl, halo, haloC₁-C₆alkyl, C₁-C₆alkoxy and halo C₁-C₆alkoxy.
- 10
9. A compound according to claim 8 wherein R³ is 4-fluorophenyl, 4-chlorophenyl, 4-methoxyphenyl or 4-methylphenyl.
- 10.
10. A compound according to any preceding claim wherein the biolabile ester-forming groups are C₁-C₆alkyl, carbocyclyl or heterocyclyl each of which may be substituted.
- 15
11. A compound according to claim 10 wherein the biolabile ester-forming groups are: i) C₁-C₆alkyl optionally substituted by hydroxy, oxo, halo, haloC₁-C₆alkyl, C₁-C₆alkoxy, haloC₁-C₆alkoxy, C₁-C₆alkylthio, haloC₁-C₆alkylthio, nitrile, carbocyclyl, heterocyclyl, carbocycloxy, heterocycloxy, C₁-C₇alkylcarbonyloxy, carbocyclylcarbonyloxy, heterocyclylcarbonyloxy, alkylcarbonylamino, and alkylaminocarbonyl, wherein any carbocyclyl or heterocyclyl group is optionally substituted by C₁-C₆alkyl, halo, haloC₁-C₆alkyl, C₁-C₆alkoxy, haloC₁-C₆alkoxy, C₁-C₆alkylthio, haloC₁-C₆alkylthio or nitrile; or ii) carbocyclyl or heterocyclyl optionally substituted by C₁-C₆alkyl, halo, haloC₁-C₆alkyl, C₁-C₆alkoxy, haloC₁-C₆alkoxy, C₁-C₆alkylthio, haloC₁-C₆alkylthio or nitrile.
- 20
- 25
12. A compound according to claim 11 wherein any carbocyclic group is phenyl and any heterocyclic group is aromatic.
- 30
13. A compound according to claim 11 wherein biolabile ester-forming groups are selected from the list: ethyl, propyl, butyl, isobutyl, cyclopentyl, benzyl, 1-(2,2-diethylbutyryloxy)ethyl, 2-ethylpropionyloxymethyl, 1-(2-ethylpropionyloxy)ethyl, 1-(2,4-dimethylbenzoyloxy)ethyl, 1-benzoyloxy)benzyl, 1-(benzoyloxy)ethyl, 2-methyl-1-propionyloxypropyl, 2,4,6-trimethylbenzoyloxymethyl, 1-(2,4,6-trimethylbenzyloxy)ethyl, pivaloyloxymethyl, phenethyl, phenpropyl, 2,2,2-
- 35

trifluoroethyl, 1-naphthyl, 2-naphthyl, 2,4-dimethylphenyl, 4-t-butylphenyl, 5-(4-methyl-1,3-dioxalynyl-2-onyl)methyl, N,N-diethylaminocarbonylmethyl and 5-indanyl.

5 14. A compound according to any preceding claim wherein R^4 and R^5 are both hydrogen.

15. A compound according to any preceding claim wherein the compound is of formula (Ia)

10



16. A compound according to claim 15 wherein

R^1 is C_1 - C_6 alkyl or C_1 - C_6 alkoxy C_1 - C_3 alkyl;

R^2 is hydrogen;

15

L is a three atom linkage selected from: $-CH_2-O-CH_2-$, $-CH_2-CH_2-O-$ and

$CH_2-CH_2-CH_2-$, where the right hand side of the linkage is attached to R^3 ;

R^3 is phenyl which may be independently substituted by one or more groups

selected from: C_1 - C_6 alkyl, halo, halo C_1 - C_6 alkyl, C_1 - C_6 alkoxy,

halo C_1 - C_6 alkoxy, C_1 - C_6 alkylthio, halo C_1 - C_6 alkylthio and nitrile; and

20

R^4 and R^5 are either both hydrogen, or one of R^4 and R^5 is hydrogen and the

other is a biolabile ester-forming group that in the body of a patient is

replaced by hydrogen.

17. A compound according to claim 16 wherein

25

R^1 is propyl or methoxyethyl;

R^2 is hydrogen;

L is $-CH_2-CH_2-O-$ or $CH_2-CH_2-CH_2-$, where the right hand side of the linkage is attached to R^3 ;

R^3 is 4-fluorophenyl, 4-chlorophenyl, 4-methoxyphenyl or 4-methylphenyl; and


30

R^4 and R^5 are both hydrogen.

18. A compound according to claim 1 selected from:

- (2*S*)-2-[(1-[[[(1*R*)-2-carboxy-1-[(4-chlorobenzyl)oxy]methyl]ethyl)-amino]carbonyl]cyclopentyl)methyl]-4-methoxybutanoic acid (Example 16);
- 5 (3*S*)-3-[[{1-[(2*R*)-2-carboxypentyl]cyclopentyl}carbonyl]amino]-5-(4-chlorophenoxy)pentanoic acid (Example 41);
- Ethyl (3*S*)-3-[[{1-[(2*S*)-2-Carboxy-4-methoxybutyl]cyclopentyl}carbonyl]amino]-5-(4-chlorophenoxy)pentanoate (Example 47);
- (3*S*)-3-[[{1-[(2*S*)-2-carboxy-4-methoxybutyl]cyclopentyl}carbonyl]amino]-5-(4-chlorophenoxy)pentanoic acid (Example 48);
- 10 (2*S*)-2-[(1-[[[(1*S*)-3-butoxy-1-[2-(4-chlorophenoxy)ethyl]-3-oxopropyl]amino]carbonyl]cyclopentyl)methyl]-4-methoxybutanoic acid (Example 49);
- (3*S*)-3-[[{1-[(2*S*)-2-carboxy-4-methoxybutyl]cyclopentyl}carbonyl]amino]-6-(4-chlorophenyl)hexanoic acid (Example 53);
- 15 Ethyl (3*S*)-3-[[{1-[(2*S*)-2-carboxy-4-methoxybutyl]cyclopentyl}carbonyl]amino]-6-(4-chlorophenyl)hexanoate (Example 52); and
- (3*S*)-3-[[{1-[(2*S*)-2-carboxy-4-methoxybutyl]cyclopentyl}carbonyl]amino]-6-(4-methoxyphenyl)hexanoic acid (Example 54).
- 20 19. The use of a compound defined in any preceding claim, a pharmaceutically acceptable salt, solvate, polymorph or prodrug thereof, in the manufacture of a medicament for treating or preventing a condition for which a beneficial response is obtained by the inhibition of neutral endopeptidase.
- 25 20. The use according to claim 19 wherein the condition is a cardiovascular disease or condition.
21. The use according to claim 20 wherein the condition is hypertension.
- 30 22. The use according to claim 19 wherein the condition is female sexual dysfunction or male erectile dysfunction.
23. A compound defined in any one of claims 1 to 18, a pharmaceutically acceptable salt, solvate, polymorph or prodrug thereof, for use as a medicament.

24. A method of treating or preventing a condition for which a beneficial response is obtained by the inhibition of neutral endopeptidase in a mammal comprising treating said mammal with a therapeutically effective amount of a compound defined in any one of claims 1 to 18, a pharmaceutically acceptable salt, solvate, polymorph or prodrug thereof.
25. The method of claim 24 wherein the condition is defined in claim 20, 21 or 22.
26. A pharmaceutical composition including a compound defined in any one of claims 1 to 18, a pharmaceutically acceptable salt, solvate, polymorph or prodrug thereof together with a pharmaceutically acceptable excipient, diluent or carrier.
27. A combination of a compound defined in any one of claims 1 to 18 and one or more active ingredients selected from the list:
- a) angiotensin receptor blockers (ARB), such as losartan, valsartan, telmisartan, candesartan, irbesartan, eprosartan and olmesartan;
 - b) calcium channel blockers (CCB) such as amlodipine;
 - c) statins, such as atorvastatin;
 - d) PDE5 inhibitors, such as sildenafil, tadalafil, vardenafil, 5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-[2-methoxyethyl]-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; 5-(5-acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidiny)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one and; the pyrazolo[4,3-d]pyrimidin-4-ones disclosed in WO00/27848 particularly N-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]-pyrimidin-5-yl)-4-propoxyphenyl]sulfonyl]-1-methyl-2-pyrrolidinepropanamide [DA-8159 (Example 68 of WO00/27848)];
 - e) beta blockers, such as atenolol or carvedilol;
 - f) ACE inhibitors, such as quinapril, enalapril and lisinopril;
 - g) alpha-blockers such as doxazosin;
 - h) selective aldosterone receptor antagonists (SARA), such as eplerenone or spironolactone;
 - i) imidazoline I₁ agonists, such as rilmenidine; and
 - j) endothelin receptor antagonists and endothelin converting enzyme inhibitors.



(I)